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Abstract 
Top-loading 
This study compared the effects on oxygen (O2) transport of four fluids: 5.9% human 
serum albumin (HSA) a non-O2 carrying iso-oncotic solution (volume control);HBOC-201 
(Hemopure, Biopure Corp., Cambridge, MA); MP50, HBOC-201 with a P50 of 18 mmHg; 
and lastly LP50, an HBOC-201 with P50 of 17 mmHg and higher viscosity (4 cP). It has 
been proposed that HBOC with a higher O2 affinity and a viscosity closer to that of whole 
blood will cause less vasoconstriction and thus a lower MAP than Hemopure (P50 = 40 
mmHg and 2.2 cP). Intravital microscopic measurements were made on the spinotrapezius 
muscle of anesthetized, male Sprague-Dawley rats. Interstitial PO2 was measured using 
phosphorescence quenching microscopy at baseline and following four top-loading 
infusions, in which increasing concentrations of HBOC-201 were infused to reach target 
plasma concentrations of 1, 10, 100 and 300 µM. Both HBOC-201 and MP50 increased 
PO2 by about 10%, but PO2 was unchanged with LP50. LP50 was more hypertensive 
(160±5mmHg) than HBOC-201 (144±5) and MP50 (141±6). Arteriolar diameters were not 
significantly different among the three HBOCs. The lower P50 HBOCs did not lead to 
higher PO2 compared with HBOC-201 and the higher viscosity HBOC led to higher MAP. 
 
 
 x
Hemorrhage and Resuscitation 
This study compared the efficacy of three resuscitation fluids in a model of hemorrhage 
and resuscitation:  HBOC-201, a hemoglobin-based oxygen carrier ([Hb] = 13 ± 1 g/dl; 
Biopure Corp.), HBOC-201 with 92 µg/ml nitroglycerin (NTG), and 5.9% human serum 
albumin, a non-oxygen carrying colloid solution.  Intravital microscopic measurements 
were made on the spinotrapezius muscle of anesthetized, male Sprague-Dawley rats.  
Interstitial fluid (ISF) oxygen tension (PO2) was measured using phosphorescence 
quenching microscopy at baseline, post-hemorrhage and three post-resuscitation time 
points.  Following 40% blood volume withdrawal, animals were maintained in this 
condition for 30 minutes before resuscitation was begun.  Baseline ISF PO2 (65 ± 2 mmHg) 
decreased during hemorrhage (3.6 ± 0.4 mmHg) and all resuscitation fluids increased ISF 
PO2 towards baseline.  HBOC-201 with nitroglycerin produced the highest PO2 throughout 
the experimental time course, and the findings are consistent with the NO scavenging 
theory because adding NO alleviated known side effects such as increased vascular 
resistance and hypertension that are associated with HBOC-201 infusions.
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Introduction 
Blood is a physiological medium that transports hormones, oxygen (O2), glucose, and metabolic 
wastes, in addition to other substances, between muscles, tissues and cells.  In addition, it plays a 
vital role in immunity and cardiac output.  When a blood sample is centrifuged, this seemingly 
homogeneous substance distinctly divides into three layers.  The upper layer, which occupies 
about 55% of the total blood volume, is a clear yellowish fluid known as plasma, and its main 
function is to bathe and suspend the white and red blood cells.  The middle section (~ 2%) 
contains leukocytes, and is straw- colored; hence, leukocytes are also known as white blood 
cells, and their primary function is to protect the body from disease and removal of foreign 
matter.  The densest layer is red in color, occupies 40-45% of the total volume, and is composed 
of erythrocytes, which are commonly known as red blood cells (RBCs).  RBCs have several 
functions, but the two most important ones are the transport of O2 to cells, and the removal of 
carbon dioxide (CO2) produced by parenchymal cells.  An RBC contains about 300 million 
hemoglobin (Hb) molecules, which cooperatively bind and carry O2 from the lungs to the cells.  
Without the provision of O2, cells would be forced to switch from oxidative phosphorylation to 
glycolysis, which would cause a drastic reduction in energy production in the form of adenosine 
5’-triphosphate (ATP), and ultimately lead to cell starvation and death.  Another critical role of 
RBCs is the transport of CO2 (a metabolic waste product of aerobic metabolism) from the cells to 
the lungs, where it is expired into the atmosphere.  RBCs contain large amounts of carbonic 
anhydrase, which is an enzyme that converts CO2 and water to bicarbonate and hydrogen ions.  
Bicarbonate is the anion that serves an essential role as a buffer against changes in pH. 
 
  
12
Page 12  
  
Although blood consists of many components that perform vital functions, this dissertation 
focuses on RBCs and Hb molecules, and their effect on tissue oxygenation and tissue O2 
consumption in the context of the microcirculation. For that reason, the next section will briefly 
familiarize the reader with the basic knowledge of O2. 
 
Importance of Oxygen (O2) 
Mammals use ATP as their main source of energy to operate and maintain cellular activity. 
Generally speaking, ATP is formed from the degradation of simple sugars and fats, and is 
produced via two mechanisms:  glycolysis and oxidative phosphorylation.  In glycolysis, one 
glucose molecule is converted to generate a net gain of two ATP molecules, independent of 
mitochondria and O2.  In the presence of an adequate O2 supply, oxidative phosphorylation 
occurs inside the mitochondria, and produces 36 ATP molecules per glucose molecule.  
Although the biochemistry of glycolysis and especially oxidative phosphorylation is complex, 
the end result is that a glucose molecule will generate about 18 times more energy when O2 is 
present.  Thus, the existence of mammalian life depends on a continuous supply of O2. 
 
Cardiopulmonary System 
 
The cardiopulmonary system relies on the coordinated activity of the lungs, heart, and blood 
vessels, which work together to supply O2to organs and tissues, while simultaneously removing 
metabolic waste products. In mammals, O2 enters the lungs from the atmosphere and passively 
diffuses from the alveolar gas spaces into the blood flowing through the pulmonary capillaries. 
Concurrently, CO2 diffuses out of the blood and is expelled into the air with each exhalation. The 
passive movement of O2 and CO2 in the pulmonary capillaries refreshes the deoxygenated blood 
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entering through the pulmonary artery, and sends O2-rich blood through the pulmonary vein into 
the left atrium of the heart. Coordination among the four chambers of the heart, i.e., left and right 
atria and left and right ventricles, via muscle contractions and valves preventing backflow, 
makes this organ highly structured and complex, yet efficient at circulating refreshed blood 
throughout the body. The left ventricle has the thickest muscle wall, and thus, exerts the most 
force, which is necessary to overcome the aortic pressure. Blood leaves the left ventricle and 
flows into the aorta.It is later divided through branching arterial networks that eventually lead to 
the microcirculation. The microvascular or microcirculatory networks consist of arterioles, 
capillaries and venules..  Arterioles are vessels that carry oxygenated blood to the capillaries, 
which are so narrow that RBCs are sometimes required to flow through them in a single file.  
This intimate contact allows for maximal exchange of both nutrients and waste products.  Blood 
leaving the capillaries will be collected in venules, which eventually returns it back to the heart. 
 
O2 Transport 
As mentioned above, O2 is transported through the cardiopulmonary system, and it is carried in 
the blood in two ways:  bound and unbound.  About 98% of O2 is reversibly bound to Hb in the 
RBC, while approximately 2% is dissolved in the blood (Pittman, 2000).  A Hb molecule has a 
molecular weight roughly 64 kDa and consists of four heme groups (two α and two β subunits), 
and each heme can bind one O2 molecule.  Thus, Hb is a tetrameric molecule that could carry up 
to four O2 molecules at a given time.  Hb binds to O2 in a positive cooperative manner, which is 
demonstrated through the sigmoidal shape of the O2 dissociation curve.  
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The PO2 at which half of the binding sites are occupied with O2is known as the P50, which is 
defined by the partial pressure of O2 (PO2) at which Hb is 50% saturated with O2. How tightly O2 
is bound to Hb is also termed O2 affitnity. If the O2 affinity increases, the O2 dissociation curve 
shifts to the left and consequently P50 decreases. Thus, there is a shift to the right with decreased 
O2 affinity or increased P50. A rightward shift of the curve will occur if the pH decreases and 
temperature, 2,3-diphosphoglycerate (DPG) and CO2increases. For example, if a person 
exercises blood temperature is elevated, and so is CO2 and 2,3-DPG, which are by-products of 
oxidative phosphorylation and glycolysis, respectively. Furthermore, the hydrogen ion 
concentration will also increase during exercise, which is best explained through the Bohr Effect 
shown below. 
 
CO2 + H2O  H2CO3  H+ + HCO3− 
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The Bohr Effect states that an increase in CO2 leads to an elevation in hydrogen ions, which 
translates to a decrease in pH, since pH is defined by the negative logarithm of the hydrogen ion 
concentration. In other words, exercise causes a rightward shift that decreases the O2 affinity, 
and therefore Hb releases O2 more readily to supply the elevated O2 demand. 
 
O2 transport is primarily explained in terms of convection, which is the movement of dissolved 
and bound O2 through the vasculature.  It is highly efficient over long distances ranging from 
meters to millimeters.  However, O2 ultimately moves via diffusion, i.e. 10 micrometers, from 
the microvascular networks to neighboring parenchymal cells where it is consumed by the 
mitochondria (Pittman, 2000). 
 
Mitochondria:The Cellular Power House 
The mitochondrion is a cytoplasmic organelle that appears as spheres, rods, or filamentous 
bodies about 0.5 – 1 micrometer (µm) in diameter and up to 7 µm in length (Devlin, 2002). 
Under aerobic conditions, the mitochondria transduce energy released during oxidation of 
NADH and FADH2 into ATP, and this process is known as oxidative phosphorylation. The 
concentration of mitochondria within a cell varies depending on the metabolic needs of the cell. 
In highly aerobic cardiac muscle, mitochondria occupy about half of the cytoplasmic volume, 
while the liver, which is also highly dependent on oxygen, contains 800 to 2000 mitochondria 
per hepatocyte (Devlin, 2002). In contrast, RBCs do not contain mitochondria, and are therefore 
not able to metabolize the O2 they carry. As previously mentioned, oxidative phosphorylation 
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produces about 18 times more ATP than does glycolysis, and that it occurs in the mitochondria, 
where O2plays a critical role as the final electron acceptor in the electron transport chain. 
 
Hemorrhage and Resuscitation Fluids 
Despite numerous advances in resuscitation technology, severe blood loss and its complications 
are the primary cause of mortality in both military and civilian trauma victims (Teixera, 2007). 
Resuscitation fluids can be divided into the following four types: crystalloids, colloids, blood, 
and blood substitutes, which are also commonly known as artificial O2 carriers. These fluids are 
used to compensate blood loss, which is commonly referred to as hemorrhage. Hemorrhage is 
clinically categorized into four classes which are based on the volume of blood lost. Class I 
hemorrhage is described as less than 15% blood volume loss, and is considered mild hemorrhage 
that does not require any medical intervention. With Class II hemorrhage, a patient has lost 
between 15 to 30% of total blood volume, and will require a fluid resuscitation of either 
crystalloids or colloids. In Class III and IV hemorrhage, there has been a loss of 30 to 40%, or 
greater than 40% of the circulating blood, respectively. Severe hemorrhage is often deadly 
without immediate correction due to hemorrhagic shock and a patient in this state will be 
resuscitated with blood. Following is an in-depth discussion of each type of resuscitation fluid. 
 
Crystalloids 
Crystalloids are the most frequently used resuscitation fluid due to their effectiveness, low 
morbidity, availability and low cost.  For example, administration of crystalloids such as normal 
saline and lactated Ringer’s solution helps to restore blood volume, cardiac output and tissue 
oxygenation (Tremblay et al, 2001).  However, one disadvantage of using these resuscitation 
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solutions is that they do not contain large molecules to maintain normal colloid osmotic pressure, 
and therefore there is a net movement of fluid out of the vasculature and into the interstitium, or 
other body cavities.  Thus edema may result due to long-term infusion of crystalloids, or large 
volumes, i.e., severe hemorrhage.  Another shortcoming of crystalloids is the lack of Hb 
molecules, which are essential in conditions such as severe hemorrhage where both volume and 
the restoration of O2 delivery are required for survival.  In summary, crystalloids are good 
resuscitation fluids for blood volume losses ranging from 15% to 30%, and are known to be 
highly effective and economical to manufacture (Tremblay et al, 2001). 
 
Colloids 
Use of colloids as resuscitation fluids aids in the restoration of blood volume and maintains 
cardiac output and tissue oxygenation. Albumin, which is extracted from purified human plasma, 
and hetastarch are examples of commonly used colloids. Since colloids can maintain the oncotic 
pressure of plasma, a smaller volume is needed to achieve the same physiological effects as 
crystalloids. Nonetheless, the literature in this area confirms that there is no significant difference 
between the two in controlled clinical trials (Choi, 2000).  
 
Blood and Packed Red Blood Cells 
Following severe hemorrhage, or blood loss of more than 30%, crystalloids and colloids are not 
sufficient to sustain adequate O2 delivery, and blood transfusion is required.  Although, blood 
transfusions can be the difference between life and death, there is a costly and potentially 
hazardous trade off.  Storing blood is expensive, and the cost continues to rise as potential donors 
are turned away during the screening process (Riess, 2001).  Furthermore, blood matching and 
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screening for diseases is becoming more thorough, and the demand for blood is expected to 
increase, which contribute to increased cost.  It is also noteworthy that the efficacy of RBCs 
appears to be inversely proportional to storage time.  One reason for this is the decrease of 2,3-
diphosphoglycerate (2,3-DPG) in stored blood, which is depleted after 7 days.  A reduction in 
2,3-DPG increases the affinity of Hb forO2, which hinders O2 release and reduces 
microcirculatory O2 supply to the tissues (Ho, 2003).  Additional limitations of blood 
transfusions are present despite extensive screening and cross-matching, and reports of 
transfusion reactions and transmission of diseases continue (Tremblay et al, 2001).  More 
specifically, patients are reported to suffer from allergic reactions (1 in 30), delayed hemolytic 
transfusion reactions (1 in 1,000), transfusion-related acute respiratory disease syndrome (1 in 
250,000-1,000,000), hepatitis B (1 in 30,000-250,000) or C (1 in 30,000-100,000), and HIV (1 in 
500,000) (Riess, 2001).  Despite the limitations and potential risks of blood transfusion, it 
remains the standard of practice to combat anemia. 
 
Blood Substitutes 
For severe hemorrhage, transfusion with crystalloids or colloids alone is insufficient to transport 
enoughO2. While blood is required for those suffering from severe hemorrhage, a victim may not 
be administered blood at the scene due to the risk of blood type mismatch.  Developing a 
universal blood substitute would allow for an immediate resuscitation with an O2 carrier, and 
could potentially save many lives.  For example, Moore et al demonstrated that rats resuscitated 
with blood immediately after hemorrhage (pre-hospital) had better outcomes than those given 
blood 30 minutes post hemorrhage (in-hospital) (Moore et al, 2006). Thus, the difference 
between life and death is often dependent on timely resuscitation. Though blood is needed to 
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maintain O2 delivery, stored blood comes with a set of potential problems in addition to blood 
type mismatch, i.e., cost, short shelf life, and spread of blood-borne disease.  Therefore extensive 
research is being conducted to develop a safe and beneficial blood substitute.  Blood substitutes 
are divided into two main categories:  perfluorocarbon (PFC) emulsions, and hemoglobin-based 
O2 carriers (HBOCs).  They have several advantages over stored blood:  longer shelf-life, do not 
transmit blood-borne diseases, do not require refrigeration, do not require blood typing and 
cross-matching, and they are renewable. 
 
Perfluorocarbons (PFCs) 
PFCs are synthetic molecules in which a linear or cyclic carbon background has its hydrogen 
atoms substituted by a fluoride and other halogens (Stowell, 2001).  Characterized with the 
properties of gas-dissolving, low viscosity, and biologically inert, PFCs are emulsified in 
solution with a vehicle (58% perfluorooctyl bromide and 2% perfluorodecyl bromide) that 
improves their movement in the blood (Nucci and Abuchowski, 1998; Spahn and Pasch, 2001).  
They are more cost-effective to manufacture than HBOCs (Stollings & Oyen, 2006), and provide 
an acceptable alternative for those who do not want to receive resuscitation fluids containing Hb 
from humans or other mammals for religious reasons (Tremblay et al, 2001).  Physiologically, 
PFCs behave similarly to RBCs by obtaining O2 in the lungs and delivering it throughout the 
body, and returning CO2 to the lungs for elimination (Stowell et al, 2001).  However, one 
significant difference between PFCs and Hb-based products, i.e., blood and HBOCs, is that PFCs 
have a linear relationship between oxygen content and PO2, while Hb has a positive 
cooperativity relationship.  If one were to trace both plots on the O2 dissociation curve, one 
would see a line with a constant slope for the PFC, while Hb would display a sigmoidal shaped 
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curve.  This difference translates to the fact that PFCs demand a high inspiratiory O2 
concentration (usually 100% O2) to provide effective oxygenation (Tremblay et al, 2001; 
Stollings and Oyen, 2006).  Although the shelf-life of PFCs is up to 2 years, their half-lives in 
the circulation are 2 to 4 hours, while HBOCs have a shelf life of 1 to 3 years and a half-life of 
18 to 24 hours (Stollings & Oyen, 2006).  In addition, there have been flu-like symptoms 
reported with PFCs, i.e., back pain, malaise, flushing and fever, as well as transient 
thrombocytopenia in which the concentration of platelets decreases 30 to 40% (Scott et al, 1997). 
 
Hemoglobin-Based Oxygen Carries (HBOCs) 
There are different types of HBOCs, and since they are the focus of this dissertation, an 
extensive review will follow. 
HBOCs: Background 
Cell-free hemoglobin (Hb) was first infused into the vascular system in 1933, when Amberson 
and colleagues demonstrated that Hb transported O2 in dogs and cats, and that they maintained 
their neurological function despite complete replacement of blood with bovine hemolysates 
(Amberson et al, 1933). Since the inception of extracellular Hb research, there have been 
multiple advances, digressions and attempts to use Hb from bovine or expired human blood for 
clinical application as a blood substitute (Moss et al, 1984). Commonly known as Hb-based 
O2carriers (HBOCs), these fluids have been viewed as a “magic bullet” that would succeed in 
areas where blood has its limitations. Although the applications are many, HBOCs would most 
commonly be utilized in trauma situations as a resuscitation fluid in response to severe 
hemorrhage, where the restoration of both volume and Hb is required for survival (Carson et al, 
2002). Unlike blood, HBOCs do not transmit blood-borne diseases such as HIV and hepatitis 
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(Riess, 2001), do not require blood typing, and can be stored at room temperature (Dubé et al, 
2008), which makes them more manageable for any paramedic, whether military or civilian. 
Furthermore, HBOCs have a longer shelf-life of one to three years (Moore, 2003) compared to 
42 days of normal blood and, in light of the ever increasing demand for blood (Scott, 1997), a 
renewable supply of blood substitutes may prove valuable. 
 
Despite the promising attributes of HBOCs as possible blood substitutes, there are disadvantages 
that trace back to their infancy, specifically abdominal pain, kidney failure, and vasoconstriction. 
It was discovered early on that the abdominal pain associated with HBOC was related to stromal 
contamination, and since then stroma-free HBOCs have been produced (Amberson et al, 1949; 
Rabiner et al, 1967). The associated kidney failure is thought to be linked to the spontaneous 
dissociation of Hb tetramers into dimers, which make them small enough to be readily filtered at 
the glomerulus (Bunn et al, 1969).  Increased levels of Hb within the tubular lumen appeared to 
cause Hb-associated nephrotoxicicty, in which renal ischemia and excretory defects were among 
some of the observations reported (Jaenike, 1967).  Significant improvements occurred with the 
stabilization of the tetramers through cross-links (DCLHb; Baxter International, Round Lake, 
IL), or by polymerization to form larger molecules that are incapable of being filtered into the 
kidney (Lieberthal, 1997).In a study by Baylis, the long-term effect on kidney function was 
investigated, and glutaraldehyde-polymerized bovine Hb (HBOC-201 Biopure Corp., 
Cambridge, MA) with an average molecular weight of 250 kDa containing about 98% 
polymerized hemoglobin, and less than 2.5% free tetramers (Dubé, 2008), was compared to 13% 
human serum albumin (HSA). After 6 weeks of daily administration of HBOC-201 or HSA, the 
kidney activity as defined by glomerular filtration rate, level of proteinuria and glomerular 
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pathology were similar between groups. Thus, Baylis concluded that “HBOC-201 had no long-
term damaging effects on renal function or structure” (Baylis, 2006). The findings highlight the 
role of molecular weight in acellular Hb on kidney failure, which is also the basis of the most 
emphasized adverse reactions associated with HBOCs, specifically vasoconstriction and the 
resulting hypertension. 
 
Conflicting Theories 
At the moment, vasoconstriction and hypertension are the most highlighted side effects of 
HBOCs, and it is crucial to have a thorough understanding of the associated physiological and 
biochemical responses in order to develop the next generation HBOCs. There is a great deal of 
controversy surrounding the mechanism by which cell-free Hb changes vascular tone when 
infused intravenously. Currently, there are two opposing theories -- ‘Nitric Oxide (NO) 
Scavenging’ and ‘Autoregulation’ -- that are both worth investigating and need to be reviewed. 
 
NO Scavenging Theory 
In order to appreciate the theory, the fundamentals of endothelial derived NO need to be 
mentioned. NO is a lipophilic, free radical, gaseous molecule that is synthesized by nitric oxide 
synthase (NOS). Endothelial NOS, also known as eNOS or NOS3, is responsible for the NO 
produced in vascular endothelium, which is the focus of the NO scavenging theory. Its synthesis 
is promoted via endothelial shear stress or a plethora of vasorelaxants (Lane and Gross, 2002) 
that creates equimolar quantities of NO and L-citruline from L-arginine with the assistance of co-
factors O2 and NADPH (Palmer et al, 1988; Chen et al, 2008). Once released as a paracrine 
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messenger, it activates soluble guanylate cyclase in the nearby vascular smooth muscles that line 
the blood vessel wall, and causes a quantitative elevation of cGMP. The resulting effect is an 
activation of a kinase cascade that phosphorylates the myosin light chain in the smooth muscle 
cells, which attenuates the contractile tone and induces vasorelaxation (Lane and Gross, 2002). 
Given that NO has been reported to react with cell-free oxyhemoglobin (HbO2) about 1000 times 
more rapidly than HbO2 found within erythrocytes (Reiter et al, 2002), it is presumed that 
infused extracellular Hb produces a significant reduction in vasorelaxation that consequently 
causes vasoconstriction. The integrated action of vasoconstricted arterioles in the 
microcirculation raises the total peripheral resistance, and as a result the mean arterial pressure 
(MAP) increases to maintain cardiac output (Olson et al, 2003). Thus, the NO scavenging theory 
states that the observed vasoconstriction seen with HBOCs is due in part to the reaction of NO 
and cell-free Hb. 
 
It has been stated that there is enough Hb to react with all the available NO to abolish NO-
mediated vasodilation (Liu et al, 2002), yet NO remains present. There are several different 
interpretations, and the most common understanding is that physiologically, Hb tetramers are 
prevented from interacting with NO by their encapsulation within the red blood cell (RBC) 
membrane (Olson et al, 2003). One hypothesis is that the membrane acts as a physical barrier 
that prevents Hb from interacting with NO via transmembrane diffusion and intracellular 
mechanisms (Vaughn et al, 2000). Another theory is that extracellular diffusion, or more 
specifically the distance between the RBC and the vessel wall, which includes the RBC-free 
layer, limits the interaction (Liu et al, 2002). On the contrary, cell-free Hb is not restricted by the 
RBC membrane or extracellular diffusion, and is therefore free to interact with NO found near 
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the vessel walls. Furthermore, the ‘NO Scavenging Theory’ also assumes that acellular Hb 
extravasates out of the vasculature and infiltrates the endothelium to directly interact with NO 
where it is synthesized (Kavdia et al, 2002). In addition, the tetramers with a molecular weight of 
64 kDa, and especially the dimers and monomers formed from the dissociation of Hb are 
believed to be small enough to penetrate the endothelium and interfere with NO signaling 
between endothelial and smooth muscle cells (Olson et al, 2003). The significance of 
extravasation is supported in a study by Rice and colleagues, in which HBOCs with different 
ratios of polymerized to tetrameric and dimeric Hb were compared. They found that the Hb 
solution with a 2% tetrameric and dimeric Hb concentration had significantly less 
vasoconstriction than one with 31% (Rice et al, 2008). On a slightly different topic of Hb size, 
Hare and other authors investigated the principle that polymerized Hb with a smaller molecular 
weight than 128 kDa caused more vasoconstriction (Winslow et al, 1998; Lieberthal et al, 1999; 
Conover et al, 1999), and demonstrated its validity with a reduction in peak MAP while having 
no negative impact on oxygen (O2) delivery (DO2) (Hare et al, 2006). In a similar study, Sakai 
and collaborators top-loaded hamsters with 10% of the total blood volume with five different 
acellular Hb solutions ranging in molecular weights, oxygen affinities, and monomeric Hb 
concentration, and then correlated the amount of vasoconstriction inversely to the molecular size 
(Sakai et al, 2000). Many investigators have suggested that the significance of molecular size is 
that larger molecules have a slower rate of extravasation, and therefore interfere less with NO 
signaling (Doherty et al, 1998; Matheson et al, 2002; Olson et al, 2003). 
 
The ’NO Scavenging Theory’ is based on the notion that cell-free Hb reacts with NO to 
substantially decrease or deplete the availability of NO. Theoretically, similar results should be 
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achieved with N(omega)-nitro-L-arginine methyl ester (L-NAME), a NOS inhibitor that prevents 
synthesis of NO. As predicted by the theory, L-NAME has been associated with hypertension 
and simultaneous vasoconstriction when infused without HBOC (Matheson et al, 1998; Sakai et 
al, 2000).  
 
The implications of vasoconstriction and hypertension are variable and depend on the amount of 
cell-free Hb infused, and the condition of the subject. While critics consider larger quantities of 
extracellular Hb pathological and comparable to sickle cell crises (Reiter et al, 2002) or even 
death (Natanson et al, 2008), others imply that there is no direct association with 
vasoconstriction and tissue and organ damage in animals and humans (Buehler and Alayash, 
2008). Furthermore, in trauma, localized vasoconstriction in the microcirculation may be 
advantageous to prevent blood loss (Olson et al, 2003), but may also limit tissue oxygenation 
(Winslow, 2003). 
 
Although the topic of vasoconstriction and hypertension is fundamental to the NO scavenging 
theory, there are other findings that are supported by the hypothesis. A functional requirement of 
Hb and HBOC is the transportation of O2, which occurs when the heme-iron is in the reduced 
state. In the reduced state, ferrous iron (Fe2+) can reversibly bind oxygen; however, when 
methemoglobin (metHb) is formed through the reaction of NO binding to HbO2 (Olson et al, 
2003), the heme-iron shifts to the oxidized state that is incapable of transporting O2 (Pittman, 
2006). Physiologically metHb is maintained at concentrations of less than two percent, in part by 
metHb reductase (Mansouri, 1985) and the RBC membrane (Liu et al, 1998). However, acellular 
Hb has been reported to elevate metHb to cause heme-mediated toxicity (Buehler and Alayash, 
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2008). With methemoglobinemia there is a reduction in tissue oxygenation that may be linked to 
hypoxic circumstances (Solheim et al, 2000), renal toxicity (Harrison et al, 1947), loss of heme 
which induces cytotoxicity (Buehler et al, 2007), elevations in free radicals (Dorman et al, 2002) 
that could cause endothelial vascular injury (Harrington et al, 2000), and oxidative stress which 
causes tissue (Buehler et al, 2007) and cellular damage (Dorman et al, 2002). 
 
A significant amount of research has been dedicated to reversing the vasoconstrictive and the 
hypertensive effects of HBOC, as well as methemoglobinemia, via NO donors. In an experiment 
by Minneci and co-workers, application of gaseous NO reduced the vasoconstrictive effects of 
cell-free Hb, despite significantly increasing the proportion of metHb (Minneci, 2005). In a study 
with sickle-cell patients, who are innately exposed to large quantities of cell-free Hb, subjects 
were given gaseous NO which resulted in the elevation of metHb (Reiter et al, 2002). However, 
Yu and colleagues showed that the pretreatment of inhaled NO in both mice and sheep prevented 
hypertension and systemic vasoconstriction associated with the infusion of HBOC-201 without 
methemoglobinemia (Yu et al, 2008). In a follow-up study, Yu and authors were able to not only 
maintain MAP and metHb at baseline values, but also prevent systemic and pulmonary 
vasoconstriction through pretreatment with inhaled NO followed by continuous low-dose 
gaseous NO during and after HBOC-201 infusion (Yu et al, 2009).This finding suggests the need 
for further investigation into the possible use of HBOCs in conjunction with a separately applied 
NO donor, and highlights the effect of NO on extracellular Hb. 
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Autoregulation Theory 
The ‘Autoregulation Theory’ underscores the important role of DO2, partial pressure of O2 
(PO2), viscosity and O2 affinity in the vasoconstriction associated with acellular Hb, while 
dismissing the role of NO (Winslow, 2003). The tetrameric Hb molecule binds up to four O2 
molecules in a positive cooperativity manner, which explains the sigmoidal shape of the oxygen-
dissociation curve. Rightward or leftward shifts occur due to changes in the O2 affinity caused by 
an increase or decrease in pH, temperature, 2,3-diphosphoglycerate (DPG) and CO2 (Pittman, 
2006).  With a leftward shift, Hb can readily bind to O2, but due to the increased affinity, O2 does 
not dissociate as easily, and thus tissue oxygenation is compromised. On the contrary, when the 
dissociation curve shifts to the right, O2 does not bind to Hb as tightly and readily, but improves 
tissue PO2 (Stollings and Oyen, 2006). Physiologically, shifts in the oxygen dissociation curve 
are seen during exercise, when there is a rightward shift due to an increase in CO2 and H+, also 
known as the Bohr Effect, and a leftward shift at high altitudes where O2 is sparse. Shifts may 
also occur due to pathology as in conditions related to pulmonary or cardiovascular disease. On 
the contrary, blood P50, defined by the PO2 in millimeters of mercury (mmHg) at which 50% of 
the Hb binding sites are occupied, is rarely altered with the exception of stored blood (Ho, 2003). 
 
In the early 1990’s, Winslow, Intaglietta and co-workers studied the effect of three cell-free Hb 
molecules that varied in size, but had similar rate constants for reaction with NO. In increasing 
order, the smallest HBOC was an alpha-alpha cross-linked Hb also known as HemeAssist 
(Baxter International, Round Lake, IL), followed by polymerized Hb (PHP; Apex Biosciences, 
Inc., Chapel Hill, NC), and lastly polyethylene glycol-modified (PEG) Hb (PEG-Hb; Enzon, 
Inc., Bridgewater, NJ). The findings showed that vasoconstriction was inversely proportional to 
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the size of the molecule (Rohlfs et al, 1998). Although people from the NO scavenging camp 
would argue that the findings are explained by the molecular size and thus the rate of 
scavenging, Winslow and colleagues pin-pointed the fact that these cell-free Hb fluids had 
similar rate constants for NO. In other words, if vasoconstriction is mediated by NO, they should 
have produced similar changes in vascular tone (Winslow, 2003). In the same study, two 
derivatives with similar characteristics were engineered to have different P50’s, and when infused 
they caused different levels of vasoconstriction. Furthermore, the molecule with higher O2 
affinity displayed a transient increase in blood pressure, while the product with higher P50 
showed a sustained elevation in pressure (Rohlfs et al, 1998). These findings sparked a theory 
that O2 may play an active role in vasoregulation. Other supporting evidence includes the notion 
that large quantities of O2 leave precapillary vessels, i.e., PO2 decreases as blood travels from 
arterioles to capillaries (Torres and Intaglietta, 1993), that terminal arterioles may regulate 
vascular tone depending on capillary flow (Guyton, 1961), and that the microcirculation 
autoregulates blood flow to maintain O2 levels in tissue (Johnson, 1986). Simply put, the 
‘Autoregulation Theory’ states that cell-free Hb delivers too much O2 to the terminal arterioles 
and that it triggers a vasoconstrictor response that ironically causes a decrease in O2 uptake by 
the tissue (Winslow, 2003). 
 
Years later, the Winslow laboratory published an article based on in vitro measurements 
comparing various acellular Hb molecules and human RBCs. They found that some products 
caused similar DO2 patterns despite different O2 affinities (McCarthy et al, 2001). This did not 
negate the importance of P50, but rather highlighted the significance of DO2. Thus, cell-free Hb 
should be engineered to have a higher affinity for O2 than RBCs (Dimino andPalmer, 2007), 
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while also increasing the colloid osmotic pressure to maintain blood volume (Winslow, 2003).  
Although it is believed that low viscosity HBOCs may enhance DO2 to peripheral tissues 
(Tremblay et al, 2001), Winslow and company think the ideal HBOC should have a viscosity 
similar to that of blood (4 cP) rather than the lower viscosities of most HBOC’s (~ 2 cP) (Tsai 
and Intaglietta, 2001). Lastly, the total Hb concentration should be sufficient to transport and 
deliver adequate O2 without affecting the cardiac output, and causing vasoconstriction due to 
excess O2 at the terminal arterioles (Ledingham,1989; Winslow, 2003). 
 
Although optimizing DO2 is beneficial, it is possible to have too much DO2 which may have 
adverse effects. In an in vivo study, hamsters with a P50 of 32 mmHg were infused with RBCs 
that had a slightly elevated P50 (37 mmHg) which increased DO2. But when the P50 was raised to 
60 mmHg, which off-loads more O2, the DO2 decreased due to vasoconstriction (Cabrales et al, 
2008). While DO2 may be improved through slightly higher P50, the best results are produced 
with lower P50 (Tsai et al, 2003). In 2008, Cabrales, Tsai and Intaglietta published an article 
where the P50 of RBCs was engineered to 10, 25, 45, 50 and 60 mmHg. These RBCs were 
transfused via hemodilution to mimic an anemic condition where the hematocrit was set to 18%. 
The findings supported their ‘Autoregulatory Theory’ in that higher O2 affinities enhanced 
microvascular function and DO2compared to higher P50 (Cabrales et al, 2008). In a similar 
experiment, they infused modified RBCs with low (10 mmHg) and high (50 mmHg) P50 into 
hamsters that had undergone a 50% blood volume reduction. After resuscitation, there was 
significant vasoconstriction, and a reduction in DO2, blood flow and capillary density in the high 
P50 group. While there was no significant difference in arteriolar PO2, the group with low P50 had 
higher tissue and venular PO2 (Villela et al, 2008). Based on these findings, increased O2affinity 
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appears to be beneficial since Hb does not unload its O2 in well oxygenated regions, but rather 
where PO2 is low. 
 
Theoretically, HBOCs are utilized in situations where DO2 has been compromised, i.e., traumatic 
and/or anemic conditions, and thus it is important that the O2 is delivered to the locations that 
need it the most. Controlling where O2 is delivered may be done via alterations in Hb P50. The 
concept of increased microvascular function due to low P50 challenges the current notion of 
efficacy as it relates to stored blood. According to most literature, the function of RBCs appears 
to be inversely proportional to storage time caused by a multitude of factors. One of the reasons 
for this is the decrease in 2,3-DPG of stored blood, which is depleted after 7 days. A reduction in 
2,3-DPG increases the affinity of Hb for O2 that is believed to impede O2 release and reduce 
microcirculatory O2 supply to the tissues (Ho, 2003). More specifically, the P50 of stored human 
blood shifts from 28 mmHg (Winslow et al, 1977) to 18 mmHg for blood that is completely 
absent of 2,3-DPG (Collins and Stechenberg, 1979). Based on the data presented by Winslow 
and colleagues, a decrease in P50 may compensate instead of deteriorate the quality of the blood 
like RBC deformability, altered RBC adhesiveness and aggregability which are observed with 
stored blood (Ho, 2003). 
 
The most current understanding of the ‘Autoregulation Theory’ is that arterioles between 20 to 
40 µm are the ones physiologically exposed to PO2 that is generally around the P50; hence, the 
PO2 region where half of the binding sites are occupied, and where the oxygen-dissociation 
curve is the steepest (Villela et al, 2008). Saltzman and co-workers have demonstrated that these 
arterioles have the densest adrenergic innervations (Saltzman et al, 1992), which may be 
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indicative of an O2 sensing area capable of channeling information to control blood flow and 
DO2 (Cabrales et al, 2004; Tsai et al, 2003). The importance of DO2 and the resulting 
vasoconstriction caused by too much O2 present i.e., high P50 or high concentration of cell-free 
Hb, is still a major factor (Cabrales et al, 2008). Furthermore, low P50 plays a central role in 
anemic and hemorrhagic conditions where O2 should be delivered to areas with low PO2 near the 
capillary circulation rather than larger arterioles (Cabrales et al, 2008; Villela et al, 2008). 
 
As mentioned earlier, the proposed mechanism of the observed vasoconstriction and increased 
MAP associated with the infusion of cell-free Hb is a controversial topic. There are many 
opinions about which theory is more logical and scientifically supported. One counter-argument 
against the ‘NO Scavenging Theory,’ besides the experiments where acellular Hb with similar 
NO reactivity causes different levels of vasoconstriction, is that biological systems whether 
human or mammalian have most likely been designed to rapidly clear cell-free Hb from the 
blood stream. Commonly seen with red cell lysis, the body will eliminate the extracellular Hb to 
prevent interference with vascular tone (Olson et al, 2003). For instance, cell-free tetramers 
quickly dissociate into dimers (Zhang et al, 1991) that bind to haptoglobin with high affinity, and 
are then transported out of the blood stream (Hargrove et al, 1997). Furthermore, dimers lose 
their hemin more readily than tetramers, and the resulting heme group is picked up by serum 
albumin and apohemopexin, and transported to the liver for recycling (Hargrove et al, 1997). The 
results indicate that cell-free Hb is easily degradable, and thus incapable to rapidly scavenge NO. 
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Therapeutic HBOCs 
HBOCs have undergone clinical development for the last few decades. While some 
products have been developed or updated, others have perished. Out of the HBOCs 
currently in development, Biopure Corporation is probably considered to be in the 
forefront. It produces two products, specifically Oxyglobin also known as HBOC-301, and 
Hemopure, or HBOC-201. Both solutions use bovine Hb that are polymerized with 
glutaraldehyde; however, there is a difference in the average molecular weight where 
HBOC-301 and HBOC-201 average 200 kDa and 250 kDa, respectively. Furthermore, 
there is also a distinction between the ratio of free tetramers and dimers to polymerized Hb 
in HBOC-301 and HBOC-201. For instance, HBOC-201 undergoes fractionation to remove 
smaller molecules and contains less than 2.5% Hb molecules with a molecular weight of 
less than 65 kDa, (Dubé et al, 2008) while HBOC-301 has up to 31% tetrameric and 
dimeric Hb (Rice et al, 2008). Oxyglobin has been approved for veterinary use by the FDA 
to treat anemia (Buehler and Alayash, 2008) and Hemopure has been approved to treat 
acute surgical anemia in South Africa since 2001 (Dubé et al, 2008). In the United States, 
Hemopure is currently in Phase III trial for use as a RBC substitute (Levy et al, 2002; 
Sprung, 2002), which is also the case for PolyHeme, an HBOC made by Northfield 
Laboratories Incorporated (Dimino and Palmer, 2007). PolyHeme is made from human Hb 
that has been polymerized with glutaraldehyde (Buehler and Alayash, 2008), and has a Hb 
concentration of 10g/dL (Carson et al, 2002), which is slightly lower than HBOC-201’s 13 
± 1 g/dL (Dubé et al, 2008). Sangart produces polyethylene glycol-modified human Hb 
(MalPEG-Hb) that has a lower Hb concentration of 4 g/dL (Wettstein, 2003). Lastly, Apex 
Bioscience produces a product made from human Hb that has been cross-linked with 
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pyridoxalated phosphate and conjugated with Polyoxoethylene (Buehler and Alayash, 
2008). 
 
Current Understanding of HBOC 
In the United States, HBOCs are classified as a biological product, and to ensure 
effectiveness and evaluate toxicity, they must be tested in a three-phase clinical trial 
process (Kim & Greenburg, 2004). Currently, Hemopure, which is also known as HBOC-
201, is in a Phase III clinical trial for use as a RBC substitute (Dimino & Palmer, 2007). 
HBOC-201 appears to do well as compared to previous HBOCs. For example, it does not 
seem to carry the two common side effects of HBOC infusion: vasoconstriction and acute 
renal failure, which traces back to the study of Amberson et al in 1949. Baylis (Baylis 
2006) looked into the long-term effect on kidney function and hypertension of HBOC-201 
in comparison to 13% human serum albumin (HSA). Although the acute response to the 
infusion was an increase in blood pressure and peripheral and renal vasoconstriction with 
HBOC-201, an overall decrease in blood pressure was observed with HSA. After 6 weeks 
of daily administration of HBOC-201 or HSA, there were similar effects on blood pressure 
and kidney activity as defined by glomerular filtration rate, level of proteinuria and 
glomerular pathology. Baylis concluded that “HBOC-201 had no long-term damaging 
effects on renal function or structure” (Baylis, 2006). 
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Purpose of Present Study 
The focus of this dissertation was to broaden the understanding of HBOC-201. A rat model 
was utilized in which two in vivo conditions were investigated: ‘Top-loading,’ and 
‘Hemorrhage and Resuscitation.’ HBOCs are associated with elevated MAP mediated 
through vasoconstriction, and therefore systemic parameters like MAP, HR, and pulse 
pressure were recorded in conjunction with microcirculatory measurements:  changes in 
vascular tone, interstitial PO2 and interstitial O2 consumption (VO2). The studies were 
supplemented with blood samples to record O2 saturation, Hb concentration, metHb, and 
lactate.  
 
There are two opposing theories that propose a mechanism to explain why HBOCs cause 
vasoconstriction and an increase in MAP. The ‘Autoregulation’ hypothesis states that 
vasoconstriction occurs through an elevation in PO2; to compensate for the change 
arterioles constrict to reduce flow and PO2. This response can presumably be reduced or 
eliminated primarily through an HBOC with a higher O2 affinity. The hypothesis also 
suggests that a product with a viscosity similar to that of blood (4 cP), instead of the 
common 2 cP for most HBOCs, would enhance HBOC performance. In Part I of the ‘Top-
loading’ study, two modified HBOC-201 products were tested to shed some insight on the 
‘Autoregulation’ hypothesis. One of the products was an HBOC-201 with a significantly 
higher O2 affinity (MP50), and the other HBOC was a modified Hemopure with higher O2 
affinity and a viscosity of 4 cP (LP50). Along with testing the ‘Autoregulation’ theory, 
HBOCs were infused with increasing doses to test whether there is a dose-dependent 
response. 
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The purpose of ‘Top-loading’ Part II was to test the response of HBOC-201-infused 
animals with increasing concentrations of nitroglycerin (NTG), which is a NO-donor, to 
provide some insight on the ‘NO Scavenging’ hypothesis. This hypothesis states that 
HBOCs cause vasoconstriction through the binding of nitric oxide (NO) found near the 
vessel wall of arterioles. NO is a vasodilator, and reducing the availability of NO causes 
vasoconstriction. The idea to test a NO-donor with HBOC originated from the curiosity of 
what would happen if NO levels were high enough to prevent vasoconstriction. 
 
Lastly, ‘Hemorrhage and Resuscitation’ experiments were conducted to observe the 
efficacy of HBOC-201 as a resuscitation fluid in comparison to an iso-oncotic non-O2 
carrying colloid or HBOC-201 with NTG. These pre-clinical results may reveal something 
new about HBOCs. 
 
Hypotheses: 
1. Animals receiving MP50 or LP50 will not have a lower MAP or less arteriolar 
constriction that HBOC-201. MP50 or LP50 will also not have a higher interstitial PO2 
than HBOC-201. 
 
2. HBOC-201 will increase MAP in a dose-dependent manner, but the interstitial PO2 will 
not display a dose-dependent response, because at baseline an animal should perform 
near the highest potential, and physiologically PO2 can only increase to a limited extent 
due to mechanisms that regulate tissue PO2. 
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3. HBOC-201 infused animals should display a dose-dependent response to NTG, and the 
changes will be apparent with MAP, but not in interstitial PO2. 
 
4. HBOC-201 is superior to colloids i.e. 5.9% human serum albumin, as determined by 
higher interstitial PO2 under conditions where hemoglobin concentration and blood 
volume are significantly compromised even though animals receiving HBOC-201 have 
greater vasoconstriction and higher MAP.  
 
5. The addition of NO-donors to HBOC-201 will significantly improve the outcome, i.e. 
decrease vasoconstriction and hypertension, and thus increase tissue oxygenation. 
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Materials and Methods 
Male Sprague-Dawley (SD) rats (Harlan, Indianapolis, IN) were maintained on regular 
laboratory rodent chow, and housed in the Virginia Commonwealth University animal 
facility in accordance with institutional guidelines. The rats were housed, two per cage, in 
plastic containers and under a 12/12 hour light/dark cycle in a climate-controlled room 
(temperature 20-230C and humidity 40-60%). A certified animal care technician ensured 
clean cages and access to food and water. The animal protocol was approved by the 
Institutional Animal Care and Use Committee (IACUC) of Virginia Commonwealth 
University, and was consistent with the National Institutes of Health (NIH) Guidelines for 
the Humane Treatment of Laboratory Animals and the American Physiological Society’s 
Guiding Principles in the Care and Use of Animals. 
 
Animal Weights 
Four animal groups were studied for the first part of the Top-loading study. The average 
weight in grams ± the standard error of mean for the four groups; 5.9% HSA, HBOC-201, 
MP50 and LP50, were 274 ± 11 (N = 9), 289 ± 9 (N = 8), 276 ± 17 (N = 7) and 313 ± 16 
(N = 8), respectively (Appendix: Animal Weight: Top-Loading Part I). In the second part 
of the Top-loading study, animals were divided into two parts: 5.9% HSA and HBOC-201, 
in which the weights were 275 ± 12 (N = 8) and 262 ± 7 (N = 12), respectively (Appendix: 
Animal Weight: Top-Loading Part II).  
 
In the ‘Hemorrhage and Resuscitation’ study, animals were categorized into three groups: 
5.9% HSA, HBOC-201, and HBOC-201 with NTG, but also divided into two studies, in 
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which those weighing around 270g were compared to those around 370g. In the lighter 
weight group, control animals average weight was 277 ± 10 g (N = 8), while the HBOC-
201 group averaged 285 ± 10 g (N = 8). Lastly, the HBOC-201 with NTG group averaged a 
weight of 256 ± 5 g (N = 6). For the heavier group, the control group was 357 ± 20 g (N = 
4), while the HBOC-201 group was 368 ± 19 g (N = 3), and lastly the HBOC-201 with 
NTG was 380 ± 30 g (N = 4) (Appendix: Animal Weight: Hemorrhage and Resuscitation). 
 
Anesthesia and Euthanasia 
Initially, a ketamine and acepromazine mixture (75 mg/kg of ketamine and 2.5 mg/kg of 
acepromazine, Henry Schein, Melville, NY) was injected intraperitoneally to sedate the 
animal. Once tranquillized, it was maintained in an anesthetized state through the 
experiment by continuous intravenous administration of Alfaxan (Alfaxalone 10 mg/ml, 
Abbeyvet Export LTD, North Yorkshire, England) via a cannulated right jugular vein using 
an infusion pump (Razel; Scientific Instruments Inc, Stamford, CT) set at a rate of 0.254 
ml/hr. At the end of the experiment, the rat was euthanized with 0.5 ml of Euthasol 
(pentobarbital 390 mg/ml and phenytoin 50 mg/ml, Delmarva Laboratories, Inc., 
Midlothian, VA). 
 
Experimental Fluids 
Phosphate Buffered Saline (PBS) 
PBS was applied to the spinotrapezius muscle to prevent desiccation, and was used for its 
pH buffering capacity instead of normal saline or lactated Ringer’s solution. PBS was also 
  
39
Page 39  
  
used in the top-loading experiments when stock solutions were made to lower the 
concentration of HBOC-201. 
 
Human Serum Albumin (HSA) 
5.9% Human Serum Albumin (25% HSA,ZLB Behring AG, Berne, Switzerland) was used 
as a control since it is iso-oncotic to blood and HBOC-201, but does not contain any Hb, 
and thus it is a non-O2 carrying agent. The 5.9% HSA solution was prepared by using 236 
parts of 25% HSA with 764 parts of normal saline. 
 
Hemoglobin Based Oxygen Carrier (HBOC) 
Different experimental solutions were used for this dissertation; however, the focus was 
around HBOC-201 (Hemopure; Biopure, Inc, Cambridge, MA). Hemopure, a 
glutaraldehyde-polymerized bovine Hb (13 ± 1 g/dL) has an average molecular weight of 
250 kDa, P50 of 40 ± 6mmHg, and a viscosity of 2.2 cP. It contains about 98% polymerized 
Hb, and less than 2.5% free tetramers. Furthermore, HBOC-201 has properties similar to 
human blood, where osmolality is from 290 to 310 milliosmole/kg, and oncotic pressure 
ranging between 25 to 27 mmHg (Dubé, 2008).  
In the first part of the top-loading study, HBOC-201 was used with the addition of two 
modified HBOC-201 products that were identical to Hemopure with the exception of 
altered viscosity and/or P50. For example, MP50 was a modified HBOC-201 solution with a 
higher O2 affinity (P50 = 18 mmHg), and LP50 also had a higher O2 affinity (P50 = 17 
mmHg) with the addition of a higher viscosity (4 cP) that is similar to blood. 
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Nitroglycerine (NTG) 
Other solutions were also used such as nitroglycerine (NTG;Nitrostat, Parke-Davis, New 
York, New York), which is a NO donor vasodilator that was either mixed with or following 
the infusion of HBOC-201.The NTG solution was prepared by dissolving a 0.4 mg tablet 
with 1 ml of PBS. 
 
Animal Preparation 
Prior to cannulations and surgical preparation of the spinotrapezius muscle, hair was 
removed from three locationswith clippers: between the clavicle and the mentum, on the 
ventral right thigh, and a rectangular area on the ventral thorax between the left upper and 
lower extremity (see Figures 1 and 2). Next, hair removal cream (Nair; Church and Dwight 
Co., Inc., Princeton, NJ) was applied and rubbing alcohol (Isopropyl Rubbing Alcohol; 
Food Lion LLC, Salisbury, NC) was used to ensure hair-free and clean surfaces. Upon hair 
removal, the animal was placed supine onto a temperature regulated heating pad to 
maintain body temperature between 36 and 37 0C (Golub and Pittman, 2003). 
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Figure 1:Animal prep - Ventral side 
 
 
 
Figure 2: Animal prep - Dorsal side 
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Tracheal and Vascular Cannulations 
Initially, the trachea was cannulated with a 3 cm piece of polyethylene tubing (PE-240; 
Clay Adams, Parsippany, NJ) to maintain a patent airway. Next, the jugular vein was 
cannulated with PE-90 tubing for infusion of hemodiluent, while the carotid artery was 
cannulated with PE-50 tubing for withdrawal of bloodrequired for the isovolemic 
hemodilution process.In addition, the carotid artery cannula was used to withdraw blood 
samples into heparinized 55 µl capillary tubes (Microhematocrit Capillary Tubes; Fisher 
Scientific, Pittsburgh, PA), which were used for measurements of arterial blood gases, i.e., 
PO2, PCO2and pH (ABL 705; Radiometer America, Westlake, OH) and hematocrit (OSM-
3 hemoximeter; Radiometer Medical ApS, Brønshøj, Denmark).Lastly, the femoral artery 
and vein were cannulated with PE-10 and PE-20 tubing, respectively. The femoral vein was 
cannulated for continuous administration of anesthetic, while the femoral artery was 
utilized to monitor mean arterial pressure using a pressure transducer (CyQ 103/301; Cyber 
Sense, Nicholasville, KY). 
Prior to cannulation, the cannulas were filled and flushed with heparinized saline, and, once 
cannulated, they were intermittently flushed to prevent or abolish clot formation in all 
vascular lines. The mixture consisted of 20 units of Heparin (Baxter, Deerfield, IL) per ml 
of 0.9% NaCl normal saline solution. 
 
Spinotrapezius Muscle Exteriorization 
The spinotrapezius muscle was used for this experiment for several reasons:  it is a thin 
(0.5-1.0 mm), superficial muscle suitable for transillumination; it has a relatively large 
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surface area of 5 x 1.5 centimeters; and its muscle fibers are oriented in parallel. In 
addition, the findings of this experiment may be translated to other skeletal muscles. 
The surgical preparation and exteriorization of the spinotrapezius muscle were similar to 
the original description by Gray (Gray 1973). Initially, a dorsal midline incision was made 
from the lumbar to the cervical region. Next, the underlying superficial connective tissue 
was removed with curved scissors to expose the spinotrapezius muscle. PBS was frequently 
applied to keep the tissues moist. In order to minimize damage to the spinotrapezius, a thin 
strap muscle located parallel to it was manipulated to exteriorize the spinotrapezius. The 
strap muscle was also sutured with 5-0 silk every centimeter to aid with the isolation of the 
spinotrapezius, and to secure the muscle in situ onto a thermostatic animal platform (see 
Figure 3) (Golub and Pittman, 2003). Once the lateral border with the strap muscle was 
freed, the other border was detached from the vertebral axis with a low-temperature cautery 
device (Gemini RS-300, Roboz Surgical Instruments Co., Rockville, MD), which was also 
used to minimize bleeding from the initial incision along the dorsal midline. Once 
detached, the border wassutured with 5-0 silk every centimeter. At this point, the animal 
was placedonto a thermostatic animal platform, and the spinotrapezius was held in place 
with sutures connected to the muscle (see Figure 4). Next, the muscle prep was covered in 
plastic film (Saran, Dow Corning, Midland, MI) to minimize desiccation and atmospheric 
gas exchange. Finally, the platform was transferred and secured to the objective for 
intravital microscopy studies. 
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Figure 3: Thermostatic animal platform 
 
 
 
Figure 4: Animal on platform, and spinotrapezius secured 
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Experiments 
In total, three different kinds of experiments were conducted during my stay in the Pittman 
Laboratory to broaden the understanding of HBOC-201 in-vivo at the microcirculation i.e. 
top-loading, hemodilution, hemorrhage and resuscitation. However, since the hemodilution 
studies were presented in part of my Master’s Thesis, I will not include it here. 
 
In short, the top-loading experiments were performed to link increasing concentrations or 
volumes with elevated responses in MAP, tissue oxygenation and vasoconstriction. Since 
we had modified HBOC-201 with varying O2 affinity and viscosity at our disposal, along 
with NTG as a NO-donor, we also wanted to test these products against the 
‘NOScavenging’ and ‘Autoregulation’ Theories. The iso-volemic studies were conducted 
to study the effect of an HBOC-201 and the iso-oncotic non-O2 carrier control solution 
under various stable RBC levels. The third study, which was the most difficult to complete 
due to devastating nature of severe hemorrhage, yet the most clinically relevant, was the 
hemorrhage and resuscitation study. For this protocol, we wanted to investigate the effects 
of different resuscitation fluids at various time points, and to study the significance of 
NTG. 
 
Top-loading 
The top-loading experiments were dividedinto two independent parts. In part I, HBOC-201 
(P50 = 40 mmHg), HBOC-201 (P50 = 18 mmHg) and HBOC-201(P50 = 17 mmHg)  with a 
higher viscosity (4 c.P) were infused with increasing volume to target a plasma Hb 
concentration of 1, 10, 100 and 300 µM.5.9% HSA was used as a volume control. 
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In part II, HBOC-201 (100 µM) was infused and followed by 0.1, 0.3, or 1.0 mg/kg of 
NTG.A volume control study was also completed, where 0.5 ml of 5.9% HSA wasinfused 
and then followed by 0.1, 0.3, or 1.0 mg/kg of NTG.  
 
Hemorrhage and Resuscitation 
The total blood volume was estimated by the equation below (Lee and Blaufox, 1985): 
 
BV (mL) = 0.06 x BW + 0.77 
 
Where, BV is blood volume in milliliters, and BW is body weight in grams. The 
hemorrhage protocol consisted of a 40% BV withdrawal followed by rest, and then 
resuscitation 30 minutes post hemorrhage. Blood was removed through a carotid artery at 
0.8 ml/min using a syringe pump (SP120P Syringe Pump; World Precision Instruments, 
Sarasota, FL), and 30 minutes after the initiation of hemorrhage an equal volume was 
resuscitated through a jugular vein at 0.4 ml/min. Thus in a 300 g rat, 7.5 ml of blood 
would be withdrawn over 9 minutes, and infused just under 19 minutes. 
 
The resuscitation fluids were 5.9% HSA, HBOC-201, and HBOC-201 with NTG. 
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Instruments and Techniques 
All of the data collected was dependent on the surgical tools, microscopes, 
infusion/withdrawal syringe pump and different equipment including Biopac, which was 
used to monitor MAP, pulse pressure and HR, but also OSM-3 hemoximeter, which was 
used to measure metHb, %O2 saturation, Hb concentration, etc. Among the instruments 
required, a few of them were more important or unique, and they will therefore be 
presented in more detail. 
 
Phosphorescence Quenching Microscopy (PQM) 
Interstitial PO2 readings were acquired from the spinotrapezius muscle using 
phosphorescence quenching microscopy (PQM), which is a non-invasive optical technique 
that measures PO2 (Vanderkooi et al, 1987; Torres Filho et al, 1994). An O2 sensitive probe 
palladium meso-tera-(4-carboxyphenyl)-porphyrin (Pd-MTCPP; Oxygen Enterprises, 
Philadelphia, PA) bound to bovine serum albumin (BSA; Fraction V, Sigma, St. Louis, 
MO) was prepared and topically applied to the surface of the tissue as described in (Golub 
et al, 2007). After application, a transparent O2 impermeable film was applied to the 
preparation to prevent desiccation, and we also let the animal sit for approximately 45 
minutes to allow the probe to diffuse into the interstitium. 
 
The PQM technique is based on the principle that a molecule can be excited by flashing it 
with a light source that consequently elevates the energy state of that molecule. However 
over time, the energy state is returned to the ground state through the release of energy that 
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is normally in the form of light. This phenomenon is known as phosphorescence, and 
explains part of PQM. Quenching describes the transfer of energy to other molecules 
through collision, and therefore a reduction in time to reach the ground state. In PQM, O2 is 
the principal quenching agent, and thus, its concentration can be derived through this 
technique. The transfer of energy to O2 causes a decrease in the duration of 
phosphorescence decay, and therefore analyzing the rate of phosphorescence decay can be 
related to the partial pressure of O2 (PO2).Interstitial PO2 was derived from the application 
of the Stern-Volmer equation to a situation with a non-uniform distribution of O2 (Golub et 
al, 1997): 
 
Equation 1: 
I(t) = I(0)exp[ - (k0 + kqM)t ]sin(h)(kqδt)/(kqδt) + Aexp[ - t/T ] + B 
 
where t is the time (µs) of phosphorescence decay, I(t) is the magnitude in volts of the 
phosphorescence signal, I(0) is the magnitude in volts of the phosphorescence signal at t = 
0, k0is the phosphorescence decay rate in the absence of oxygen, kq is the quenching 
coefficient, M is the mean PO2 in mmHg, δ is the half-width of the PO2 distribution, A is 
the magnitude of the fast-excitation transient in volts, T is the lifetime (µs) of the fast post-
excitation transient, and B is the baseline offset. The values for constants k0and kq, 18.3x10-
4
µs-1 and 3.06x10-4µs-1mmHg-1, respectively, were determined by Zheng et al. (Zheng, 
1996). 
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The phosphorescence signal was collected by the objective of the microscope and sent to 
an analog-to-digital converter (SCB-68, National Instruments, Austin, TX), which was 
connected to a personal computer. To excite the probe and measure the interstitial PO2 in 
an area of 276 µm in diameter, the tissue preparation was flashed with a xenon lamp (FX-
249, EG%G Optoelectronics, Salem, MA) with an output of 0.5 Joules per 3 µs flash at a 
rate of 1 Hertz (Hz). To prevent the signal from exceeding the maximal input (10 volts), 
which would saturate the analog-to-digital converter, an oscilloscope (model 72-3055, 
Tenma Test Equipment, Springboro, OH) was used. 
 
Data acquisition was accomplished via a custom computer program using Lab View and 
designed by A. S. Golub (see Figure 5). The signals from the analog-to-digital converter 
were sampled at a rate of 200 kHz. A total of 400 points were collected for each curve, and 
were analyzed using Equation 1 above. 
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Figure 5: Data acquisition software 
 
400 points were collected for each curve. Signal-to-noise ratios seen as yellow on the 
phosphorescence decay curve (top right) were drawn with a continuous line fit (pink). After 
analysis using Equation 1, interstitial PO2 was calculated and plotted over time (bottom 
left). 
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Dual-Stage Stop-Flow Device 
The stop-flow device, which was designed by A. S. Golub to determine tissue O2 
consumption following arrest of blood flow, was utilized in this experiment. Plastic food 
wrap (Costco Wholesale Corp., Seattle, WA) was secured over the objective between a 
rubber fitting, which was placed around the objective, and a gasket (see Figures 6 - 8). The 
plastic film was a transparent bag that was inflated to arrest blood flow in the desired area, 
and deflated to restore perfusion of the ischemic tissue. The bag was inflated and deflated 
via a pressure-generating pump that was set to either maintain a constant 120 mmHg of 
pressure (ON) or 5 mmHg (OFF). The lower pressure, which was slightly above 
atmospheric pressure, was found to be very important in eliminating a thin fluid layer 
between the muscle and the plastic film, which consequently improved the noise-to-signal 
ratio. The film was elastic enough to endure the pressure and stretch cycle, yet transparent 
enough not to interfere with the use of the objective. In order to prevent friction between 
the bag and the Saran film placed on top of the spinotrapezius, a clear liquid lubricant (KY 
Touch Massage™, Personal Products Company, Division of McNeil-PPC, Inc., Skillman, 
NJ) was applied. The purpose of this device was to apply enough pressure quickly (1-2 
seconds) to arrest blood flow, and to release the applied pressure instantaneously. 
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Figure 6: Layout of “bag” without plastic film 
 
A rubber grommet (3) was placed around a 20X objective. A needle (1) with a blunt tip 
was inserted carefully through the rubber fitting, so as not to puncture the plastic film, 
which was then placed on top. Hot glue (4) was placed on the bottom of the rubber fitting 
to maintain 120mmHg of pressure upon inflation, and to prevent air leakage. Lastly, once 
the plastic film was placed around the objective, the gasket (2) was placed over the film 
and tightly secured into the groove of the rubber fitting. 
 
 
 
Figure 7: Stop-flow device OFF 
Figure 8: Stop-flow device ON 
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VO2 Measurements 
The oxygen consumption rate (VO2) was derived using the interstitial PO2 recordings when 
the Stop-Flow device was activated. When the bag was inflated, the blood flow was 
arrested and PO2 decreased rapidly. The decrease in PO2 per unit time (in seconds) was 
plotted and found to have a constant slope, which was calculated and used as a measure of 
the rate of change in interstitial PO2. In addition to the rate of change in interstitial PO2, the 
oxygen solubility (αO2) of the interstitium is required to calculate VO2. For the conditions 
of this study αO2 had the constant value 1.745 ml x kg-1 x mmHg-1 (Golub et al, 2005), in 
which the constant included the unit conversion from seconds to minutes. Therefore the 
units of VO2 were presented as ml O2 x kg-1 x mmHg-1.The oxygen consumption was 
calculated as: 
 
Equation 2: 
VO2 = – αO2 x rate of change in PO2 
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Experimental Protocol 
Once the surgical procedure was completed, the animal was secured onto the platform, the 
probe was applied for approximately 45 minutes, and then the intravital microscopy studies 
began. Initially, blood samples were collected to establish baseline hematocrit and blood 
PO2, CO2, pH, Hb concentration, metHb, O2 saturation, etc. Prior to interstitial PO2 
measurements, the spinotrapezius muscle was explored microscopically to find areas with 
clear views of the microvasculature that would be good sites for measurements. The sites 
chosen were areas close to larger arterioles, i.e., feed, arcade and transverse arterioles. It 
was important that those sites were located near “landmarks,” i.e., bifurcations and turns of 
arterioles, since repeat measurements of the same sites were crucial for consistency. The 
procedures beyond this point would be unique to one specific protocol, and will therefore 
be discussed separately. 
 
Top-loading 
As mentioned earlier, the top-loading protocol was divided into two parts. Part I was 
designed to identify a dose-response of HBOC-201, while Part II was used to study a dose-
response for NTG. 
 
For both Part I and II, we used six sites where four were allocated for interstitial PO2 
measurements, while two sites, which were always located down-stream, were used to 
measure VO2. Before any measurements were taken, two heparinized micro-hematocrit 
capillary tubes were collected to derive Hct, and parameters gathered through OSM-3 
hemoximeter. Once the baseline arteriolar diameter, PO2 and VO2 recordings were 
  
55
Page 55  
  
collected, either HBOC-201 or 5.9% HSA was infused. For Part I, the target plasma 
concentration of Hemopure was 1, 10, 100 and 300 µM for doses 1, 2, 3 and 4, 
respectively. The volumes for doses 1 through 4 was close to 0.1, 0.1, 0.5 and 1.5 ml, and 
was therefore the volumes given for our control. In other words, dose 1 was given after 
baseline measurements, which either contained 1 µM HBOC-201, or 0.1 ml of 5.9% HSA. 
After a few minutes, we returned to the same six sites to measure PO2, VO2, and arteriolar 
diameter. The cycle then repeated with dose 2, 3 and 4, which was the end of the protocol. 
Lastly, a final blood sample was drawn for the OSM-3 hemoximeter to compare the final 
values with baseline. 
 
In Part II, we only used two doses. After baseline measurements, 100 µM of HBOC-201 
(P50 = 40 mmHg) or 0.5 ml of 5.9% HSA was infused. Upon the first dose, PO2, VO2, and 
arteriolar diameter were recorded and then dose 2 followed, which contained one of three 
concentrations: 0.1, 0.3, or 1.0 mg/kg NTG. After the NTG dose, PO2, VO2, and arteriolar 
diameter were collected once again, and lastly, blood samples were taken to the OSM-3 
hemoximeter. 
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Hemorrhage and Resuscitation 
Up to five locations were selected for this study, and a three-minute PQM protocol was 
implemented for each site to collect both interstitial PO2 and VO2 measurements. The first 
minute established a baseline, then the bag of the dual stage stop flow device was inflated 
for a minute to arrested blood flow, and the last minute was designated for recovery time. 
Following the baseline interstitial PO2 measurements, the diameters of nearby arterioles 
were recorded. Blood samples were collected in heparinized micro-hematocrit capillary 
tubes to determine the hematocrit level and collect information such as systemic Hb 
concentration, %Hb saturation, %metHb, %CarboxyHb, and volume %O2 content using 
OSM-3 Hemoximeter. When all baseline measurements were completed, 40% of the total 
blood volume was withdrawn at 0.8 ml/min.  
 
When the hemorrhage was complete, the same sequence of data collected for baseline was 
repeated: interstitial PO2 was first collected, then arteriolar diameters, and lastly blood 
samples were taken for analysis.  
 
Resuscitation was initiated 30 minutes after the start of hemorrhage at a rate of 0.4 ml/s, 
and would take about 20 minutes to complete. This is the reason why the data points 
collected after hemorrhage that signifies the result of resuscitation are marked R20. 
 
The same order of data collection (interstitial PO2 followed by arteriolar diameters, and 
lastly blood samples) was also performed 60 (R60) and 120 (R120) minutes past the 
beginning of resuscitation.  
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Statistical Analysis 
Data are presented as means ± standard error unless otherwise noted. Statistical analysis 
was performed with Origin 7.0 (OriginLab, North Hampton, MA). One Way Analysis of 
Variance (ANOVA) and Tukey post-hoc was conducted to assess statistical significance 
between doses of a given solution, and to find significance between solutions in a given 
dose. Student’s t-test was used to determine the statistical significance between baseline 
and final OSM-3 values. Statistical significance was defined as p < 0.05. 
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Results 
The results section will be presented in the following order: ‘Top-loading Part I,’ followed 
by ‘Part II,’ and lastly ‘Hemorrhage and Resuscitation.’ 
 
Top-loading Part I 
Interstitial PO2 
ISF PO2 was measured at baseline, and after doses 1 through 4. A one-way ANOVA was 
initially used to test for statistical significance, and in the event that there was significance, 
a post hoc Tukey study was then done. 
 
The volume control iso-oncotic 5.9% HSA solution did not demonstrate a significant 
increase from baseline (58 ± 2 mmHg; N = 21) with the first two 0.1 ml doses, which 
resulted in PO2 levels of 60 ± 2 mmHg (N = 21) and 62 ± 3 mmHg (N = 21), respectively. 
However, ISF PO2 did increase from baseline with dose 3 (~0.5 ml) and dose 4 (~1.5 ml) to 
68 ± 3 mmHg (N = 21) and 72 ± 4 mmHg (N = 21), respectively (Figure 9). 
 
Both HBOC-201 and MP50 (HBOC-201 with a higher O2 affinity, P50 = 18 mmHg) 
increased ISF PO2 starting from the first dose (1 µM) and maintained an elevated level 
through all of the doses, the only exception observed with dose 3 of MP50, in which the 
value was not significantly different from baseline (Figures 10 and 11). With HBOC-201, 
the animals started with a baseline ISF PO2 of 58 ± 2 mmHg (N = 14); however, the PO2 
was increased significantly with all four doses compared to baseline. 1, 10, 100 and 300 
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µM doses of HBOC-201 produced PO2 values of 65 ± 4 mmHg (N = 14), 66 ± 5 mmHg (N 
= 14), 67 ± 3 mmHg (N = 14) and 66 ± 4 mmHg (N = 14), respectively (Figure 10).  
 
Animals treated with MP50 started with a baseline PO2 of 57 ± 2 mmHg (N = 21), and it 
was raised to 64 ± 3 mmHg (N = 21) with 1 µM. Doses 2 (10 µM) and 4 (300 µM) of 
MP50 animals produced a significantly higher PO2 of 69 ± 3 (N = 21) and 66 ± 4 (N = 21) 
mmHg, respectively, compared to baseline. However, with dose 3 (100 µM) the PO2 was 
65 ± 4 mmHg (N = 21), and it was not statistically different from baseline (Figure 11). 
Presumably, dose 3 would be significant with a greater N value, since both the lower and 
the higher concentrations yielded a statistical significance. 
 
Animals treated with LP50 started with a baseline of 67 ± 1 mmHg (N = 28) and did not 
demonstrate a significant difference with doses 1 (69 ± 2 mmHg (N = 21)) and 2 (66 ± 3 
mmHg (N = 21)). However, doses 3 (60 ± 4 mmHg (N = 21)) and 4 (56 ± 4 mmHg (N = 
21)) produced a significantly lower ISF PO2 compared to baseline, while being 
insignificant from each other. 
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Figure 9: Top-loading - Part I - ISF PO2 - 5.9% HSA 
BL = 0 ml of HSA, D1 = 0.1 ml of HSA, D2 = 0.1 ml of HSA, D3 = 0.5 ml of HSA, and 
lastly D4 = 1.5 ml of HSA.  
* = significantly different from baseline. (p < 0.05) 
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Figure 10: Top-loading - Part I - ISF PO2 - HBOC-201 
BL = 0 µM of HBOC-201, D1 = 1 µM of HBOC-201, D2 = 10 µM of HBOC-201, D3 = 
100 µM of HBOC-201, and lastly D4 = 300 µM of HBOC-201.  
* = significantly different from baseline. (p < 0.05) 
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Figure 11: Top-loading - Part I - ISF PO2 - MP50 
BL = 0 µM of MP50, D1 = 1 µM of MP50, D2 = 10 µM of MP50, D3 = 100 µM of MP50, 
and lastly D4 = 300 µM of MP50.  
* = significantly different from baseline. (p < 0.05) 
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Figure 12: Top-loading - Part I - ISF PO2 - LP50 
BL = 0 µM of LP50, D1 = 1 µM of LP50, D2 = 10 µM of LP50, D3 = 100 µM of LP50, 
and lastly D4 = 300 µM of LP50.  
* = significantly different from baseline. (p < 0.05) 
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Arteriolar Diameter 
The diameters of arterioles near the sites of PO2 and VO2 measurements were recorded at 
five time points: baseline and after doses 1 through 4. We targeted arcade arterioles with 
diameters ranging between 40 to 80 µm. One-way ANOVA was used to determine 
significance between baseline and the four doses. 
 
All of the data at any given dose was not statistically significant compared to baseline for 
5.9% HSA (Figure 13), HBOC-201 (Figure 14), MP50 (Figure 13), and LP50 (Figure 16). 
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Figure 13: Top-loading - Part I - Arteriolar Diameter - HSA 
BL = 0 ml of HSA, D1 = 0.1 ml of HSA, D2 = 0.1 ml of HSA, D3 = 0.5 ml of HSA, and 
lastly D4 = 1.5 ml of HSA.  
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Figure 14: Top-loading - Part I - Arteriolar Diameter - HBOC-201 
BL = 0 µM of HBOC-201, D1 = 1 µM of HBOC-201, D2 = 10 µM of HBOC-201, D3 = 
100 µM of HBOC-201, and lastly D4 = 300 µM of HBOC-201.  
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Figure 15: Top-loading - Part I - Arteriolar Diameter - MP50 
BL = 0 µM of MP50, D1 = 1 µM of MP50, D2 = 10 µM of MP50, D3 = 100 µM of MP50, 
and lastly D4 = 300 µM of MP50.  
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Figure 16: Top-loading - Part I - Arteriolar Diameter - LP50 
BL = 0 µM of LP50, D1 = 1 µM of LP50, D2 = 10 µM of LP50, D3 = 100 µM of LP50, 
and lastly D4 = 300 µM of LP50.  
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Mean Arterial Pressure 
MAP was continuously recorded throughout the experiment, but 60 second-averages (pre-
dose and post-dose) were made before and after each dose. Statistical significance was 
measured between the pre- and post- values of each dose through paired t-tests. 
 
With the volume control solution of 5.9% HSA there was no significant change between 
the pre- and post- values of doses 1 and 2. However, there was a significance with dose 3 
where MAP increased from 100 ± 3 mmHg (N = 8) to 109 ± 3 mmHg (N = 8), and with 
dose 4, in which the pressure rose from 104 ± 5 mmHg (N = 8) to 121 ± 5 mmHg (N = 8) 
(Figure 17). 
 
All of the HBOCs produced an elevation of MAP. Significant changes were observed in 
HBOC-201 in doses 1 through 3. In dose 1, MAP increased from 95 ± 5 mmHg (N = 6) to 
106 ± 6 mmHg (N = 6), and with dose 2 MAP increased from 101 ± 10 mmHg (N = 3) to 
124 ± 7 mmHg (N = 3). With dose 3, it increased from 111 ± 11 mmHg (N = 3) to 142 ± 10 
mmHg (N = 6). Although there was an increase in the mean values of MAP with dose 4, 
there was no statistical difference between 138 ± 11 mmHg (N = 3) and 149 ± 7 mmHg (N 
= 3) (Figure 18). 
 
With MP50, there was a statistical significance between all pre- and post- doses with the 
exception of dose 2. The MAP of pre- and post- doses 1, 2, 3 and 4 was 90 ± 6 mmHg (N = 
6) and 96 ± 6 mmHg (N = 6), 96 ± 8 mmHg (N = 6) and 103 ± 8 mmHg (N = 6), 95 ± 6 
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mmHg (N = 6) and 137 ± 8 mmHg (N = 6), and 128 ± 8 mmHg (N = 6) and 141 ± 6 mmHg 
(N = 6), respectively (Figure 19).  
 
LP50, which is the HBOC-201 with a higher viscosity, produced statistical significance 
compared to baseline through all of the doses. The MAP of pre- and post- doses 1, 2, 3 and 
4 was 93 ± 4 mmHg (N = 8) and 113 ± 4 mmHg (N = 8), 95 ± 4 mmHg (N = 8) and 138 ± 
3 mmHg (N = 8), 112 ± 5 mmHg (N = 8) and 149 ± 4 mmHg (N = 8), and 137 ± 5 mmHg 
(N = 8) and 160 ± 5 mmHg (N = 8), respectively (Figure 20). 
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Figure 17: Top-loading - Part I - MAP - HSA 
Dose 1 = 0.1 ml of HSA, Dose 2 = 0.1 ml of HSA, Dose 3 = 0.5 ml of HSA, and lastly 
Dose 4 = 1.5 ml of HSA. MAP was compared between pre and post values of a given dose.  
* = significantly different from pre-dose. (p < 0.05) 
  
72
Page 72  
  
 
 
Figure 18: Top-loading - Part I - MAP - HBOC-201 
Dose 1 = 1 µM of HBOC-201, Dose 2 = 10 µM of HBOC-201, Dose 3 = 100 µM of 
HBOC-201, and lastly Dose 4 = 300 µM of HBOC-201. MAP was compared between pre 
and post values of a given dose. 
* = significantly different from pre-dose. (p < 0.05) 
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Figure 19: Top-loading - Part I - MAP - MP50 
Dose 1 = 1 µM of MP50, Dose 2 = 10 µM of MP50, Dose 3 = 100 µM of MP50, and lastly 
Dose 4 = 300 µM of MP50. MAP was compared between pre and post values of a given 
dose. 
* = significantly different from pre-dose. (p < 0.05) 
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Figure 20: Top-loading - Part I - MAP - LP50 
Dose 1 = 1 µM of LP50, Dose 2 = 10 µM of LP50, Dose 3 = 100 µM of LP50, and lastly 
Dose 4 = 300 µM of LP50. MAP was compared between pre and post values of a given 
dose. 
* = significantly different from pre-dose. (p < 0.05) 
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Delta MAP 
Delta MAP, which is described as the pressure difference in mmHg between post- and pre- 
dose values, was plotted. Two-way ANOVA and Tukey post hoc studies were done to 
identify any statistical significance between doses of a given solution, and the significance 
between solutions within a given dose. 
 
In the HSA group, the 4th dose with a delta MAP of 17 ± 5 mmHg (N = 8) was statistically 
significant from doses 1 (5 ± 1 mmHg (N = 8)) and 2 (2 ± 1 mmHg (N = 5)), while it was 
not different from dose 3 (10 ± 2 mmHg (N = 8)); although, dose 3 was not significant 
from doses 1 and 2 (Figure 21). 
 
The delta MAP for the 3rd dose (30 ± 1 mmHg (N = 3)) for animals treated with HBOC-
201 was significantly different from doses 1 (13 ± 5 mmHg (N = 6)) and 4 (11 ± 6 mmHg 
(N = 3)), while not different from dose 2 (24 ± 4 mmHg (N = 3)). Doses 1 and 4 were not 
significantly different from dose 2 (Figure 22). 
 
For animals treated with MP50, doses 1 (6 ± 2 mmHg (N = 6)), 2 (9 ± 3 mmHg (N = 5)) 
and 4 (13 ± 2 mmHg (N = 6)) were not significant from one another, but they were all 
different compared to dose 3 (41 ± 4 mmHg (N = 6)) (Figure 23). 
 
The delta MAP values of LP50 were not statistically significant between doses 1 through 4 
(Figure 24). 
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Figure 25 displays the statistical analysis done between the solutions of a given dose. In 
doses 1 and 2, HSA and MP50 were similar to each other yet significantly lower than 
LP50, while HBOC-201 was not significantly different from HSA, MP50 and LP50. For 
dose 3, HSA is statistically different from HBOC-201, MP50 and LP50, while HBOC-201, 
MP50 and LP50 are insignificant from each other. With the last dose, there is no significant 
difference of delta MAP between any groups. 
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Figure 21: Top-loading - Part I - Delta MAP - HSA 
Doses 1 and 2 had delta MAPs that were significantly lower than dose 4. There was no 
other significance observed. 
4 = significantly different from dose 4. (p < 0.05) 
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Figure 22: Top-loading - Part I - Delta MAP - HBOC-201 
Doses 1 and 4 had a delta MAP that was significantly lower than dose 3. There was no 
other significance observed. 
3 = significantly different from dose 3. (p < 0.05) 
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Figure 23: Top-loading - Part I - Delta MAP - MP50 
Dose 3 caused a delta MAP that was significantly higher than dose 1, 2 and 4. There was 
no other significance observed. 
3 = significantly different from dose 3. (p < 0.05) 
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Figure 24: Top-loading - Part I - Delta MAP - LP50 
There was no statistical significance between the delta MAPs for any given dose. 
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Figure 25: Top-loading - Part I - Delta MAP - Combined 
 
With dose 1, there is a significant difference between HSA and LP50, and MP50 and LP50. 
 
 
LP50 = significantly different from LP50. (p < 0.05) 
MP50 = significantly different from LP50. (p < 0.05) 
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Pulse Pressure 
PP was continuously recorded with Biopack. PP was compared before and after each dose 
for doses 1 through 4. Statistical significance was measured between the pre and post 
values of each dose with a paired t-test. 
 
Pulse pressure did not change for HSA between pre and post doses until dose 4, where it 
increased from 43 ± 4 mmHg (N = 6) to 48 ± 4 mmHg (N = 6) (Figure 26). 
 
There was no statistical significance between any of the pre and post doses of HBOC-201 
(Figure 27), and although the results with MP50 ware similar to HBOC-201, there was a 
statistical significance between pre and post dose 2 where PP increased from 37 ± 6 mmHg 
(N = 6) to 39 ± 6 mmHg (N = 6) (Figure 28). Presumably, the significance will dissolve 
with a higher N value, because the means are very close to each other, and the errors bars 
are clearly over-lapping.  
 
In the LP50 group, the PP increased significantly with doses 2 and 4 from 57 ± 4 mmHg (N 
= 8) to 66 ± 2 mmHg (N = 8) and 61 ± 2 mmHg (N = 8) to 77 ± 4 mmHg (N = 8), 
respectively (Figure 29). Although there was no significance with dose 3, in which the pre-
dose value was 61 ± 3 mmHg (N = 8) and the post-dose value was 68 ± 2 mmHg (N = 8), 
the p value was 0.00501. Therefore, adding one to two animals may demonstrate 
significance with dose 3. 
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Figure 26: Top-loading - Part I - Pulse Pressure - HSA 
Dose 1 = 0.1 ml of HSA, Dose 2 = 0.1 ml of HSA, Dose 3 = 0.5 ml of HSA, and lastly 
Dose 4 = 1.5 ml of HSA. PP was compared between pre and post values of a given dose.  
* = significantly different from pre-dose. (p < 0.05) 
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Figure 27: Top-loading - Part I - Pulse Pressure - HBOC-201 
Dose 1 = 1 µM of HBOC-201, Dose 2 = 10 µM of HBOC-201, Dose 3 = 100 µM of 
HBOC-201, and lastly Dose 4 = 300 µM of HBOC-201. MAP was compared between pre 
and post values of a given dose. 
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Figure 28: Top-loading - Part I - Pulse Pressure - MP50 
Dose 1 = 1 µM of MP50, Dose 2 = 10 µM of MP50, Dose 3 = 100 µM of MP50, and lastly 
Dose 4 = 300 µM of MP50. MAP was compared between pre and post values of a given 
dose. 
* = significantly different from pre-dose. (p < 0.05) 
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Figure 29: Top-loading - Part I - Pulse Pressure - LP50 
Dose 1 = 1 µM of LP50, Dose 2 = 10 µM of LP50, Dose 3 = 100 µM of LP50, and lastly 
Dose 4 = 300 µM of LP50. MAP was compared between pre and post values of a given 
dose. 
* = significantly different from pre-dose. (p < 0.05) 
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Heart Rate 
HR was continuously recorded throughout the experiment, but 60 seconds-averages (pre-
dose and post-dose) were made before and after each dose. Statistical significance was 
measured between the pre and post values of each dose with a paired t-test.  
 
For the volume control 5.9% HSA, the HR only increased significantly with the last dose of 
1.5 ml, in which it rose from 372 ± 16 bpm (N = 6) to 386 ± 13 bpm (N = 6) (Figure 30). 
 
The HR did not change significantly from post to pre dose with HBOC-201 (Figure 31), 
MP50 (Figure 32), and LP50 (Figure 33). 
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Figure 30: Top-loading - Part I - HR –HSA 
BL = 0 ml of HSA, D1 = 0.1 ml of HSA, D2 = 0.1 ml of HSA, D3 = 0.5 ml of HSA, and 
lastly D4 = 1.5 ml of HSA.  
* = significantly different from pre-dose. (p < 0.05) 
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Figure 31: Top-loading - Part I - HR - HBOC-201 
BL = 0 µM of HBOC-201, D1 = 1 µM of HBOC-201, D2 = 10 µM of HBOC-201, D3 = 
100 µM of HBOC-201, and lastly D4 = 300 µM of HBOC-201.  
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Figure 32: Top-loading - Part I - HR - MP50 
BL = 0 µM of MP50, D1 = 1 µM of MP50, D2 = 10 µM of MP50, D3 = 100 µM of MP50, 
and lastly D4 = 300 µM of MP50.  
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Figure 33: Top-loading - Part I - HR - LP50 
BL = 0 µM of LP50, D1 = 1 µM of LP50, D2 = 10 µM of LP50, D3 = 100 µM of LP50, 
and lastly D4 = 300 µM of LP50.  
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Blood Gases 
Blood samples were collected via the carotid artery and collected into heparinized capillary 
tubes at baseline and after the experiment. The blood was analyzed through an OSM-3 
machine, in which five variables were collected: Total Hemoglobin (g/dl), Oxygen 
Saturation (%), Carboxyhemoglobin (%), Methemoglobin (%), and Oxygen Content (ml 
O2/dl). 
 
Total Hemoglobin (g/dl) 
The Hb concentration before and after the experiment changed and depended on the fluid 
infused. When the colloid 5.9% HSA was infused, the mean decreased from 12.9 ± 0.2 g/dl 
(N = 6) to 12.4 ± 0.3 g/dl (N = 6); however, this is not a significant change. To the 
contrary, there was a significant increase in total Hb with all HBOC products. HBOC-201 
produced an increase from 12.8 ± 0.1 g/dl (N = 6) to 13.8 ± 0.2 g/dl (N = 6), and MP50 
raised the levels from 13.7 ± 0.5 g/dl (N = 4) to 14.7 ± 0.4 g/dl (N = 4). LP 50 caused an 
elevation from 14.3 ± 0.4 g/dl (N = 5) to 15.4 ± 0.3 g/dl (N = 5) (Figure 34). 
 
Oxygen Saturation (%) 
The baseline O2 saturation was about 99% for all of the animals. The final value which was 
collected after the last dose was only significantly lower in the MP50 animals, where the 
values decreased form 99.4 ± 1.0 % (N = 5) to 92.4 ± 2.4 % (N = 5) (Figure 35). 
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Oxygen Content (ml O2/dl) 
O2 content decreased with 5.9% HSA (17.0 ± 0.2 to 15.9 ± 0.4), remained unchanged with 
HBOC-201 (16.9 ± 0.2 to 16.3 ± 1.0) and MP50 (17.4 ± 1.0 to 17.8 ± 0.7), and increased 
with LP50 (18.1 ± 0.5 to 19.3 ± 0.4) (Figure 36).  
 
Methemoglobin (%) 
MetHb remained unchanged with 5.9% HSA (0.28 ± 0.04 to 0.42 ± 0.08), but increased 
with HBOC-201 (0.37 ± 0.06 to 0.67 ± 0.18), MP50 (0.22 ± 0.13 to 0.98 ± 0.13), and LP50 
(0.8 ± 0.12 to 1.36 ± 0.25) (Figure 37). 
 
Carboxyhemoglobin (%) 
HbCO was not significantly altered with 5.9% HSA (3.9 ± 0.1 to 3.8 ± 0.2), MP50 (4.0 ± 
0.09 to 3.8 ± 0.1), and LP50 (4.0 ± 0.09 to 3.8 ± 0.16). However, it decreased with HBOC-
201 (4.0 ± 0.08 to 3.5 ± 0.2) (Figure 38). 
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Figure 34: Top-loading - Part I - Total Hb 
Volume control 5.9% HSA did not change the total Hb concentration, but HBOC-201, 
MP50 and LP50 did increase total Hb significantly from final to baseline concentrations. 
* = significantly different from baseline. (p < 0.05) 
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Figure 35: Top-loading - Part I – O2 Saturation 
MP50 was the only solution that displayed a significant reduction in O2 saturation. 
* = significantly different from baseline. (p < 0.05) 
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Figure 36: Top-loading - Part I – O2 Content 
There was a decrease in O2 content from baseline to final values of HSA, but no changes in 
HBOC-201 and MP50. However, there was significant increase with LP50. 
* = significantly different from baseline. (p < 0.05) 
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Figure 37: Top-loading - Part I - MetHb 
MetHb was unchanged with 5.9% HSA infusion, but increased with all HBOC-201, MP50 
and LP50. 
* = significantly different from baseline. (p < 0.05) 
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Figure 38: Top-loading - Part I - HbCO 
There was no significant change in HbCO fir the HSA, MP50 and LP50 animals, but there 
was a significant decrease with HBOC-201. 
* = significantly different from baseline. (p < 0.05) 
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Top-loading Part II 
Interstitial PO2 
ISF PO2was measured at baseline and after either a 0.5 ml of 5.9% HSA (volume control) 
or 100 µM (~0.5 ml) HBOC-201 dose. A third PO2 measurement was taken after a NTG 
dose of 0.1, 0.3, or 1.0 mg/kg. Statistical analysis utilized a one-way ANOVA followed 
with Tukey post hoc test if significance was detected. 
 
ISF PO2 did not change significantly from baseline with either 5.9% HSA or HBOC-201. 
Addition of NTG did not change ISF PO2 at doses 0.1 or 0.3 mg/kg for both HSA and 
HBOC-201 animals. However, the largest NTG dose of 1.0 mg/kg caused a significant 
reduction in ISF PO2 for both HSA (Figure 41) and HBOC-201 (Figure 44) treated animals. 
In the HSA group, NTG reduced the PO2 to 59 ± 3 mmHg (N = 5), which was significantly 
lower compared to both baseline (66 ± 2 mmHg (N = 9)) and HSA infusion (64 ± 3 mmHg 
(N = 5)). In the HBOC-201 group, 1.0 mg/kg of NTG caused a ISF PO2 of 54 ± 3 mmHg 
(N = 14), which is significantly different from baseline (63 ± 2 mmHg (N = 14)). 
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Figure 39: Top-loading - Part II - ISF PO2 - HSA - 0.1 mg/kg 
BL = 0 ml of HSA, HSA = 0.5 ml of HSA, and NTG = 0.1 mg/kg NTG.  
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Figure 40: Top-loading - Part II - ISF PO2 - HSA - 0.3 mg/kg 
BL = 0 ml of HSA, HSA = 0.5 ml of HSA, and NTG = 0.3 mg/kg NTG.  
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Figure 41: Top-loading - Part II - ISF PO2 - HSA - 1.0 mg/kg 
BL = 0 ml of HSA, HSA = 0.5 ml of HSA, and NTG = 1.0 mg/kg NTG.  
NTG = significantly different from NTG. (p < 0.05) 
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Figure 42: Top-loading - Part II - ISF PO2 - HBOC-201 - 0.1 mg/kg 
BL = 0 ml of HSA, HBOC-201 = 100 µM of HBOC-201, and NTG = 0.1 mg/kg NTG.  
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Figure 43: Top-loading - Part II - ISF PO2 - HBOC-201 - 0.3 mg/kg 
BL = 0 ml of HSA, HBOC-201 = 100 µM of HBOC-201, and NTG = 0.3 mg/kg NTG.  
.  
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Figure 44: Top-loading - Part II - ISF PO2 - HBOC-201 - 1.0 mg/kg 
BL = 0 ml of HSA, HBOC-201 = 100 µM of HBOC-201, and NTG = 1.0 mg/kg NTG.  
NTG = significantly different from NTG. (p < 0.05) 
  
106
Page 
106 
 
  
Arteriolar Diameter 
Arcade arterioles that range between 40 to 80 µm were investigated. 
There was no significant vasoconstriction or vasodilation observed with either 5.9% HSA 
(Figures 45, 46 and 47) or (Figures 48, 49 and 50) HBOC-201. NTG did also not change 
arteriolar diameters. 
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Figure 45: Top-loading - Part II – Arteriolar Diameter - HSA - 0.1 mg/kg NTG 
BL = 0 ml of HSA, HSA = 0.5 ml of HSA, and NTG = 0.1 mg/kg NTG.  
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Figure 46: Top-loading - Part II – Arteriolar Diameter - HSA - 0.3 mg/kg NTG 
BL = 0 ml of HSA, HSA = 0.5 ml of HSA, and NTG = 0.3 mg/kg NTG.  
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Figure 47: Top-loading - Part II – Arteriolar Diameter - HSA - 1.0 mg/kg NTG 
BL = 0 ml of HSA, HSA = 0.5 ml of HSA, and NTG = 1.0 mg/kg NTG.  
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Figure 48: Top-loading - Part II – Arteriolar Diameter - HBOC-201 - 0.1 mg/kg NTG 
BL = 0 ml of HSA, HBOC-201 = 100 µM of HBOC-201, and NTG = 0.1 mg/kg NTG.  
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Figure 49: Top-loading - Part II – Arteriolar Diameter - HBOC-201 - 0.3 mg/kg NTG 
BL = 0 ml of HSA, HBOC-201 = 100 µM of HBOC-201, and NTG = 0.3 mg/kg NTG.  
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Figure 50: Top-loading - Part II – Arteriolar Diameter - HBOC-201 - 1.0 mg/kg NTG 
BL = 0 ml of HSA, HBOC-201 = 100 µM of HBOC-201, and NTG = 1.0 mg/kg NTG.  
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Mean Arterial Pressure 
MAP was measured continuously, but the pressure was compared between baseline (pre-
dose 1) and either HSA or HBOC-201 (post-dose 1), and before (pre-dose 2) and after 
(post-dose 2) the different concentrations of NTG. 
 
HSA and HBOC-201 caused a significant increase in MAP compare to baseline, and there 
was also a statistical difference between the rise in MAP from baseline in HSA and HBOC-
201 animals. 
 
NTG was infused once per animal and given at 0.1, 0.3, or 1.0 mg/kg. With HSA animals, 
the three concentrations were not significant from each other or the MAP caused by HSA. 
In the HBOC-201 group, the MAPs caused by the three NTG concentrations were 
significantly different from the MAPs caused by HBOC-201. Even though there appears to 
be a trend towards dose-dependence of NTG in HBOC-201 animals, i.e. 0.1mg/kg of NTG 
reduced MAP by 21 ± 4 mmHg, 0.3mg/kg decreased MAP by 29 ± 5 mmHg, and 1.0 
mg/kg dropped MAP by 33 ± 5 mmHg, these MAPs are not statistically different from each 
other (Figure 51). 
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Figure 51: Top-loading - Part II – Delta MAP 
0.5 ml of 5.9% HSA (white) increases MAP by about 20 mmHg, while 0.5 ml (100 µM) of 
HBOC-201 (red) elevates MAP by circa 50 mmHg. NTG had no significant effect on 5.9% 
HSA, but it was hypotensive with HBOC-201. 0.1 mg/kg of NTG (blue) reduced MAP by 
21 ± 4 mmHg, while 0.3 mg/kg (green) decreased MAP by 29 ± 5 mmHg, and lastly, 1.0 
mg/kg (yellow) dropped MAP by 33 ± 5 mmHg. However, these values were not 
significant from one another.  
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Pulse Pressure 
PP, which is the pressure difference in mmHg between systolic and diastolic pressures 
were measured throughout the experiment via Biopac. A 60 second-average was measured 
at baseline (pre-HSA or pre-HBOC-201), and after an infusion of either 0.5 ml of HSA or 
100 µM of HBOC-201 (post-HSA or post-HBOC-201). A measurement was taken before 
NTG infusion (pre-NTG), and after a NTG dose with a concentration of 0.1, 0.3 or 1.0 
mg/kg (post-NTG). 
 
There is no statistical significance in the volume-control animals, in which the infusion of 
0.5 ml followed by NTG does not alter the PP compared to baseline (Figures 52, 53 and 
54). There is no significance observed with HBOC-201 followed by the lowest NTG dose 
(0.1 mg/kg) (Figure 55). However, in the 0.3 mg/kg animals, the PP immediately after 
HBOC-201 infusion was significantly different from the response of 0.3 mg/kg of NTG, 
and vice versa. Although, Post HBOC and Post NTG values were different from each other 
they were not statistically different from Pre HBOC or Pre NTG (Figure 56). Animals that 
received the highest NTG dose (1.0 mg/kg) had a baseline or Pre HBOC PP that was 
significantly lower than Post HBOC, but not different from Pre and Post NTG. Post HBOC 
PP is higher than Pre HBOC and Post NTG. Post NTG is significantly lower then Post 
HBOC and Pre NTG. 
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Figure 52: Top-loading - Part II - PP - HSA - 0.1 mg/kg NTG 
Pre HSA = 0 ml of HSA, Post HSA = 0.5 ml of HSA, Pre NTG = 0 mg/kg NTG, and post 
NTG = 0.1 mg/kg NTG.  
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Figure 53: Top-loading - Part II - PP - HSA - 0.3 mg/kg NTG 
Pre HSA = 0 ml of HSA, Post HSA = 0.5 ml of HSA, Pre NTG = 0 mg/kg NTG, and post 
NTG = 0.3 mg/kg NTG.  
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Figure 54: Top-loading - Part II - PP - HSA - 1.0 mg/kg NTG 
Pre HSA = 0 ml of HSA, Post HSA = 0.5 ml of HSA, Pre NTG = 0 mg/kg NTG, and post 
NTG = 1.0 mg/kg NTG.  
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Figure 55: Top-loading - Part II - PP - HBOC-201 - 0.1 mg/kg NTG 
Pre HBOC-201 = 0 ml of HBOC-201, Post HBOC-201 = 100 µM of HBOC-201, Pre NTG 
= 0 mg/kg NTG, and post NTG = 0.1 mg/kg NTG.  
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Figure 56: Top-loading - Part II - PP - HBOC-201 - 0.3 mg/kg NTG 
Pre HBOC-201 = 0 ml of HBOC-201, Post HBOC-201 = 100 µM of HBOC-201, Pre NTG 
= 0 mg/kg NTG, and post NTG = 0.3 mg/kg NTG.  
Pre HBOC and Pre NTG are not significantly different from any condition; however, Post 
HBOC is significantly different from Post NTG, and vice versa. 
** = significantly different from **. (p < 0.05) 
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Figure 57: Top-loading - Part II - PP - HBOC-201 - 1.0 mg/kg NTG 
Pre HBOC-201 = 0 ml of HBOC-201, Post HBOC-201 = 100 µM of HBOC-201, Pre NTG 
= 0 mg/kg NTG, and post NTG = 1.0 mg/kg NTG.  
BL = significantly different from baseline. (p < 0.05) 
HBOC = significantly different from Post HBOC. (p < 0.05) 
Pre NTG = significantly different from Pre NTG. (p < 0.05) 
NTG = significantly different from Post NTG. (p < 0.05) 
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Heart Rate 
HR was compared before and after the infusion of either HSA (Figures 58, 59 and 60) or 
HBOC-201 (Figures 61, 62 and 63), and before and after an infusion of NTG that ranged in 
concentrations (0.1, 0.3 and 1.0 mg/kg). Statistical analysis was done through one-way 
ANOVA and a Tukey post hoc test. 
 
There was no statistical significance in HR with the infusion of either HSA (Figures 58, 59 
and 60) or HBOC-201 (Figures 61, 62 and 63), and NTG. 
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Figure 58: Top-loading - Part II - HR - HSA - 0.1 mg/kg NTG 
 
Pre-HSA = 0 ml of HSA, Post-HSA = 0.5 ml of HSA, Pre-NTG = 0 mg/kg NTG, and post-
NTG = 0.1 mg/kg NTG.  
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Figure 59: Top-loading - Part II - HR - HSA - 0.3 mg/kg NTG 
 
Pre-HSA = 0 ml of HSA, Post-HSA = 0.5 ml of HSA, Pre-NTG = 0 mg/kg NTG, and post-
NTG = 0.3 mg/kg NTG.  
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Figure 60: Top-loading - Part II - HR - HSA - 1.0 mg/kg NTG 
 
Pre-HSA = 0 ml of HSA, Post-HSA = 0.5 ml of HSA, Pre-NTG = 0 mg/kg NTG, and post-
NTG = 1.0 mg/kg NTG.  
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Figure 61: Top-loading - Part II - HR - HBOC-201 - 0.1 mg/kg NTG 
Pre-HBOC-201 = 0 ml of HBOC-201, Post-HBOC-201 = 100 µM of HBOC-201, Pre-NTG 
= 0 mg/kg NTG, and post-NTG = 0.1 mg/kg NTG.  
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Figure 62: Top-loading - Part II - HR - HBOC-201 - 0.3 mg/kg NTG 
Pre-HBOC-201 = 0 ml of HBOC-201, Post-HBOC-201 = 100 µM of HBOC-201, Pre-NTG 
= 0 mg/kg NTG, and post-NTG = 0.3 mg/kg NTG.  
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Figure 63: Top-loading - Part II - HR - HBOC-201 - 1.0 mg/kg NTG 
Pre-HBOC-201 = 0 ml of HBOC-201, Post-HBOC-201 = 100 µM of HBOC-201, Pre-NTG 
= 0 mg/kg NTG, and post-NTG = 1.0 mg/kg NTG.  
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Blood Gases 
Blood samples were collected via the carotid artery into heparinized capillary tubes at 
baseline and after the experiment. The blood was analyzed through an OSM-3 
Hemeoximeter, in which five variables were collected: Total Hemoglobin (g/dl), Oxygen 
Saturation (%), Carboxyhemoglobin (%), Methemoglobin (%), and Oxygen Content (ml 
O2/dl). 
 
For this protocol, there were two groups which received either 0.5 ml of 5.9% HSA or 100 
µM of HBOC-201. Following the HSA or HBOC-201 infusion, these animals were subject 
to one of three NTG concentrations, which were 0.1, 0.3 or 1.0 mg/kg. 
 
Total Hemoglobin (g/dl)  
In the volume control animals, there was no change in the total Hb concentration (~13 g/dl) 
upon HSA infusion, and there was also no change with the addition of any NTG 
concentrations (Figure 64). The results were similar in the HBOC-201 group, in which 
HBOC-201 and the addition of NTG did not change the total Hb (Figure 65). 
 
Oxygen Saturation (%) 
There was no statistically significant difference between baseline and HSA (Figure 66), or 
HBOC-201 (Figure 67). The addition of NTG did not affect O2 saturation of either group. 
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Oxygen Content (ml O2/dl) 
O2 content was not significantly altered from baseline with 5.9% HSA (Figure 68) or 
HBOC-201 (Figure 69), and it was also unchanged with the addition NTG for both groups.  
 
Methemoglobin (%) 
MetHb remained unchanged from baseline with both 5.9% HSA (Figure 70) and HBOC-
201 (Figure 71). Addition of NTG did not significantly change MetHb for both HSA and 
HBOC-201 animals.  
 
Carboxyhemoglobin (%) 
HbCO did not change with 5.9% HSA (Figure 72) and HBOC-201 (Figure 73), and it was 
not affected with the addition of NTG for both groups. 
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Figure 64: Top-loading - Part II - Total Hb - HSA 
All animals received a 0.5 ml 5.9% HSA infusion, but were given a single dose of NTG 
that varied in concentration. Column “A” animals received 0.1 mg/kg of NTG. Column 
“B” animals received 0.3 mg/kg of NTG, and column “C” animals received 1.0 mg/kg of 
NTG. 
* = significantly different from baseline. (p < 0.05) 
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Figure 65: Top-loading - Part II - Total Hb - HBOC-201 
All animals received 100 µM of HBOC-201, but were given a single dose of NTG that 
varied in concentration. Column “A” animals received 0.1 mg/kg of NTG. Column “B” 
animals received 0.3 mg/kg of NTG, and column “C” animals received 1.0 mg/kg of NTG. 
* = significantly different from baseline. (p < 0.05) 
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Figure 66: Top-loading - Part II - O2 Saturation - HSA 
All animals received a 0.5 ml 5.9% HSA infusion, but were given a single dose of NTG 
that varied in concentration. Column “A” animals received 0.1 mg/kg of NTG. Column 
“B” animals received 0.3 mg/kg of NTG, and column “C” animals received 1.0 mg/kg of 
NTG. 
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Figure 67: Top-loading - Part II – O2 Saturation - HBOC-201 
All animals received 100 µM of HBOC-201, but were given a single dose of NTG that 
varied in concentration. Column “A” animals received 0.1 mg/kg of NTG. Column “B” 
animals received 0.3 mg/kg of NTG, and column “C” animals received 1.0 mg/kg of NTG. 
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Figure 68: Top-loading - Part II - O2 Content - HSA 
All animals received a 0.5 ml 5.9% HSA infusion, but were given a single dose of NTG 
that varied in concentration. Column “A” animals received 0.1 mg/kg of NTG. Column 
“B” animals received 0.3 mg/kg of NTG, and column “C” animals received 1.0 mg/kg of 
NTG. 
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Figure 69: Top-loading - Part II - O2 Content - HBOC-201 
All animals received 100 µM of HBOC-201, but were given a single dose of NTG that 
varied in concentration. Column “A” animals received 0.1 mg/kg of NTG. Column “B” 
animals received 0.3 mg/kg of NTG, and column “C” animals received 1.0 mg/kg of NTG. 
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Figure 70: Top-loading - Part II - MetHb - HSA 
All animals received a 0.5 ml 5.9% HSA infusion, but were given a single dose of NTG 
that varied in concentration. Column “A” animals received 0.1 mg/kg of NTG. Column 
“B” animals received 0.3 mg/kg of NTG, and column “C” animals received 1.0 mg/kg of 
NTG. 
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Figure 71: Top-loading - Part II - MetHb - HBOC-201 
All animals received 100 µM of HBOC-201, but were given a single dose of NTG that 
varied in concentration. Column “A” animals received 0.1 mg/kg of NTG. Column “B” 
animals received 0.3 mg/kg of NTG, and column “C” animals received 1.0 mg/kg of NTG. 
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Figure 72: Top-loading - Part II - HbCO - HSA 
All animals received a 0.5 ml 5.9% HSA infusion, but were given a single dose of NTG 
that varied in concentration. Column “A” animals received 0.1 mg/kg of NTG. Column 
“B” animals received 0.3 mg/kg of NTG, and column “C” animals received 1.0 mg/kg of 
NTG. 
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Figure 73: Top-loading - Part II - HbCO - HBOC-201 
All animals received 100 µM of HBOC-201, but were given a single dose of NTG that 
varied in concentration. Column “A” animals received 0.1 mg/kg of NTG. Column “B” 
animals received 0.3 mg/kg of NTG, and column “C” animals received 1.0 mg/kg of NTG. 
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Hemorrhage and Resuscitation 
 
Interstitial PO2 (270g) 
Interstitial PO2 was measured at five time points throughout the course of the hemorrhage-
resuscitation procedure.  As expected, there was no significant difference between the 
groups at baseline and after hemorrhage (Figure 77).  Blood flow in the spinotrapezius 
muscle usually stopped completely during hemorrhage, leading to near-zero PO2 readings.  
After resuscitation, restoration of flow brought PO2 levels towards baseline values; 
although, HBOC-201 with NTG was the only group that was similar to baseline with 57 ± 
3 mmHg (N = 19) (Figure 76). On the other hand, HSA with 45 ± 3 mmHg (N = 18) 
(Figure 74) and HBOC-201 with 46 ± 2 mmHg (N = 12) (Figure 75) were significantly 
lower at R20 than baseline values 63 ± 2 mmHg (N = 18) and 67 ± 2 mmHg (N = 12), 
respectively. From R20 to R120 the PO2 decreased significantly for all groups, in which the 
PO2 at R120 for HSA was 27 ± 3 mmHg (N = 18), while HBOC-201 was 4 ± 1 mmHg (N 
= 7), and lastly HBOC-201 with NTG was 36 ± 7 mmHg (N = 6). Among the groups 
within R120, HBOC-201 was statistically lower from HSA and HBOC-201 with NTG, 
while HSA and HBOC-201 with NTG were not different from each other (Figure 77).   
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Figure 74: H&R (~270g) - ISF PO2 - HSA 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from H, R20, R60 and R120. (p < 0.05) 
** = significantly different from BL, R20, R60 and R120. (p < 0.05) 
*** = significantly different from BL, H, and R120. (p < 0.05) 
**** = significantly different from BL, H, and R20. (p < 0.05) 
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Figure 75: H&R (~270g) - ISF PO2 - HBOC-201 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from ** and BL. (p < 0.05) 
** = significantly different from * and BL. (p < 0.05)
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Figure 76: H&R (~270g) - ISF PO2 - BOC-201 + NTG 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from BL, R20, R60 and R120. (p < 0.05) 
** = significantly different from BL, H, R20 and R120. (p < 0.05) 
*** = significantly different from BL, H, R20 and R60. (p < 0.05) 
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Figure 77: H&R (~270g) - ISF PO2 - Combined 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from HSA and HBOC-201. (p < 0.05) 
** = significantly different from HSA and HBOC-201 with NTG. (p < 0.05) 
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Interstitial PO2 (~370g) 
Interstitial PO2 was measured at five time points throughout the course of the hemorrhage-
resuscitation procedure: baseline (BL), after hemorrhage (H) and resuscitation (R20), and 
at two time points measured 60 (R60) and 120 (R120) minutes from the start of the 
resuscitation.  Baseline ISF PO2 for HSA, HBOC-201 and HBOC with NTG groups were 
64 ± 1 mmHg (N = 24), 66 ± 1 mmHg (N = 36), and 68 ± 1 mmHg (N = 36), respectively. 
Although, these baseline values are about the same, the HSA group is statistically different 
from HBOC with NTG (Figure 82). With hemorrhage, the blood flow in the spinotrapezius 
muscle is reduced and sometimes partially stopped which caused the ISF PO2 to 
significantly decrease from baseline. All groups had a PO2 of 8 to 9 mmHg during 
hemorrhage, and they were not significantly different from each other (Figure 82). At R20, 
when the resuscitation was completed and 40% of the lost BV was restored, HSA and 
HBOC with NTG animals had PO2 values that were not significantly different to baseline. 
Although, the PO2 of HBOC-201 animals were not significantly different from HSA and 
HBOC with NTG at R20, it was less than its baseline (Figure 80). 
 
The R60 and R120 PO2 values were different between the three groups. With HSA, the 
average PO2 was increased from R20 to R60, and from R60 to R120; however, there was 
only a statistical increase between R20 and R120 (Figure 79). With HBOC-201, there was 
no statistical difference between R20 through R120, and they were maintained at a level 
lower than baseline (Figure 80). Lastly, the PO2 of the HBOC-201 with NTG animals at 
R20 was 60 ± 3 mmHg (N = 35), but it significantly dropped to 54 ± 2 mmHg (N = 25) by 
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R60, and increased to 70 ± 4 mmHg (N = 11) that was significantly higher than R20 and 
R60 (Figure 81). 
 
Comparing the groups under similar conditions, the PO2 is about the same at R20, and 
although HSA is significantly higher than both HBOC-201 and HBOC-201 with NTG at 
R60, only HBOC-201 is significantly lower by R120 (Figure 82). 
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Figure 78: H&R (~370g) - ISF PO2 - HSA 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from BL, R20, R60 and R120. (p < 0.05) 
R120 = significantly different R120. (p < 0.05) 
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Figure 79: H&R (~370g) - ISF PO2 - HBOC-201 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from BL, R20, R60 and R120. (p < 0.05) 
** = significantly different from BL and H. (p < 0.05) 
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Figure 80: H&R (~370g) - ISF PO2 - HBOC-201 + NTG 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from BL, R20, R60 and R120. (p < 0.05) 
BL = significantly different from BL. (p < 0.05) 
R20 = significantly different from R20. (p < 0.05) 
R60 = significantly different from R60. (p < 0.05) 
R120 = significantly different from R120. (p < 0.05) 
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Figure 81: H&R (~370g) - ISF PO2 - Combined 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
HSA = significantly different from HSA. (p < 0.05) 
NTG = significantly different from NTG. (p < 0.05) 
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Interstitial VO2 (~370g) 
Interstitial VO2 was only measured for the ~370g rats. The baseline VO2 was about 8 ml O2 
x kg-1 x mmHg-1 for all of the animals and the baseline values were not different among the 
different groups. During hemorrhage, it decreased significantly to about 1 ml O2 x kg-1 x 
mmHg-1 for all groups; however, the HBOC-201 group had a VO2 that was significantly 
higher compared to HSA and HBOC-201 (Figure 86). After resuscitation all of the groups 
had a VO2 that was similar to baseline (Figures 83, 84 and 85), and there was no statistical 
difference between the groups. At R60, the VO2 for all groups were significantly lower 
than baseline and within the groups, HBOC-201 with NTG was significantly lower than 
HSA and HBOC-201. By R120, the VO2 of HSA and HBOC-201 was raised from R60, in 
which they were insignificant from baseline. However, VO2 of HBOC-201 with NTG was 
unchanged at R120 compared to R60, and was still significantly lower than HSA and 
HBOC-201.
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Figure 82: H&R (~370g) - ISF VO2 - HSA 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from ** and BL. (p < 0.05) 
** = significantly different from * and BL. (p < 0.05) 
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Figure 83: H&R (~370g) - ISF VO2 - HBOC-201 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from ** and BL. (p < 0.05) 
** = significantly different from * and BL. (p < 0.05) 
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Figure 84: H&R (~370g) - ISF VO2 - HBOC-201 + NTG 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from ** and BL. (p < 0.05) 
** = significantly different from * and BL. (p < 0.05) 
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Figure 85: H&R (~370g) - ISF VO2 - Combined 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from HSA and HBOC-201 + NTG. (p < 0.05) 
** = significantly different from HSA and HBOC-201. (p < 0.05) 
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Arteriolar Diameter (~370g) 
A one-way ANOVA was done for all of the conditions per group, and a Tukey post hoc 
was done if there was significance. 
 
For the arteriolar diameters, arcade arterioles ranging in diameters of 40 to 80 µm were 
compared for HSA (N = 33), HBOC-201 (N = 14), and HBOC-201 with NTG (N = 17). 
For HSA animals, the arteriolar diameter decreased from 57 ± 2 µm to 46 ± 2 µm during 
hemorrhage. Even though the diameter increased towards baseline with resuscitation, it 
stayed significantly lower than baseline for R60 and R120 (Figure 86). For the HBOC-201 
animals, the diameter decreased from 58 ± 2 µm to 43 ± 4 µm with hemorrhage. The 
diameters increased upon resuscitation and were not significantly different from baseline at 
R20, R60 and R120 (Figure 87). There was no statistical significance of arteriolar 
diameters observed with the HBOC-201 with NTG animals (Figure 88), and there were 
also no significant difference between the groups of any given condition (Figure 89). 
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Figure 86: H&R (~270g) - Diameter - HSA 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from BL. (p < 0.05) 
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Figure 87: H&R (~270g) - Diameter - HBOC-201 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from BL. (p < 0.05) 
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Figure 88: H&R (~270g) - Diameter - HBOC-201 + NTG 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
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Figure 89: H&R (~270g) - Diameter - Combined 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
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Arteriolar Diameter (~370g) 
A total of 9 arterioles were measured for the HSA group (N = 3), 9 arterioles in the HBOC-
201 group (N = 3), and 15 arterioles in the HBOC-201 with NTG group (N = 5).  All 
groups exhibited a decrease in arteriolar diameter; although, the HBOC-201 group was not 
statistically significant, during hemorrhage. For example, the HSA group decreased its 
arteriolar diameter significantly from 115 ± 2 µm to 74 ± 5 µm with hemorrhage (Figure 
90), while the HBOC-201 with NTG group reduced its diameter from 112 ± 5 µm to 84 ± 
3 µm  (Figure 92). As mentioned earlier, even though the diameter was reduced from 103 ± 
5 µm to 85 ± 7 µm in the HBOC-201 group, it was not statistically significant (Figure 91).  
 
After resuscitation (R20, R60 and R120), all groups returned their diameters to baseline 
values. For example at baseline HSA was 115 ± 2 µm, and at R20, R60 and R120 the 
diameters were 112 ± 2 µm, 114 ± 3 µm and 114 ± 3 µm, respectively. Similar patterns 
were observed with both the HBOC-201 and HBOC-201 with NTG groups. There was no 
significant difference in arteriolar diameter among the resuscitation fluids within each 
branching category (Figure 93). 
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Figure 90: H&R (~370g) - Diameter - HSA 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from BL, R20, R60 and R120. (p < 0.05) 
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Figure 91: H&R (~370g) - Diameter - HBOC-201 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
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Figure 92: H&R (~370g) - Diameter - HBOC-201 + NTG 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from BL, R20, R60 and R120. (p < 0.05) 
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Figure 93: H&R (~370g) - Diameter - Combined 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
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Mean Arterial Pressure (~270g) 
All of the animals started with a MAP baseline of about 100 mmHg. The MAP decreased 
significantly from baseline with hemorrhage, and increased significantly compared to 
baseline and hemorrhage MAPs after resuscitation (R20) for all groups (Figures 94, 95 and 
96). Despite similar trends, HBOC-201 animals had a significantly higher MAP during 
hemorrhage and R20 compared to HSA and HBOC-201 with NTG (Figure 97). For R60 
and R120, the MAPs were similar to baseline values in all groups.
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Figure 94: H&R (~270g) - MAP - HSA 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from BL, R20, R60 and R120. (p < 0.05) 
R120 = significantly different from R120. (p < 0.05) 
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Figure 95: H&R (~270g) - MAP - HBOC-201 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from BL, R20, R60 and R120. (p < 0.05) 
** = significantly different from BL, H, R60 and R120. (p < 0.05) 
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Figure 96: H&R (~270g) - MAP - HBOC-201 + NTG 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from BL, R20, R60 and R120. (p < 0.05) 
** = significantly different from BL, H, R60 and R120. (p < 0.05) 
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Figure 97: H&R (~270g) - MAP - Combined 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from HBOC-201. (p < 0.05) 
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Mean Arterial Pressure (~370g) 
Baseline values of MAP were between 90 to 100 mmHg for all three groups, and all of 
them reduced significantly to about 20 mmHg with hemorrhage. However immediately 
after resuscitation (R20), the HBOC-201 group showed a significant increase in pressure 
(164 ± 5 mmHg) that returned to baseline values for R60 and R120 (Figure 99).  Adding 
NTG to HBOC-201 (Figure 100) decreased MAP (123 ± 5 mmHg) compared to HBOC-
201 at R20, and it was also statistically insignificant from HSA (113 ± 4 mmHg) (Figure 
101).  
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Figure 98: H&R (~370g) - MAP - HSA 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from BL. (p < 0.05) 
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Figure 99: H&R (~370g) - MAP - HBOC-201 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from ** and BL. (p < 0.05) 
** = significantly different from * and BL. (p < 0.05) 
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Figure 100: H&R (~370g) - MAP - HBOC-201 + NTG 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from BL. (p < 0.05) 
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Figure 101: H&R (~370g) - MAP - Combined 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from HBOC-201. (p < 0.05) 
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Pulse Pressure (~370g) 
PP under the different conditions were not statistically significant from one another in the 
HSA group, because of the low number of animals (N = 1) (Figure 102). In the HBOC-201 
group, there was significance between hemorrhage and R20 and R60, while baseline was 
insignificant to any condition (N = 3) (Figure 103). For HBOC-201 with NTG, the PP at 
hemorrhage was significantly lower than baseline, R20, R60 and R120, while there was no 
significance between baseline, R20, R60 and R120 (N =3) (Figure 104). For each condition 
there was no statistical difference between the groups: HSA, HBOC-201 and HBOC-201 
with NTG (Figure 105). 
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Figure 102: H&R (~370g) - PP - HSA 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
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Figure 103: H&R (~370g) - PP - HBOC-201 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
H = significantly different from H. (p < 0.05) 
R20 = significantly different from R20. (p < 0.05) 
R60 = significantly different from R60. (p < 0.05) 
 
  
180
Page 
180 
 
  
 
Figure 104: H&R (~370g) - PP - HBOC-201 + NTG 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from BL, R20, R60 and R120. (p < 0.05) 
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Figure 105: H&R (~370g) - PP - Combined 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
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Heart Rate (~270g) 
In the volume control group, the HR at R20 was significantly higher compared to the HR 
during hemorrhage, and at R60 and R120, the HR was significantly higher than baseline, 
hemorrhage and R20 (Figure 107). To the contrary, there were no statistical significane in 
HR during any time point for the HBOC-201 and the HBOC-201 with NTG groups 
(Figures 108 and 109). There was also no significance between the groups at a given time 
point (figure 110).
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Figure 106: H&R (~270g) - HR - HSA 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from BL. (p < 0.05) 
** = significantly different from H. (p < 0.05) 
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Figure 107: H&R (~270g) - HR - HBOC-201 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
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Figure 108: H&R (~270g) - HR - HBOC-201 + NTG 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
  
186
Page 
186 
 
  
 
Figure 109: H&R (~270g) - HR - Combined 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
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Heart Rate (~370g) 
For the volume control group, the HR at hemorrhage was not significantly less compared to 
baseline, even though the average was ~150 bpm compared to ~300 bpm. However, at R60 
and R120 the HR was significantly higher compared to baseline (Figure 111). With the 
HBOC-201 group, the HR at hemorrhage was significantly lower than baseline, and at R60 
and R120, the HR was significantly higher than baseline and hemorrhage (Figure 112). For 
the HBOC-201 with the NTG group, the HR at hemorrhage was significantly lower than 
baseline (Figure 113). There was no statistical significance between the groups at a given 
time point (Figure 114).  
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Figure 110: H&R (~370g) - HR - HSA 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from BL. (p < 0.05) 
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Figure 111: H&R (~370g) - HR - HBOC-201 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from ** and BL. (p < 0.05) 
** = significantly different from * and BL. (p < 0.05) 
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Figure 112: H&R (~370g) - HR - HBOC-201 + NTG 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
* = significantly different from BL. (p < 0.05) 
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Figure 113: H&R (~370g) - HR - Combined 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
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Blood Gases (~270g) 
Total Hb concentration decreased from baseline values of 14 ± 0.4 g/dl to 10.3 ± 0.3 g/dl 
with hemorrhage.  When 5.9% HSA was used as a resuscitation fluid, the Hb concentration 
continued to fall (8.1± 0.3 g/dl).  However, resuscitation with HBOC increased the 
concentration to 12.6 ± 1.1 g/dl, while the combination of HBOC with NTG did not affect 
the Hb concentration (10.5 ± 0.6 g/dl).  Hb concentrations remained constant in all groups 
after R20 (Figure 114). 
 
Hb oxygen saturation (Figure 115) was 97.6 ± 0.6% at baseline and 99.5 ± 0.9% during 
hemorrhage for all groups. Immediately after resuscitation Hb oxygen saturation in both the 
HBOC and the HBOC with NTG groups decreased to 82.8 ± 2.5% and 88.1 ± 2.7%, 
respectively.  The HSA group stayed constant at 99.5 ± 0.2%. Reduced O2 exchange in the 
lungs may have contributed to low saturation levels in both groups containing HBOC.  
Fluid, which was secreted into the lungs and removed through the tracheal tube was 
consistently noted in the HBOC group, infrequent in the HBOC with NTG group and not 
noted at all in the HSA group. 
 
The metHb concentration as a percentage of total hemoglobin (Figure 117) was 0.42 ± 
0.04% at baseline, and 0.35 ± 0.04% for hemorrhage.  After resuscitation (R20) with 5.9% 
HSA, metHb rose minimally to 0.50 ± 0.05%, while HBOC elevated it to 2.9 ± 0.8%. An 
even higher increase was observed when HBOC with NTG was infused (10.1 ± 2.8%).  
MetHb concentration for both the HSA and the HBOC groups remained relatively constant 
through R60 and R120, but in the HBOC with NTG group metHb decreased to 8.5 ± 2.2% 
  
193
Page 
193 
 
  
and then 6.3 ± 1.5%.  When metHb was measured for the HBOC and HBOC with NTG 
solutions prior to infusion they were 15 ± 0.04% and 20 ± 0.04%, respectively. 
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Figure 114: H&R (~270g) - Total Hb 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
  
195
Page 
195 
 
  
 
Figure 115: H&R (~270g) - O2 Saturation 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
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Figure 116: H&R (~270g) - O2 Content 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
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Figure 117: H&R (~270g) - MetHb 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
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Blood Gases (~370g) 
 
 
 
 
 
 
  
199
Page 
199 
 
  
 
Figure 118: H&R (~370g) - Total Hb 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
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Figure 119: H&R (~370g) - O2 Saturation 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
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Figure 120: H&R (~370g) - O2 Content 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
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Figure 121: H&R (~370g) - MetHb 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
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Figure 122: H&R (~370g) – Lactate 
BL = Baseline, H = 40% BV withdrawal, R20, R60 and R120 = 20, 60 and 120 minutes, 
respectively, from the beginning of resuscitation. 
 
Baseline lactate values were about 1 mmol/L and increased to about 8 mmol/L with 
hemorrhage. Following resuscitation, the lactate values decreased significantly, and were 
close to baseline values after an hour. 
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Discussion 
The Discussion section will be divided into two parts, in which results from the ‘Top-
loading’ protocol will be discussed first, followed by results from the ‘Hemorrhage and 
Resuscitation’ protocol. 
 
Top-loading 
The Discussion section will be divided into two parts, in which results from the ‘Top-
loading’ protocol will be discussed first, followed by results from the ‘Hemorrhage and 
Resuscitation’ protocol. 
 
Top-loading 
The first HBOC solution used by investigators was a mixture of hemolysates and since then 
there have been many attempts to formulate the ideal HBOC product.  Cross-linking, 
polymerization, purification, and PEGylation of the Hb molecule(s) are a few of the 
techniques implemented to help reduce or eliminate undesirable effects, such as 
hypertension and peripheral vasoconstriction, from HBOC infusion. 
 
As mentioned in the Introduction, there are primarily two competing theories that attempt 
to describe why extracellular Hb causes vasoconstriction and increased MAP.  The ‘NO 
Scavenging’ theory states that NO produced in the endothelium of the arteriolar wall binds 
readily to the infused HBOC thus leading to vasoconstriction. Furthermore, small 
fragments in HBOC preparations, such as Hb dimers and monomers, are small enough to 
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extravasate out of the vasculature and bind NO diffusing to the smooth muscle cells 
surrounding the endothelium.  This removal of NO, which is a naturally occurring 
vasodilator, is expected to cause peripheral vasoconstriction that ultimately raises the total 
peripheral resistance (TPR).  To overcome the increased resistance to blood flow, the heart 
needs to pump more forcefully, which leads to an increased MAP.  Contrary to the ‘NO 
Scavenging’ theory, the ‘Autoregulation’ theory suggests that hypertension is not mediated 
through NO, but rather through O2.  The concept is that HBOCs elevate the O2 availability 
in blood beyond normal levels, which then cause arterioles to constrict in order to reduce 
flow and, therefore, restore O2 levels back to baseline.  In addition, the theory speculates 
that the low viscosity of HBOCs (~2 cP) decreases O2 delivery and that an increase in 
viscosity similar to that of normal blood (~4 cP) would produce more desirable effects. 
 
The purpose of this study was to investigate the significance of O2 affinity, viscosity and 
NO in the context of HBOC solutions with properties believed to modify the 
aforementioned factors and to broaden our understanding of the actions of HBOCs.  In the 
first set of experiments (Part I), we compared HBOC-201 (P50 = 40 mmHg and viscosity of 
2.2 cP) to a modified HBOC-201 with a lower P50 of 18 mmHg (MP50), and a modified 
HBOC-201 with both a lower P50 of 17 mmHg and a higher viscosity of 4 cP (LP50).  
Hence, all of these HBOCs were obtained from the same source and were designed to have 
the same properties with the exception of O2 affinity and viscosity.  As a volume control, 
5.9% HSA was utilized because it is a colloid that is iso-oncotic to HBOC-201. 
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The results demonstrated that the ISF PO2 increased significantly from baseline with the 
first dose of HBOC-201, with a targeted plasma concentration of 1 µM. With each 
increasing concentration (10, 100 and 300 µM), the PO2 did not significantly change from 
the elevated PO2 of dose 1, and thus every dose of HBOC-201 caused an ISF PO2 that was 
above baseline. A similar PO2 trend was also observed with MP50, in which the PO2 
increased significantly from baseline at the 1 µM plasma concentration, and remained 
elevated with all other doses. However, with the 100 µM dose of MP50, the PO2 was not 
statistically significant from baseline, although the average PO2 was higher. Because the 
PO2 values for the dose before (10 µM) and after (300 µM) were significantly higher than 
baseline, it seems likely that the PO2 at 100 µM would become statistically significant with 
additional experiments. The addition of LP50 did not change ISF PO2 with the first two 
doses (1 and 10 µM), but ISF PO2 declined significantly from baseline with doses 3 and 4 
(100 and 300 µM). With the volume control solution, the ISF PO2 was unaffected with the 
first two doses (0.1 and 0.1 ml), but the PO2 increased significantly compared to baseline 
with doses 3 and 4, which is partially explained by increased pre-load and higher stroke 
volume (SV) and improved flow by a dilutional effect (decreased RBC concentration and 
therefore decreased resistance to flow). 
 
HBOCs are known to cause arteriolar constriction, yet this response was not observed with 
the ‘Top-loading’ experiments in the spinotrapezius muscle preparation. This finding does 
not, however, dismiss the possibility that vasoconstriction could occur in tissue beds other 
than in the spinotrapezius muscle. An increase in MAP can presumably be an indicator of 
increased TPR, which is the end result of vasoconstriction, and thus MAP was analyzed. 
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With the addition of Hemopure, MP50 or LP50, there was a significant rise in MAP with 
the first dose of 1 µM and on to the last dose of 300 µM. There were two exceptions, in 
which dose 2 (10 µM) of MP50 did not significantly elevate MAP. However, increasing the 
number of experiments would most likely yield significance, since there was significance 
with the 1 µM and 300 µM doses. The other exception was found with the last dose of 
HBOC-201 in which the MAP was substantially elevated, reflecting a near maximal 
response of increased resistance or CO. 
 
Accordingly, MAP cannot be directly correlated to TPR and thus vasoconstriction unless 
CO remains unchanged, since MAP is the product of TPR and cardiac output (CO). 
Although, CO was not directly measured in this study, its change could be roughly 
estimated through recorded values of HR and SV. HR was measured using the Biopac 
recordings and the results indicated that there was no significant change with Hemopure, 
MP50 and LP50 at any given concentration. SV was not directly measured, but it should be 
roughly proportional to pulse pressure (PP), which was also recorded using Biopac. With 
the addition of HBOC-201, there was no statistical significance in PP at any dose, and the 
same response was also observed with MP50. However, with dose 2 of MP50, there was a 
significant increase in PP between pre-dose 2 and post-dose 2 even though the averages 
were virtually identical and the standard error bars were overlapping on both ends. Thus, 
presumably there would not be statistical significance at dose 2, if the power of the study 
was increased. On the contrary, there was an increase in PP with LP50, which could be 
explained by the fact that it caused an elevated MAP that was statistically higher than 
HBOC-201 and MP50. From a consideration of the passive pressure-volume relationship 
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for the large arteries, an elevated MAP would correspond to a region of the curve with 
lower arterial compliance.  Thus, even with the same stroke volume ejected by the left 
ventricle, the difference between systolic and diastolic pressures (i.e., pulse pressure) 
would be expected to increase.  Thus the increased PP of LP50 compared to HBOC-201 
and MP50 can be explained by the higher MAP caused by the higher viscosity LP50 in 
comparison to HBOC-201 and MP50. 
 
The increased MAP observed with the HBOCs used in this study would thus appear to 
cause vasoconstriction and increased TPR, despite the finding of no significant decrease in 
arteriolar diameters in the spinotrapezius muscle. Since there is no change in HR and PP, 
this presumably means that there is no significant change in CO. Therefore, 
vasoconstriction may be occurring in other vascular beds. 
 
By top-loading an animal with HBOC, the total amount of Hb, which is the summation of 
both intra and extracellular Hb, increases. This added amount of Hb binds and transports 
O2, which is apparent with the increase of ISF PO2 starting as early as 1 µM of both 
Hemopure and MP50. The trend is different for LP50, which did not increase PO2, yet 
decreased it below baseline following 100 and 300 µM infusions. This finding is linked to a 
MAP of about 160 mmHg, a value significantly higher and about 20 mmHg more than 
observed with HBOC-201 or MP50. This additional increase of MAP is presumably linked 
to higher TPR, which will reduce blood flow, and thus decrease O2 delivery and tissue 
oxygenation. In other words, HBOCs appear to be beneficial to the system as long as the 
MAP does not become too elevated, and therefore we conducted the ‘Top-loading: Part II’ 
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study in which nitroglycerin, a nitric oxide (NO) mediated vasodilator, was introduced with 
HBOC-201. 
 
For Part II, we targeted a plasma HBOC concentration of 100 µM since that dose produced 
the highest change in MAP in the ‘Top-loading: Part I’ protocol. Following the infusion of 
HBOC-201, one of three concentrations of NTG (0.1, 0.3 or 1.0 mg/kg) was administrated.  
 
The results demonstrated that HBOC-201 and/or NTG did not significantly change ISF 
PO2, and similar to Part I, there were no changes in arteriolar diameter and HR. However, 
there was a significant increase in MAP, in which 100 µM HBOC-201 increased MAP by 
50 mmHg. When NTG was infused, the pressure decreased significantly, and although the 
averages displayed a dose-dependent trend where increasing concentrations of NTG 
showed a larger reduction in MAP, the results were not significant. Statistical significance 
may be achieved by raising the number of animals from 4 per group to perhaps 8. The 
volume control solution (5.9% HSA) had a different response compared to HBOC-201. 
After HSA infusion, MAP increased 20 mmHg, and thus part of the increased MAP 
observed with HBOC-201 is partially a volume-dependent response. Although MAP 
decreased suddenly with a bolus of NTG in the control animals, it was a transient response 
of less than a minute, in which MAP returned to the value prior to NTG infusion. The 
transient response is in-line with the short half-life of NO, which is less than a few seconds 
in the circulation (Archer, 1993 and Bates, 1992). Hence, the effect of NTG on the 
‘control’ MAPs was transient, while NTG impacted the steady-state of HBOC-201 infused 
animals, because the decrease in MAP was maintained throughout the rest of the 
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experiment (20 minutes or more).  It is intriguing that MAP reaches a new steady-state 
despite the short half-life of NO. These results suggest that HBOCs may work through a 
NO-mediated pathway. 
 
There were some contradictory PP results found in the HBOC-201 animals. Three different 
NTG concentration groups were compared in which the response to 100 µM HBOC-201 
should have been the same. Two of the three groups demonstrated no change in PP with 
HBOC-201, which is in agreement with the results from Part I. However, the group that 
received 1.0 mg/kg of NTG demonstrated a significant increase in PP with HBOC-201. The 
same group also showed a significant decrease in PP compared to pre-NTG pressures. This 
is partially explained by the significant decrease in MAP, which corresponds to a decreased 
systemic arterial blood volume. However, the pressure with HBOC-201 and 1.0 mg/kg of 
NTG was still higher than baseline; yet, for this particular group, PP was less than the 
baseline value. These results are difficult to explain, and increasing the number of animals 
may cause this group to display responses to HBOC-201 and NTG that is consistent with 
all of the other groups. 
 
The ‘Autoregulation’ theory states that the vasoconstriction associated with HBOCs is 
caused by increased O2 levels in the arterioles. This theory suggests that by increasing the 
O2 affinity, the arteriolar constriction will be reduced or eliminated because the offloading 
of O2 would be decreased. MP50, which has the same properties as HBOC-201 with the 
exception of a lower P50, produced similar ISF PO2, MAP, PP and arteriolar diameters 
compared to HBOC-201, suggesting that increased O2 affinity does not play a significant 
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role in the performance of these HBOCs. In fact, our results create some doubt regarding 
the ‘Autoregulation’ theory because starting at the lowest dose of 1 µM, there was a 
significant increase in MAP, which is presumably caused by vasoconstriction. Increasing 
the plasma concentration of Hb by 1 µM is such a small contribution to the animal that it is 
questionable whether ‘autoregulation,’ which is observed with significantly higher PO2, 
actually takes place. It is more plausible that the increased MAP observed with 1 µM 
HBOC-201 is linked to vasoconstriction through the binding of NO to HBOC, and thus 
supportive of the ‘NO Scavenging’ theory. NO binds to extracellular Hb about 500 to 1000 
times more readily than does O2, and therefore it is possible that 1 µM Hb could bind up to 
4 µM NO, since a Hb tetramer can bind up to four NO molecules. According to the 
literature it is difficult to measure NO concentrations near the arteriolar wall, and 
‘physiological’ concentrations have been measured that range from a femtomolar 
(Ricciardolo et al, 1999) to hundreds of micromolar (Ahern et al, 1999), although it is 
likely that the physiological concentration of NO is between 1 to 1000 nM (Hall and 
Garthwaite, 2009). Thus, it is not inconceivable that 1 µM HBOC-201 has the ability to 
react with most of the NO found near the vessel walls. This is also partially supported by 
the significant increase in metHb observed with Hemopure, MP50 and LP50 infusion. 
MetHb is the byproduct of the reaction of HbO2 and NO. The ‘Autoregulation’ theory also 
suggests that an HBOC with a viscosity similar to that of whole blood would increase O2 
delivery, but our findings demonstrate the opposite with LP50.  HBOC-201 already 
possesses hypertensive responses, and by increasing the viscosity and therefore the 
resistance of flow, LP50 caused MAP to rise by an additional 20 mmHg. 
 
  
212
Page 
212 
 
  
The results gathered through measurements of ISF PO2, MAP, HR and PP demonstrated 
the importance of preventing an HBOC from raising MAP to the point where flow and thus 
O2 delivery was compromised. In the second part of this study, we found that a NO-donor 
reduced the hypertensive response of HBOC-201, while the same NO donor had no effect 
when an iso-oncotic colloid (5.9% HSA) was infused.  The results demonstrate that a NO 
donor can positively affect the outcome of an HBOC infusion, yet the mechanism and 
specific pathway remains to be elucidated and beyond the scope of this study. However, the 
results are suggestive of a NO-mediated mechanism and hence the results of this study are 
more consistent with the ‘NO scavenging’ theory. 
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Hemorrhage and Resuscitation 
After severe hemorrhage, the body activates compensatory mechanisms in response to 
reduced MAP by increasing the activity of the sympathetic nervous system.  When the 
body is incapable of maintaining blood flow and delivering adequate O2 to the peripheral 
tissues, therapeutic intervention is required.  In severe hemorrhage, which is defined by the 
American College of Surgeons' Advanced Trauma Life Support as a blood volume loss of 
40%, the recommended treatment is resuscitation with whole blood. This is because whole 
blood increases both blood volume and O2 carrying capacity unlike colloids and 
crystalloids, which increase volume but not O2 carrying capacity.  A complication 
associated with reduced blood volume is hemorrhagic shock, which, if untreated, leads to 
multiple organ failure and death.  Even without a deficit in blood volume, a reduction in 
blood Hb content can lead to high levels of morbidity and mortality.  For example, Carson 
and associates found that at 7 – 8 g/dl Hb in rats there was 10% morbidity, and for every 
g/dl decrement in Hb, there was a 2.5-fold increase in mortality (Carson et al, 2002).  In 
general, HBOCs are designed to be similar to blood and could arguably make better 
resuscitation fluids than colloids or crystalloids because of their additional O2 carrying 
capacity proportional to their Hb concentration.  For instance, in a clinical trial where 
patients were given PolyHeme (Northfield Laboratories Inc, Evanston, IL), a polymerized 
human Hb with a concentration of 10g/dl (Carson et al, 2002), to treat traumatic 
hemorrhage, patients had a much lower mortality (Gould, 2002) when compared to a 
retrospective cohort of patients who refused blood for religious reasons (Carson et al, 
2002).  Furthermore, Wettstein et al conducted a hemorrhage and resuscitation study where 
polyethylene glycol-modified human Hb (MalPEG-Hb; Sangart, San Diego, CA) with a 
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concentration of 4 g/dl was compared to 5% hydroxyethyl starch (HES) in hamsters 
(Wettstein et al, 2003).  After resuscitation, the extravascular PO2 was similar in both 
groups, which is partially explained by the fact that both MalPEG-Hb and HES groups had 
an equally low Hb concentration of 7.5 g/dl.  Thus, the restoration of both volume and Hb 
concentration is essential for successful resuscitation of a patient with severe hemorrhage. 
 
Our study demonstrated that HBOC-201 provided a significantly higher Hb concentration 
upon resuscitation than did 5.9% HSA. Based on improved Hb concentration and O2 
content, it appeared as if HBOC was the better resuscitation fluid.  However, HBOC-201 is 
still an imperfect solution because, although the total Hb increased, the Hb O2 saturation 
decreased significantly at R20 due to observed pulmonary edema that most likely 
compromised O2 diffusion in the lungs.  Furthermore, ISF PO2 was near zero at R120 for 
the HBOC-201 group in the smaller body weight group (~270 g), which is significantly less 
than ISF PO2 for the HSA group at the same time point.  Thus the efficacy of HBOC-201 
appears to be inferior compared to HSA as a resuscitation fluid despite increased O2 
carrying capacity.  
 
When NTG was added to HBOC-201, the resulting dilution lowered the Hb concentration 
of the HBOC-201/NTG mixture, and it also converted some of the Hb to MetHb.  Despite 
the elevation in non-O2 carrying Hb (MetHb) and a decrease in total Hb concentration, the 
HBOC-201/NTG mixture oxygenated the tissue significantly better than either HSA or 
HBOC-201 alone at R20 of the ~270 g rats. The HBOC-201/NTG group always performed 
better than the HBOC-201 group at R120 for both the ~270 g and ~370 g rats. The addition 
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of NO also had a systemic effect whereby it decreased the elevated MAP observed with 
HBOC-201 alone to the point where it was the same as volume control.  The results suggest 
that adding NO alleviates known side effects of increased vascular resistance and 
hypertension that are associated with HBOC-201 alone. 
 
Since HBOC-201 caused an elevation in MAP, we expected that there would be more 
vasoconstriction observed for animals in this group, but there was too much variability in 
all groups to discern a trend.  Even within the same animal both vasoconstriction and 
vasodilation were observed in different arterioles, and it may be explained by the 
devastating nature of severe hemorrhage and possibly the rapid blood withdrawal rate of 
0.8 ml/min. For example, in the smaller animals (~270 g), 40% of the BV was removed 
within 8 minutes. However, the increased MAP at R20 could be caused by vasoconstriction 
despite arteriolar constriction not being observed in the spinotrapezius muscle. This point 
was addressed in the Discussion section of ‘Top-loading.’ 
 
VO2 was measured for the larger weight (~370 g) rats, and VO2 was similar under baseline, 
hemorrhage and following resuscitation (R20) for HSA, HBOC-201 and HBOC-201/NTG 
animals. However at R60 and R120, VO2 was significantly lower with HBOC-201/NTG 
than HSA and HBOC-201. This decrease is probably caused by the increased concentration 
of NO, which inhibits mitochondrial respiration by binding to the cytochrome c oxidase 
(Olson et al, 2004). It could be expected that VO2 would increase with the HBOC-201 
group, since the ‘NO Scavenging’ theory suggests that HBOC decreases the NO 
availability, and thus less inhibition of mitochondrial respiration. The results did not 
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demonstrate a significant difference in VO2 between HSA and HBOC-201 animals, and 
this could be explained by the possibility that HBOC is not able to react with the NO in or 
near the mitochondria. 
 
Two weight classes (~270 g and ~370 g) of rats were studied for the ‘Hemorrhage and 
Resuscitation’ protocol, and even though these animals were set to lose 0.8 ml of blood per 
minute, the outcome was quite different. With the smaller rats, the ISF PO2 plot had a 
downward trend over time, while the larger rats had PO2 values insignificant from baseline 
at R120. Not surprisingly there was a higher mortality rate with the smaller animals than 
with the larger animals. This difference is most likely correlated to the duration of 
hemorrhage, in which a large rat would hemorrhage for a longer time, and thus the % 
volume per minute was lower, which translates to a less severe hemorrhage. Another factor 
is the weight of the rats, which is most likely correlated to age. Thus a mature male rat has 
a higher chance of survival than an adolescent male under the same stress condition.   
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Conclusions 
This study investigated the impact of HBOC-201 systemically and in the microcirculation 
of the male Sprague-Dawley rat spinotrapezius muscle.  Unique to other studies, PO2 was 
measured in the interstitium, which is a site closer to the mitochondrion than other systems 
such as whole-animal, organ or capillary.   
 
Several hypotheses were made and the studies carried out in this project were designed in 
an attempt to test them. 
 
Hypothesis 1. Animals receiving MP50 or LP50 will not have a lower MAP or less 
arteriolar constriction that HBOC-201. MP50 or LP50 will also not have a higher 
interstitial PO2 than HBOC-201. 
 
The “Autoregulation” theory was tested through modified HBOC-201 preparations and it 
was found that increasing the O2 affinity (MP50) and/or increasing the viscosity (LP50) did 
not reverse the hypertensive responses of HBOC-201. MP50 and LP50 did not have a 
higher ISF PO2 compared to HBOC-201. 
 
 
Hypothesis 2. HBOC-201 will increase MAP in a dose-dependent manner, but the 
interstitial PO2 will not display a dose-dependent response, because at baseline an animal 
should perform near the highest potential, and physiologically PO2 can only increase to a 
limited extent due to mechanisms that regulate tissue PO2. 
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There was a dose-dependent response between increasing concentrations of HBOC-201 
and elevated MAP. Although the ISF PO2 was higher with HBOC-201 infusion (1 – 300 
µM plasma Hb concentration) compared to baseline, no dose-dependent response was 
observed. 
 
 
Hypothesis 3. HBOC-201-infused animals should display a dose-dependent response to 
NTG, and the changes will be apparent with MAP, but not in interstitial PO2. 
 
In ‘Top-loading: Part II,’ the NO donor NTG reduced the elevated MAP caused by 
HBOC-201, while NTG had no effect on the volume control colloid solution, 5.9% HSA.  
Even though there was a dose-dependent trend, in which increasing concentrations of NTG 
caused an increasing change in MAP towards baseline values, the results were not 
statistically significant. 
 
 
Hypothesis 4. HBOC-201 is superior to colloids i.e. 5.9% human serum albumin, as 
determined by higher interstitial PO2 under conditions where hemoglobin concentration 
and blood volume are significantly compromised even though animals receiving HBOC-
201 have greater vasoconstriction and higher MAP. 
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For the ‘Hemorrhage and Resuscitation’ model, we predicted that HBOC-201 would 
perform better than 5.9% HSA at any time point after resuscitation. At R20 the HSA group 
produced a PO2 similar to the HBOC-201 group in both the ~270 g and the ~370 g rats. 
However by R120, the PO2 observed with HSA was always significantly higher than that 
observed with HBOC-201, which indicates that the iso-oncotic colloid is a better 
resuscitation fluid than HBOC-201 in this model of hemorrhage. 
 
 
Hypothesis 5. The addition of NO-donors to HBOC-201 will significantly improve the 
outcome, i.e. decrease vasoconstriction and hypertension, and thus increase tissue 
oxygenation. 
 
The results demonstrate that the HBOC-201/NTG group produced a higher ISF PO2 
compared to HSA and HBOC-201 at R20. However by R120 the PO2 of the HBOC-
201/NTG group was similar to that found with 5.9% HSA. The HBOC-201/NTG group had 
a significantly lower MAP compared to HBOC-201 at R20, and in fact the MAP of the 
HBOC-201/NTG group was not significantly different from the volume control group. By 
R120, the ISF PO2 was significantly higher in the HBOC-201/NTG group that HBOC-201 
for both the ~270 g and the ~370 g rats. 
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Appendix 
 
Following tables summarize data collected for each animal. For example, E7 symbolizes 
experimental (E) animal number 7, while C4 is control (C) animal number 4. 
Zones 1 through 4 are explained in Figure 2 (above). 
 
There are five sites;labeled A through E, where data were collected.  
Control signifies a state in which no hemodilution (HD) had occurred. 
HD1 (mild hemodilution) is the condition after the first isovolemic hemodilution, and 
HD2 (severe hemodilution) is the condition after the second isovolemic hemodilution. 
 
M = Mean 
SD or S = Standard Deviation 
SE = Standard Error [SE = SD / (srt (# of measurements)) 
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Animal Weight 
Top-Loading Part I  
 
5.9% HSA 
Date Weight (g) 
12/7/2009 287 
12/8/2009 303 
12/15/2009 307 
12/18/2009 330 
1/22/2010 265 
2/26/2010 247 
3/2/2010 230 
3/3/2010 253 
3/5/2010 245 
N = 9 274 ± 11 
 
HBOC-201 
Date Weight (g) 
11/2/2009 277 
11/4/2009 343 
11/13/2009 255 
11/17/2009 290 
11/18/2009 290 
1/27/2010 284 
2/2/2010 283 
2/3/2010 290 
N = 8 289 ± 9 
 
MP50 
Date Weight (g) 
2/12/2010 300 
2/16/2010a 350 
2/16/2010b 308 
2/23/2010 231 
2/24/2010 240 
3/1/2010 268 
3/2/2010a 234 
N = 7 276 ± 17 
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LP50 
Date Weight (g) 
9/2/2010 315 
9/2/2010 320 
9/3/2010 320 
9/16/2010 292 
9/21/2010 305 
9/27/2010 298 
9/28/2010 343 
9/30/2010 314 
N = 8 313 ± 16 
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Top-Loading Part II  
 
5.9% HSA 
Date Weight (g) NTG Dose (mg/kg) 
7/15/2010 A 280 0.1 
7/15/2010 B 277 0.1 
11/17/2010 B 246 0.1 
11/18/2010 243 0.1 
6/8/2010 245 0.3 
8/5/2010 320 0.3 
7/9/2010 263 1.0 
8/6/2010 329 1.0 
N = 8 275 ± 12  
 
HBOC-201 
Date Weight (g) NTG Dose (mg/kg) 
3/8/2010 255 0.1 
3/9/2010 280 0.1 
3/11/2010 241 0.1 
7/13/2010 241 0.1 
3/15/2010 266 0.3 
3/30/2010 233 0.3 
4/6/2010 282 0.3 
8/3/10 308 0.3 
3/10/2010 234 1.0 
3/24/2010 252 1.0 
3/25/2010 270 1.0 
7/14/2010 277 1.0 
N = 12 262 ± 7  
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Hemorrhage and Resuscitation  
  
~270g Rats 
5.9% HSA 
Date Weight (g) 
9-29-08 273 
10-2-08 288 
10-6-08 282 
10-28-08 288 
1-28-09 288 
3-4-09 246 
3-19-09 322 
4-7-09 229 
N = 8 277 ± 10 g 
 
HBOC-201 
Date Weight (g) 
10-10-08 306 
10-10-08 307 
10-14-08 323 
10-20-08 263 
1-28-09 281 
2-4-09 249 
2-5-09 252 
4-2-09 299 
N = 8 285 ± 10 g 
 
MP50 
Date Weight (g) 
10-29-08 244 
1-15-09 259 
1-23-09 238 
1-27-09 271 
3-6-09 262 
3-24-09 261 
N = 6 256 ± 5 g 
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~370g Rats 
5.9% HSA 
Date Weight (g) 
10-1-10 328 
10-15-10 344 
11-15-10 415 
12-3-10 340 
N = 4 357 ± 20 g 
 
HBOC-201 
Date Weight (g) 
10-6-10 353 
11-10-10 405 
12-9-10 345 
N = 3 368 ± 19 g 
 
MP50 
Date Weight (g) 
10-13-10 326 
11-11-10 400 
11-29-10 455 
12-2-10 340 
N = 4 380 ± 30 g 
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Top-loading Animals 
Part I 
 
5.9% HSA 
Date ISF PO2 ISF VO2 MAP / HR Diameter OSM-3 
12/7/2009   Yes N = 3 Yes 
12/8/2009   Yes N = 3 Yes 
12/15/2009   Yes N = 3 No 
12/18/2009   Yes N = 4 Yes 
1/22/2010   Yes N = 4 Yes 
2/26/2010   Yes N = 3 Yes 
3/2/2010   Yes N = 4 Yes 
3/3/2010   No N = 4 No 
3/5/2010   Yes N = 3 No 
 
N = 9   N = 8 N =  N = 6 
 
 
HBOC-201 (P50 = 40 mmHg) 
Date ISF PO2 ISF VO2 MAP / HR Diameter OSM-3 
11/2/2009   Yes N = 3 Yes 
11/4/2009   Yes N = 5 Yes 
11/13/2009   Yes N = 3 Yes 
11/17/2009   Yes N = 3 Yes 
11/18/2009   N/A N = 1 Yes 
1/27/2010   Yes N = 4 Yes 
2/2/2010   Yes N = 3 Yes 
2/3/2010   Yes N = 4 Yes 
 
N = 8   N = 7 N = 26 N = 8 
 
 
MP50 (HBOC-201with P50 = 18 mmHg) 
Date ISF PO2 ISF VO2 MAP / HR Diameter OSM-3 
2/12/2010   N/A N = 3 N/A 
2/16/2010a   Yes N = 3 Yes 
2/16/2010b   Yes N/A N/A 
2/23/2010   Yes N = 3 Yes 
2/24/2010   Yes N = 6 Yes 
3/1/2010   Yes N = 4 N/A 
3/2/2010a   Yes N = 3 Yes 
 
N = 7   N = 6 N = 22 N = 4 
 
 
LP50 (HBOC-201 with P50 = 17 mmHg and 4.0 cP) 
Date ISF PO2 ISF VO2 MAP / HR Diameter OSM-3 
9/2/2010   Yes N = 4 Yes 
9/2/2010   Yes N = 4 Yes 
9/3/2010   Yes N = 5 No 
9/16/2010   No N = 5 No 
9/21/2010   Yes N = 6 Yes 
9/27/2010   Yes N = 4 Yes 
9/28/2010   Yes N = 6 Yes 
9/30/2010   Yes N = 4 Yes 
 
N = 8   N = 7 N = 38 N = 7 
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Part II 
 
0.5 ml of 5.9% HSA w/ 0.1 mg/kg NTG 
Date ISF PO2 ISF VO2 MAP / HR Diameter OSM-3 
7/15/2010 A   Yes N = 4 Yes 
7/15/2010 B   Yes N = 6 Yes 
      
 
N = 2      
 
0.5 ml of 5.9% HSA w/ 0.3 mg/kg NTG 
Date ISF PO2 ISF VO2 MAP / HR Diameter OSM-3 
6/8/2010   Yes N = 7 Yes 
8/5/2010   Yes N = 4 Yes 
      
 
N = 2      
 
0.5 ml of 5.9% HSA w/ 1.0 mg/kg NTG 
Date ISF PO2 ISF VO2 MAP / HR Diameter OSM-3 
7/9/2010   Yes N = 5 Yes 
8/6/2010   Yes N = 4 Yes 
      
 
N = 2      
 
 
 
 
100 uM (0.5 ml) HBOC-201 (P50 = 40 mmHg) w/ 0.1 mg/kg 
Date ISF PO2 ISF VO2 MAP / HR Diameter OSM-3 
3/8/2010   Yes N = 5 Yes 
3/9/2010   Yes N = 5 Yes 
3/11/2010   Yes N = 4 Yes 
7/13/2010   Yes N = 8 Yes 
 
N = 4   N = 4 N = 22 N = 4 
 
100 uM (0.5 ml) HBOC-201 (P50 = 40 mmHg) w/ 0.3 mg/kg 
Date ISF PO2 ISF VO2 MAP / HR Diameter OSM-3 
3/15/2010   Yes N = 5 N/A 
3/30/2010   Yes N = 6 Yes 
4/6/2010   Yes N = 6 Yes 
8/3/10   Yes N = 4 Yes 
 
N = 4   N = 4 N = 21 N = 3 
 
 
100 uM (0.5 ml) HBOC-201 (P50 = 40 mmHg) w/ 1.0 mg/kg 
Date ISF PO2 ISF VO2 MAP / HR Diameter OSM-3 
3/10/2010   Yes N = 4 N/A 
3/24/2010   Yes N = 5 Yes 
3/25/2010   Yes N = 2 N/A 
7/14/2010   Yes N = 6 Yes 
 
N = 4   N = 3 N = 17 N = 1 
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HBOC Top-load Study 
 
GROUP: 5.9% Human Serum Albumin 
Animal ID/Date of Experiment: 12/7/2009 
Scheduled Delivery: 11/30/2009 
 
Weight: 287 g 
Baseline Hct: 40.0% Final Hct: N/A 
 
Volume infused: 
Dose 1:  0.1 mL 
Dose 2:  0.1 mL 
Dose 3: 0.5 mL 
Dose 4: 1.5 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
13.3  G/L tHb 12.4  G/L tHb  
99.0 % SAT 97.4 % SAT 
 
 
4.1 % HbCO 3.8 % HbCO
 
 
0.3  % metHb 0.6 % metHb 
17.5 Vol % O2 ct 16.0 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
50 50  70  70  60 
100 90  80  80  60 
105 80  95  90  85 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 97 104 363  363 
Dose 2 102 375 
Dose 3 90 107 363 
Dose 4 88 125 387 
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HBOC Top-load Study 
 
GROUP: 5.9% Human Serum Albumin 
Animal ID/Date of Experiment: 12/8/2009 
Scheduled Delivery: 11/30/2009 
 
Weight: 303 g 
Baseline Hct: 38.9% Final Hct: N/A 
 
Volume infused: 
Dose 1:  0.1 mL 
Dose 2:  0.1 mL 
Dose 3: 0.5 mL 
Dose 4: 1.5 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
13.0  G/L tHb 11.9  G/L tHb  
99.1 % SAT 99.3 % SAT 
 
 
4.1 % HbCO 4.0 % HbCO
 
 
0.4 % metHb 0.3 % metHb 
17.1 Vol % O2 ct 15.7 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
95 100 100  110  N/A 
70 70  75  90  N/A 
100 110 110  110  N/A 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 92 96 400  387 
Dose 2 93 98 413  413 
Dose 3 105 118 413  428 
Dose 4 110 144 428  444 
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HBOC Top-load Study 
 
GROUP: 5.9% Human Serum Albumin 
Animal ID/Date of Experiment: 12/15/2009 
Scheduled Delivery: 11/30/2009 
 
Weight: 307 g 
Baseline Hct: 40.3% Final Hct: N/A 
 
Volume infused: 
Dose 1:  0.1 mL 
Dose 2:  0.1 mL 
Dose 3: 0.5 mL 
Dose 4: 1.5 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
13.7  G/L tHb N/A G/L tHb  
103 % SAT N/A % SAT 
 
 
4.2 % HbCO N/A % HbCO
 
 
0.4  % metHb N/A % metHb 
18.7 Vol % O2 ct N/A Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
120 145 140  140  130 
140 140 140  130  140 
135 140 135  135  135 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 100 105 333  352 
Dose 2 N/A N/A 
Dose 3 108 118 363 387 
Dose 4 114 129 363  375 
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HBOC Top-load Study 
 
GROUP: 5.9% Human Serum Albumin 
Animal ID/Date of Experiment: 12/18/2009 
Scheduled Delivery: 11/30/2009 
 
Weight: 330 g 
Baseline Hct: 43.7% Final Hct: N/A 
 
Volume infused: 
Dose 1:  0.1 mL 
Dose 2:  0.1 mL 
Dose 3: 0.5 mL 
Dose 4: 1.5 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
13.6  G/L tHb 13.0 G/L tHb  
97.5 % SAT 99.3 % SAT 
 
 
3.8 % HbCO 3.8 % HbCO
 
 
0.3  % metHb 0.4 % metHb 
17.7 Vol % O2 ct 17.2 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
115 130 120  130  135 
135 140 135  140  130 
70 75 80  80  75 
145 145 140 150 140 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 83 88 333  342 
Dose 2 94 95 352  352 
Dose 3 101 107 363 363 
Dose 4 116 121 375  387 
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HBOC Top-load Study 
 
GROUP: 5.9% Human Serum Albumin 
Animal ID/Date of Experiment: 1/22/2010 
Scheduled Delivery: 1/19/2010 
 
Weight: 265 g 
Baseline Hct: N/A Final Hct: N/A 
 
Volume infused: 
Dose 1:  0.1 mL 
Dose 2:  0.1 mL 
Dose 3: 0.5 mL 
Dose 4: 1.5 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
12.7  G/L tHb 11.4 G/L tHb  
97.6 % SAT 99.1 % SAT 
 
 
4.0 % HbCO 3.8 % HbCO
 
 
0.3  % metHb 0.7 % metHb 
16.5  Vol % O2 ct 15.0 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
70 75 70  70  55 
90 70 75  80  70 
50 45 55  50  50 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 96 104 352  400 
Dose 2 100 104 363  375 
Dose 3 107 115 387  400 
Dose 4 110 119 400  413 
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HBOC Top-load Study 
 
GROUP: 5.9% Human Serum Albumin 
Animal ID/Date of Experiment: 2/26/2010 
Scheduled Delivery: 2/22/2010 
 
Weight: 247 g 
Baseline Hct: N/A Final Hct: N/A 
 
Volume infused: 
Dose 1:  0.1 mL 
Dose 2:  0.1 mL 
Dose 3: 0.5 mL 
Dose 4: 1.5 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
12.8  G/L tHb 13.5 G/L tHb  
96.8 % SAT 94.6 % SAT 
 
 
3.6 % HbCO 3.8 % HbCO
 
 
0.3  % metHb 0.3 % metHb 
16.5  Vol % O2 ct 17.0 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
90 85 80  65  55 
70 85 75  65  60 
50 60 45  50  40 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 97 101 N/A 
Dose 2 95 96 N/A 
Dose 3 99 108 N/A 
Dose 4 99 119 N/A 
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HBOC Top-load Study 
 
GROUP: 5.9% Human Serum Albumin 
Animal ID/Date of Experiment: 3/2/2010 
Scheduled Delivery: 3/1/2010 
 
Weight: 230 g 
Baseline Hct: 42.3% Final Hct: N/A 
 
Volume infused: 
Dose 1:  0.1 mL 
Dose 2:  0.1 mL 
Dose 3: 0.5 mL 
Dose 4: 1.5 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
12.9  G/L tHb 12.3 G/L tHb  
98.0 % SAT 89.0 % SAT 
 
 
3.9 % HbCO 3.3 % HbCO
 
 
0.1  % metHb 0.2 % metHb 
16.9 Vol % O2 ct 14.7 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
95 105 100  100 105 
105 100 105  110  110 
30 25 30  30  25 
105 105 105 110 115 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 85 85 308  316 
Dose 2 99 99 316  316 
Dose 3 105 110 333  375 
Dose 4 114 115 342  363 
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HBOC Top-load Study 
 
GROUP: 5.9% Human Serum Albumin 
Animal ID/Date of Experiment: 3/3/2010 
Scheduled Delivery: 3/1/2010 
 
Weight: 253 g 
Baseline Hct: 42.3% Final Hct: N/A 
 
Volume infused: 
Dose 1:  0.1 mL 
Dose 2:  0.1 mL 
Dose 3: 0.5 mL 
Dose 4: 1.5 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
11.3  G/L tHb N/A G/L tHb  
98.7 % SAT N/A % SAT 
 
 
3.8 % HbCO N/A % HbCO
 
 
0.4  % metHb N/A % metHb 
14.9 Vol % O2 ct N/A Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
85 90 85  95 105 
90 90 85  95  95 
20 15 15  20  20 
95 95 90 100 95 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 N/A N/A 
Dose 2 N/A N/A 
Dose 3 N/A N/A 
Dose 4 N/A N/A 
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HBOC Top-load Study 
 
GROUP: 5.9% Human Serum Albumin 
Animal ID/Date of Experiment: 3/5/2010 
Scheduled Delivery: 3/1/2010 
 
Weight: 245 g 
Baseline Hct: 38.0% Final Hct: N/A 
 
Volume infused: 
Dose 1:  0.1 mL 
Dose 2:  0.1 mL 
Dose 3: 0.5 mL 
Dose 4: 1.5 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
12.6  G/L tHb N/A G/L tHb  
96.5 % SAT N/A % SAT 
 
 
3.7 % HbCO N/A % HbCO
 
 
0.6  % metHb N/A % metHb 
16.2 Vol % O2 ct N/A Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
90 100 110  105  110 
120 120 120  115  120 
20 25 25 25 25 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 85 76 333  324 
Dose 2 80 76 316  300 
Dose 3 8388 316  316 
Dose 4 8194 324  333 
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HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) 
Animal ID/Date of Experiment: 11/2/2009 
Scheduled Delivery: 10/26/2009 
 
Weight: 277 g 
Baseline Hct: 40.0% Final Hct: N/A 
 
Volume infused: 
Dose 1 (1 µM):  0.005 mL 
Dose 2 (10 µM):  0.050 mL 
Dose 3 (100 µM): 0.525 mL 
Dose 4 (300 µM): 1.812 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
13.0  G/L tHb 13.7 G/L tHb  
98.4 % SAT 91.2 % SAT 
 
 
3.8 % HbCO 3.5 % HbCO
 
 
0.4  % metHb 0.6 % metHb 
17.0 Vol % O2 ct 16.7 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
100 100 95  95  95 
50 55 55  50  50 
95 100 100 95 100 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 N/A N/A 
Dose 2 N/A N/A 
Dose 3 N/A N/A 
Dose 4 N/A N/A 
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HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) 
Animal ID/Date of Experiment: 11/4/2009 
Scheduled Delivery: N/A 
 
Weight: 343 g 
Baseline Hct: 42.5% Final Hct: N/A 
 
Volume infused: 
Dose 1 (1 µM):  0.006 mL 
Dose 2 (10 µM):  0.062 mL 
Dose 3 (100 µM): 0.642 mL 
Dose 4 (300 µM): 2.163 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
13.2  G/L tHb 14.6 G/L tHb  
101 % SAT 95.6 % SAT 
 
 
4.1 % HbCO 3.8 % HbCO
 
 
0.3  % metHb 0.7 % metHb 
17.7  Vol % O2 ct 18.5 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
95 95 85  80  80 
95 90 85  80  80 
45 40 40 40 40 
40 40 35 35 40 
30 25 25 20 25 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Baseline 100 387 
Dose 1 109 413 
Dose 2 113 400 
Dose 3 146 400 
Dose 4 149 387 
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HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) 
Animal ID/Date of Experiment: 11/13/2009 
Scheduled Delivery: 11/9/2009 
 
Weight: 255 g 
Baseline Hct: 37.5% Final Hct: N/A 
 
Volume infused: 
Dose 1 (1 µM):  0.005 mL 
Dose 2 (10 µM):  0.046 mL 
Dose 3 (100 µM): 0.486 mL 
Dose 4 (300 µM): 1.695 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
12.4  G/L tHb 13.1 G/L tHb  
97.9 % SAT 64.0 % SAT 
 
 
3.8 % HbCO 2.5 % HbCO
 
 
0.4  % metHb 0.4 % metHb 
16.2  Vol % O2 ct 11.3 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
N/A N/A N/A N/A N/A 
 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Baseline 95 342 
Dose 1 107 324 
Dose 2 120 363 
Dose 3 140 352 
Dose 4 134 342 
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HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) 
Animal ID/Date of Experiment: 11/17/2009 
Scheduled Delivery: 11/9/2009 
 
Weight: 290 g 
Baseline Hct: 38.5% Final Hct: N/A 
 
Volume infused: 
Dose 1 (1 µM):  0.005 mL 
Dose 2 (10 µM):  0.052 mL 
Dose 3 (100 µM): 0.548 mL 
Dose 4 (300 µM): 1.881 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
12.7  G/L tHb 14.0 G/L tHb  
99.3 % SAT 97.0 % SAT 
 
 
4.0 % HbCO 3.7 % HbCO
 
 
0.5  % metHb 0.6 % metHb 
16.8  Vol % O2 ct 18.1 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
90 85 80 80 75 
80 80 75 70 65 
50 45 40 45 45 
 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Baseline 82 400 
Dose 1 89 413 
Dose 2 105 428 
Dose 3 125 413 
Dose 4 132 413 
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HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) 
Animal ID/Date of Experiment: 11/18/2009 
Scheduled Delivery: 11/9/2009 
 
Weight: 290 g 
Baseline Hct: N/A Final Hct: N/A 
 
Volume infused: 
Dose 1 (1 µM):  0.005 mL 
Dose 2 (10 µM):  0.052 mL 
Dose 3 (100 µM): 0.548 mL 
Dose 4 (300 µM): 1.881 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
12.4  G/L tHb 14.2 G/L tHb  
93.7 % SAT 84.5 % SAT 
 
 
3.7 % HbCO 3.2 % HbCO
 
 
0.3  % metHb 0.6 % metHb 
15.5  Vol % O2 ct 16.0 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
75 75 75 70 70 
 
 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Baseline N/A N/A 
Dose 1 N/A N/A 
Dose 2 N/A N/A 
Dose 3 N/A N/A 
Dose 4 N/A N/A 
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HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) 
Animal ID/Date of Experiment: 1/27/2010 
Scheduled Delivery: 1/19/2010 
 
Weight: 284 g 
Baseline Hct: 43.0% Final Hct: N/A 
 
Volume infused: 
Dose 1 (1 µM):  0.005 mL 
Dose 2 (10 µM):  0.051 mL 
Dose 3 (100 µM): 0.537 mL 
Dose 4 (300 µM): 1.849 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
13.0  G/L tHb N/A G/L tHb  
99.2 % SAT N/A % SAT 
 
 
3.4 % HbCO N/A % HbCO
 
 
0.3  % metHb N/A % metHb 
17.3 Vol % O2 ct N/A Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
70 70 65 75 75 
70 60 65 65 65 
90 100 105 110 110 
100 105 105 110 105 
 
 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 117 124 400  387 
Dose 2 119 139 400  413 
Dose 3 129159 444  480 
Dose 4 159163 444  400 
  
252
Page 
252 
 
  
HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) 
Animal ID/Date of Experiment: 2/2/2010 
Scheduled Delivery: 1/25/2010 
 
Weight: 283 g 
Baseline Hct: 37.5% Final Hct: N/A 
 
Volume infused: 
Dose 1 (1 µM):  0.005 mL 
Dose 2 (10 µM):  0.051 mL 
Dose 3 (100 µM): 0.537 mL 
Dose 4 (300 µM): 1.844 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
12.7  G/L tHb 13.5 G/L tHb  
99.1 % SAT 92.7 % SAT 
 
 
3.8 % HbCO 3.7 % HbCO
 
 
0.5  % metHb 0.9 % metHb 
16.7 Vol % O2 ct 16.6 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
110 110 115 112 125 
50 55 55 50 45 
110 120 120 120 125 
 
 
 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 81 89 375  375 
Dose 2 96 116 387  387 
Dose 3 114142 375  387 
Dose 4 134141 363  352 
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HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) 
Animal ID/Date of Experiment: 2/3/2010 
Scheduled Delivery: 1/25/2010 
 
Weight: 290 g 
Baseline Hct: 39.4% Final Hct: N/A 
 
Volume infused: 
Dose 1 (1 µM):  0.005 mL 
Dose 2 (10 µM):  0.052 mL 
Dose 3 (100 µM): 0.548 mL 
Dose 4 (300 µM): 1.881 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
12.6 G/L tHb 13.7 G/L tHb  
101.9 % SAT 89.5 % SAT 
 
 
4.3 % HbCO 3.5 % HbCO
 
 
0.1  % metHb 0.8 % metHb 
17.1 Vol % O2 ct 16.3 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
50 60 60 60 55 
100 115 125 125 120 
120 125 130 130 130 
50 45 50 45 45 
 
 
 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 92 115 342  363 
Dose 2 87 118 352  375 
Dose 3 91124 342  352 
Dose 4 120144 428  375 
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HBOC Top-load Study 
 
GROUP: MP50 (HBOC-201 with P50 = 18 mmHg) 
Animal ID/Date of Experiment: 2/12/2010 
Scheduled Delivery: 1/25/2010 
 
Weight: 300 g 
Baseline Hct: N/A Final Hct: N/A 
 
Volume infused: 
Dose 1 (1 µM):  0.005 mL 
Dose 2 (10 µM):  0.054 mL 
Dose 3 (100 µM): 0.566 mL 
Dose 4 (300 µM): 1.935 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
N/A G/L tHb N/A G/L tHb  
N/A % SAT N/A % SAT 
 
 
N/A % HbCO N/A % HbCO
 
 
N/A % metHb N/A % metHb 
N/A Vol % O2 ct N/A Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
60 65 60 55 50 
120 100 100 105 100 
105 100 90 100 100 
 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 N/A N/A 
Dose 2 N/A N/A 
Dose 3 N/A N/A 
Dose 4 N/A N/A 
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HBOC Top-load Study 
 
GROUP: MP50 (HBOC-201 with P50 = 18 mmHg) 
Animal ID/Date of Experiment: 2/16/2010 
Scheduled Delivery: 1/25/2010 
 
Weight: 350 g 
Baseline Hct: 41.1% Final Hct: N/A 
 
Volume infused: 
Dose 1 (1 µM):  0.006 mL 
Dose 2 (10 µM):  0.063 mL 
Dose 3 (100 µM): 0.655 mL 
Dose 4 (300 µM): 2.201 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
13.5 G/L tHb 14.6 G/L tHb  
96.1 % SAT 91.6 % SAT 
 
 
3.7 % HbCO 3.7 % HbCO
 
 
0.2  % metHb 0.6 % metHb 
17.3  Vol % O2 ct 17.8 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
120 120 120 120 120 
120 120 120 120 110 
105 105 115 110 105 
 
 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 68 77 292  300 
Dose 2 70 72 285  300 
Dose 3 72110 300  293 
Dose 4 106121 300  307 
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HBOC Top-load Study 
 
GROUP: MP50 (HBOC-201 with P50 = 18 mmHg) 
Animal ID/Date of Experiment: 2/16/2010 
Scheduled Delivery: 1/25/2010 
 
Weight: 308 g 
Baseline Hct: 48.6% Final Hct: N/A 
 
Volume infused: 
Dose 1 (1 µM):  0.006 mL 
Dose 2 (10 µM):  0.056 mL 
Dose 3 (100 µM): 0.580 mL 
Dose 4 (300 µM): 1.978 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
15.2 G/L tHb 15.7 G/L tHb  
99.8 % SAT 90.5 % SAT 
 
 
3.6 % HbCO 3.5 % HbCO
 
 
0.1  % metHb 0.8 % metHb 
20.3  Vol % O2 ct 18.9 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
N/A N/A N/A N/A N/A 
 
 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 83 92 325  324 
Dose 2 81 97 285  300 
Dose 3 83122 292  308 
Dose 4 112131 324  308 
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HBOC Top-load Study 
 
GROUP: MP50 (HBOC-201 with P50 = 18 mmHg) 
Animal ID/Date of Experiment: 2/23/2010 
Scheduled Delivery: 2/22/2010 
 
Weight: 231 g 
Baseline Hct: 42.5% Final Hct: N/A 
 
Volume infused: 
Dose 1 (1 µM):  0.004 mL 
Dose 2 (10 µM):  0.042 mL 
Dose 3 (100 µM): 0.444 mL 
Dose 4 (300 µM): 1.568 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
13.1 G/L tHb 14.9 G/L tHb  
99.9 % SAT 99.8 % SAT 
 
 
4.0 % HbCO 4.3 % HbCO
 
 
0.1  % metHb 1.3 % metHb 
17.4  Vol % O2 ct 19.5 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
45 40 40 30 30 
90 85 90 80 80 
90 85 80 80 80 
 
 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 110  120 375  375 
Dose 2 106  124 414  400 
Dose 3 110  163 400  387 
Dose 4 160  166 375  400 
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HBOC Top-load Study 
 
GROUP: MP50 (HBOC-201 with P50 = 18 mmHg) 
Animal ID/Date of Experiment: 2/24/2010 
Scheduled Delivery: 2/22/2010 
 
Weight: 240 g 
Baseline Hct: N/A Final Hct: N/A 
 
Volume infused: 
Dose 1 (1 µM):  0.004 mL 
Dose 2 (10 µM):  0.044 mL 
Dose 3 (100 µM): 0.459 mL 
Dose 4 (300 µM): 1.616 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
13.0 G/L tHb 13.7 G/L tHb  
102.2 % SAT 94.7 % SAT 
 
 
4.2 % HbCO 4.0 % HbCO
 
 
0.3  % metHb 1.0 % metHb 
17.6 Vol % O2 ct 17.1 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
85 80 80 80 85 
55 55 55 50 50 
80 85 90 95 90 
55 55 55 55 55 
25 20 25 25 20 
60 60 60 60 55 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 90 93 400  400 
Dose 2 91 96 413  414 
Dose 3 95147 444  400 
Dose 4 131 148 375  363 
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HBOC Top-load Study 
 
GROUP: MP50 (HBOC-201 with P50 = 18 mmHg) 
Animal ID/Date of Experiment: 3/1/2010 
Scheduled Delivery: 2/22/2010 
 
Weight: 268 g 
Baseline Hct: N/A Final Hct: N/A 
 
Volume infused: 
Dose 1 (1 µM):  0.005 mL 
Dose 2 (10 µM):  0.048 mL 
Dose 3 (100 µM): 0.510 mL 
Dose 4 (300 µM): 1.765 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
N/A G/L tHb N/A G/L tHb  
N/A % SAT N/A % SAT 
 
 
N/A % HbCO N/A % HbCO
 
 
N/A % metHb N/A % metHb 
N/A Vol % O2 ct N/A Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
70 60 55 40 35 
95 100 95 90 80 
85 90 90 90 85 
80 75 80 80 80 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 102 102 N/A 
Dose 2 102 105 N/A 
Dose 3 107137 N/A 
Dose 4 128 137 N/A 
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HBOC Top-load Study 
 
GROUP: MP50 (HBOC-201 with P50 = 18 mmHg) 
Animal ID/Date of Experiment: 3/2/2010 
Scheduled Delivery: 3/1/2010 
 
Weight: 234 g 
Baseline Hct: 36.6% Final Hct: N/A 
 
Volume infused: 
Dose 1 (1 µM):  0.004 mL 
Dose 2 (10 µM):  0.042 mL 
Dose 3 (100 µM): 0.449 mL 
Dose 4 (300 µM): 1.584 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
N/A G/L tHb 13.7 G/L tHb  
98.9 % SAT 85.2 % SAT 
 
 
3.9 % HbCO 3.4 % HbCO
 
 
0.4  % metHb 1.2 % metHb 
14.2  Vol % O2 ct 15.5 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
60 55 50 55 55 
80 85 90 80 80 
85 95 90 85 90 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 86 91 332  324 
Dose 2 126 124 324  333 
Dose 3 105141 363  363 
Dose 4 133 142 352  375 
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HBOC Top-load Study 
 
GROUP: LP50 (HBOC-201 with P50 = 18 mmHg and 4 cP) 
Animal ID/Date of Experiment:9/2/2010 
Scheduled Delivery: 8/16/2010 
 
Weight: 315 g 
Baseline Hct: 44.4% Final Hct: 42.0% 
 
Volume infused: 
Dose 1 (1 µM):  0.006 mL 
Dose 2 (10 µM):  0.057 mL 
Dose 3 (100 µM): 0.593 mL 
Dose 4 (300 µM): 2.014 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
14.0 G/L tHb 14.5 G/L tHb  
94.5 % SAT 94.1 % SAT 
 
 
3.8 % HbCO 3.6 % HbCO
 
 
0.4  % metHb 0.5 % metHb 
17.6  Vol % O2 ct 18.2 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
125 125 125 125 125 
50 45 40 45 45 
120 120 120 120 120 
110 125 125 120 125 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 98 109 347  357 
Dose 2 100 136 360  366 
Dose 3 123140 378  362 
Dose 4 129 145 368  347 
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HBOC Top-load Study 
 
GROUP: LP50 (HBOC-201 with P50 = 18 mmHg and 4 cP) 
Animal ID/Date of Experiment:9/2/2010 
Scheduled Delivery: 8/16/2010 
 
Weight: 320 g 
Baseline Hct: N/A Final Hct: N/A 
 
Volume infused: 
Dose 1 (1 µM):  0.006 mL 
Dose 2 (10 µM):  0.058 mL 
Dose 3 (100 µM): 0.602 mL 
Dose 4 (300 µM): 2.041 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
N/A G/L tHb N/A G/L tHb  
N/A % SAT N/A % SAT 
 
 
N/A % HbCO N/A % HbCO
 
 
N/A % metHb N/A % metHb 
N/A Vol % O2 ct N/A Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
110 120 115 120 110 
130 100 115 105 105 
100 100 90 85 70 
130 120 115 115 120 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 105 115 439  438 
Dose 2 109 119 440  441 
Dose 3 114135 443  436 
Dose 4 124 153 444  438 
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HBOC Top-load Study 
 
GROUP: LP50 (HBOC-201 with P50 = 18 mmHg and 4 cP) 
Animal ID/Date of Experiment:9/3/2010 
Scheduled Delivery: 8/16/2010 
 
Weight: 320 g 
Baseline Hct: N/A Final Hct: N/A 
 
Volume infused: 
Dose 1 (1 µM):  0.006 mL 
Dose 2 (10 µM):  0.058 mL 
Dose 3 (100 µM): 0.602 mL 
Dose 4 (300 µM): 2.041 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
N/A G/L tHb N/A G/L tHb  
N/A % SAT N/A % SAT 
 
 
N/A % HbCO N/A % HbCO
 
 
N/A % metHb N/A % metHb 
N/A Vol % O2 ct N/A Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
115 115 115 110 105 
25 25 20 20 20 
120 125 115 120 110 
20 20 20 20 15 
125 120 120 115 110 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 93 111 395  397 
Dose 2 88 151 400  401 
Dose 3 124162 400  387 
Dose 4 156 178 399  385 
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HBOC Top-load Study 
 
GROUP: LP50 (HBOC-201 with P50 = 18 mmHg and 4 cP) 
Animal ID/Date of Experiment:9/16/2010 
Scheduled Delivery: 9/7/2010 
 
Weight: 292 g 
Baseline Hct: 40.3% Final Hct: 38.6% 
 
Volume infused: 
Dose 1 (1 µM):  0.005 mL 
Dose 2 (10 µM):  0.053 mL 
Dose 3 (100 µM): 0.552 mL 
Dose 4 (300 µM): 1.892 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
N/A G/L tHb N/A G/L tHb  
N/A % SAT N/A % SAT 
 
 
N/A % HbCO N/A % HbCO
 
 
N/A % metHb N/A % metHb 
N/A Vol % O2 ct N/A Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
40 40 35 35 N/A 
10 10 10 65 N/A 
40 40 35 35 N/A 
100 95 95 80 N/A 
90 85 90 90 N/A 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 75 99 335  348 
Dose 2 76 135 337  365 
Dose 3 102138 357  368 
Dose 4 118 138 369  370 
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HBOC Top-load Study 
 
GROUP: LP50 (HBOC-201 with P50 = 18 mmHg and 4 cP) 
Animal ID/Date of Experiment:9/21/2010 
Scheduled Delivery: 9/7/2010 
 
Weight: 305 g 
Baseline Hct: 43.7% Final Hct: 43.1% 
 
Volume infused: 
Dose 1 (1 µM):  0.005 mL 
Dose 2 (10 µM):  0.055 mL 
Dose 3 (100 µM): 0.575 mL 
Dose 4 (300 µM): 1.961 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
14.3 G/L tHb 15.4 G/L tHb  
97.1 % SAT 98.6 % SAT 
 
 
4.3 % HbCO 3.8 % HbCO
 
 
0.9 % metHb 1.3 % metHb 
18.3 Vol % O2 ct 20.0 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
135 135 130 130 125 
75 85 80 80 85 
105 115 110 105 120 
40 55 45 35 40 
25 30 20 15 15 
50 55 45 30 40 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 103 119 308  323 
Dose 2 104 135 329  335 
Dose 3 118149 344  354 
Dose 4 141 167 364  367 
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HBOC Top-load Study 
 
GROUP: LP50 (HBOC-201 with P50 = 18 mmHg and 4 cP) 
Animal ID/Date of Experiment:9/27/2010 
Scheduled Delivery: 9/7/2010 
 
Weight: 298 g 
Baseline Hct: 42.3% Final Hct: 41.7% 
 
Volume infused: 
Dose 1 (1 µM):  0.005 mL 
Dose 2 (10 µM):  0.054 mL 
Dose 3 (100 µM): 0.563 mL 
Dose 4 (300 µM): 1.924 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
14.1 G/L tHb 15.1 G/L tHb  
97.9 % SAT 96.6 % SAT 
 
 
3.9 % HbCO 4.1 % HbCO
 
 
1.1 % metHb 1.8 % metHb 
18.2 Vol % O2 ct 19.1 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
115 110 115 115 115 
110 115 115 115 120 
30 30 30 30 25 
115 120 120 115 120 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 97 110 288  303 
Dose 2 95 140 288  339 
Dose 3 130146 342  357 
Dose 4 127 164 355  345 
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HBOC Top-load Study 
 
GROUP: LP50 (HBOC-201 with P50 = 18 mmHg and 4 cP) 
Animal ID/Date of Experiment:9/28/2010 
Scheduled Delivery: 9/7/2010 
 
Weight: 343 g 
Baseline Hct: 43.7% Final Hct: 43.6% 
 
Volume infused: 
Dose 1 (1 µM):  0.006 mL 
Dose 2 (10 µM):  0.062 mL 
Dose 3 (100 µM): 0.642 mL 
Dose 4 (300 µM): 2.163 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
13.2 G/L tHb 15.6 G/L tHb  
95.9 % SAT 93.0 % SAT 
 
 
3.9 % HbCO 4.2 % HbCO
 
 
0.7 % metHb 1.3 % metHb 
16.8 Vol % O2 ct 19.1 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
30 30 30 30 30 
50 50 55 60 55 
50 50 60 60 55 
60 50 50 60 50 
80 80 85 80 80 
75 75 70 70 75 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 93 126 316  353 
Dose 2 105 142 343  364 
Dose 3 100169 353  375 
Dose 4 159 175 400  387 
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HBOC Top-load Study 
 
GROUP: LP50 (HBOC-201 with P50 = 18 mmHg and 4 cP) 
Animal ID/Date of Experiment:9/30/2010 
Scheduled Delivery: 9/7/2010 
 
Weight: 314 g 
Baseline Hct: 47.7% Final Hct: 45.7% 
 
Volume infused: 
Dose 1 (1 µM):  0.006 mL 
Dose 2 (10 µM):  0.057 mL 
Dose 3 (100 µM): 0.591 mL 
Dose 4 (300 µM): 2.009 mL 
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
15.8 G/L tHb 16.4 G/L tHb  
95.0 % SAT 93.5 % SAT 
 
 
4.1 % HbCO 3.3 % HbCO
 
 
0.9 % metHb 1.9 % metHb 
19.8 Vol % O2 ct 20.2 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  Dose 3  Dose 4 
110 105 105 110 105 
55 55 55 60 55 
110 110 110 110 110 
105 100 105 105 100 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 79 127 284  319 
Dose 2 81 145 392  320 
Dose 3 87151 300  323 
Dose 4 141 162 329  314 
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HBOC Top-load Study 
 
GROUP: 5.9% HSA + NTG 
Animal ID/Date of Experiment:7/15/2010 A 
Scheduled Delivery: 7/6/2010 
 
Weight: 280 g 
Baseline Hct: 42.3% Final Hct: 40.9% 
 
Volume infused: 
Dose 1: (0.5 ml of 5.9% HSA)  
Dose 2: (0.1 mg/kg NTG)   
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
13.8 G/L tHb 13.3 G/L tHb  
96.3 % SAT 97.7 % SAT 
 
 
4.0 % HbCO 4.0 % HbCO
 
 
0.3 % metHb 0.4 % metHb 
17.7 Vol % O2 ct 17.3 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2   
90 90 95  
110 100 110  
110 110 110  
55 70 70  
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 79 134 413  429 
Dose 2 124 111 418  429 
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HBOC Top-load Study 
 
GROUP: 5.9% HSA + NTG 
Animal ID/Date of Experiment:7/15/2010 B 
Scheduled Delivery: 7/6/2010 
 
Weight: 277 g 
Baseline Hct: 40.0% Final Hct: 38.0% 
 
Volume infused: 
Dose 1: (0.5 ml of 5.9% HSA)  
Dose 2: (0.1 mg/kg NTG)   
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
13.6 G/L tHb 12.9 G/L tHb  
92.5 % SAT 93.6 % SAT 
 
 
3.9 % HbCO 3.9 % HbCO
 
 
0.3 % metHb 0.5 % metHb 
16.7 Vol % O2 ct 16.0 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2   
45 50 50  
25 14 25  
45 50 45  
70 75 85 
45 50 45 
70 75 85 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 82 136 363  444 
Dose 2 121 115 428  428 
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HBOC Top-load Study 
 
GROUP: 5.9% HSA + NTG 
Animal ID/Date of Experiment:11/17/2010 B 
Scheduled Delivery: 11/15/2010 
 
Weight: 246 g 
Baseline Hct: N/A Final Hct: N/A 
 
Volume infused: 
Dose 1: (0.5 ml of 5.9% HSA)  
Dose 2: (0.1 mg/kg NTG)   
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
N/A G/L tHb N/A G/L tHb  
N/A % SAT N/A % SAT 
 
 
N/A % HbCO N/A % HbCO
 
 
N/A % metHb N/A % metHb 
N/A Vol % O2 ct N/A Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2   
125 130 150  
110 115 120  
115 110 135  
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 98 118 390  408 
Dose 2 106 106 447  416 
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HBOC Top-load Study 
 
GROUP: 5.9% HSA + NTG 
Animal ID/Date of Experiment:11/18/2010 
Scheduled Delivery: 11/15/2010 
 
Weight: 243 g 
Baseline Hct: N/A Final Hct: N/A 
 
Volume infused: 
Dose 1: (0.5 ml of 5.9% HSA)  
Dose 2: (0.1 mg/kg NTG)   
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
N/A G/L tHb N/A G/L tHb  
N/A % SAT N/A % SAT 
 
 
N/A % HbCO N/A % HbCO
 
 
N/A % metHb N/A % metHb 
N/A Vol % O2 ct N/A Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2   
45 55 55  
45 45 45  
95 95 90 
90 100 100 
100 100 100  
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 117 132 450  447 
Dose 2 112 110 449  405 
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HBOC Top-load Study 
 
GROUP: 5.9% HSA + NTG 
Animal ID/Date of Experiment:6/8/2010 
Scheduled Delivery: 6/7/2010 
 
Weight: 245 g 
Baseline Hct: 43.6% Final Hct: 39.1% 
 
Volume infused: 
Dose 1: (0.5 ml of 5.9% HSA)  
Dose 2: (0.3 mg/kg NTG)   
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
13.4 G/L tHb 12.7 G/L tHb  
101.6 % SAT 96.9 % SAT 
 
 
4.2 % HbCO 3.8 % HbCO
 
 
0.7 % metHb 0.8 % metHb 
18.0 Vol % O2 ct 16.3 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2   
54 54 50  
34 36 38  
30 30 20  
58 64 60 
44 47 45 
100 97 105 
110 108 110 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 97 122 375  413 
Dose 2 120 114 428  414 
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HBOC Top-load Study 
 
GROUP: 5.9% HSA + NTG 
Animal ID/Date of Experiment:8/5/2010 
Scheduled Delivery: 7/19/2010 
 
Weight: 320 g 
Baseline Hct: 43.6% Final Hct: 40.3% 
 
Volume infused: 
Dose 1: (0.5 ml of 5.9% HSA)  
Dose 2: (0.3 mg/kg NTG)   
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
13.3 G/L tHb 13.5 G/L tHb  
99.1 % SAT 99.8 % SAT 
 
 
3.8 % HbCO 3.8 % HbCO
 
 
0.4 % metHb 0.4 % metHb 
17.5 Vol % O2 ct 17.9 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  
80 70 78  
80 75 82  
60 75 60  
73 75 75 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 111 122 414  400 
Dose 2 124 125 387  400 
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HBOC Top-load Study 
 
GROUP: 5.9% HSA + NTG 
Animal ID/Date of Experiment:7/9/2010 
Scheduled Delivery: 7/6/2010 
 
Weight: 263 g 
Baseline Hct: 38.9% Final Hct: N/A 
 
Volume infused: 
Dose 1: (0.5 ml of 5.9% HSA)  
Dose 2: (1.0 mg/kg NTG)   
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
12.0 G/L tHb 11.5 G/L tHb  
91.2 % SAT 90.2 % SAT 
 
 
3.5 % HbCO 3.5 % HbCO
 
 
0.8 % metHb 0.4 % metHb 
14.6 Vol % O2 ct 13.8 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  
70 70 70  
25 30 30  
70 60 60  
70 70 70 
30 25 30 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 106 134 414  428 
Dose 2 130 126 428  414 
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HBOC Top-load Study 
 
GROUP: 5.9% HSA + NTG 
Animal ID/Date of Experiment:8/6/2010 
Scheduled Delivery: 7/19/2010 
 
Weight: 329 g 
Baseline Hct: 43.6% Final Hct: 39.4% 
 
Volume infused: 
Dose 1: (0.5 ml of 5.9% HSA)  
Dose 2: (1.0 mg/kg NTG)   
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
13.9 G/L tHb 12.4 G/L tHb  
98.4 % SAT 96.9 % SAT 
 
 
3.9 % HbCO 3.9 % HbCO
 
 
0.2 % metHb 0.5 % metHb 
18.1 Vol % O2 ct 16.0 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  
135 120 95  
140 130 85  
54 50 35  
100 110 70 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 111 121 431  433 
Dose 2 121 121 430  456 
  
277
Page 
277 
 
  
HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) + NTG 
Animal ID/Date of Experiment:3/8/2010 
Scheduled Delivery: 3/1/2010 
 
Weight: 255 g 
Baseline Hct: 40.5% Final Hct: N/A 
 
Volume infused: 
Dose 1: (100 µM HBOC) 
Dose 2: (0.1 mg/kg NTG)  
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
14.3 G/L tHb 14.2 G/L tHb  
99.0 % SAT 89.3 % SAT 
 
 
4.1 % HbCO 3.4 % HbCO
 
 
0.5 % metHb 0.7 % metHb 
18.8 Vol % O2 ct 16.9 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  
125 110 115 
110 105 115  
35 45 50  
110 110 115 
45 45 45 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 101 140 400  400 
Dose 2 126 111 387  444 
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HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) + NTG 
Animal ID/Date of Experiment:3/9/2010 
Scheduled Delivery: 3/1/2010 
 
Weight: 280 g 
Baseline Hct: 35.9% Final Hct: N/A 
 
Volume infused: 
Dose 1: (100 µM HBOC) 
Dose 2: (0.1 mg/kg NTG)  
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
12.6 G/L tHb 13.9 G/L tHb  
98.7 % SAT 96.1 % SAT 
 
 
4.0 % HbCO 3.9 % HbCO
 
 
0.5 % metHb 0.4 % metHb 
16.5 Vol % O2 ct 17.8 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  
90 95 90 
25 25 40  
90 110 105  
55 35 35 
95 100 110 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 83 142 375  375 
Dose 2 139 113 400  387 
 
  
279
Page 
279 
 
  
HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) + NTG 
Animal ID/Date of Experiment:3/11/2010 
Scheduled Delivery: 3/8/2010 
 
Weight: 241 g 
Baseline Hct: 37.0% Final Hct: N/A 
 
Volume infused: 
Dose 1: (100 µM HBOC) 
Dose 2: (0.1 mg/kg NTG)  
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
11.8 G/L tHb 13.3 G/L tHb  
98.5 % SAT 93.6 % SAT 
 
 
3.8 % HbCO 3.8 % HbCO
 
 
0.3 % metHb 0.4 % metHb 
15.5 Vol % O2 ct 16.6 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  
80 85 80 
115 120 120  
70 70 70  
105 100 110 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 100 148 387  378 
Dose 2 148 133 413  413 
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HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) + NTG 
Animal ID/Date of Experiment:7/13/2010 
Scheduled Delivery: 7/6/2010 
 
Weight: 241 g 
Baseline Hct: 41.7% Final Hct: 40.8% 
 
Volume infused: 
Dose 1: (100 µM HBOC) 
Dose 2: (0.1 mg/kg NTG)  
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
13.0 G/L tHb 12.7 G/L tHb  
101.0 % SAT 73.5 % SAT 
 
 
3.6 % HbCO 3.1 % HbCO
 
 
0.5 % metHb 0.6 % metHb 
17.5 Vol % O2 ct 12.5 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  
95 70 45 
100 55 45  
90 75 65  
45 45 40 
95 50 50 
95 70 65 
95 75 65 
35 40 30 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 85 134 353  352 
Dose 2 125 96 364  400 
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HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) + NTG 
Animal ID/Date of Experiment:3/15/2010 
Scheduled Delivery: 3/8/2010 
 
Weight: 266 g 
Baseline Hct: N/A Final Hct: N/A 
 
Volume infused: 
Dose 1: (100 µM HBOC) 
Dose 2: (0.3 mg/kg NTG)  
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
12.7 G/L tHb N/A G/L tHb  
98.8 % SAT N/A % SAT 
 
 
4.2 % HbCO N/A % HbCO
 
 
0.3 % metHb N/A % metHb 
16.7 Vol % O2 ct N/A Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  
130 135 140 
150 145 145  
50 45 55  
60 60 60 
55 55 45 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 93 147 363  375 
Dose 2 140 118 375  363 
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HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) + NTG 
Animal ID/Date of Experiment:3/30/2010 
Scheduled Delivery: 3/29/2010 
 
Weight: 233 g 
Baseline Hct: 43.1% Final Hct: N/A 
 
Volume infused: 
Dose 1: (100 µM HBOC) 
Dose 2: (0.3 mg/kg NTG)  
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
13.4 G/L tHb 14.0 G/L tHb  
97.6 % SAT 95.5 % SAT 
 
 
4.2 % HbCO 4.0 % HbCO
 
 
0.3 % metHb 0.6 % metHb 
17.4 Vol % O2 ct 17.7 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  
70 70 70 
40 40 45  
70 60 65  
115 120 120 
50 55 55 
120 120 125 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 80 162 324  342 
Dose 2 148 110 333  333 
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HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) + NTG 
Animal ID/Date of Experiment:4/6/2010 
Scheduled Delivery: 3/29/2010 
 
Weight: 282 g 
Baseline Hct: 34.7% Final Hct: N/A 
 
Volume infused: 
Dose 1: (100 µM HBOC) 
Dose 2: (0.3 mg/kg NTG)  
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
12.5 G/L tHb 12.5 G/L tHb  
96.1 % SAT 93.3 % SAT 
 
 
3.8 % HbCO 3.6 % HbCO
 
 
0.4 % metHb 0.5 % metHb 
16.0 Vol % O2 ct 15.6 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  
65 70 60 
35 35 35  
60 60 60  
105 105 105 
50 60 45 
105 110 105 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 105 164 364  375 
Dose 2 158 121 375  375 
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HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) + NTG 
Animal ID/Date of Experiment:8/3/2010 
Scheduled Delivery: 7/19/2010 
 
Weight: 308 g 
Baseline Hct: 46.5% Final Hct: 46.5% 
 
Volume infused: 
Dose 1: (100 µM HBOC) 
Dose 2: (0.3 mg/kg NTG)  
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
14.7 G/L tHb 14.3 G/L tHb  
99.7 % SAT 99.6 % SAT 
 
 
4.0 % HbCO 3.5 % HbCO
 
 
0.5 % metHb 0.4 % metHb 
19.5 Vol % O2 ct 19.2 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  
100 90 80 
60 100 100  
120 105 110  
110 110 105 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 108 135 400  400 
Dose 2 138 120 400  387 
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HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) + NTG 
Animal ID/Date of Experiment:3/10/2010 
Scheduled Delivery: 3/8/2010 
 
Weight: 234 g 
Baseline Hct: 37.9% Final Hct: N/A 
 
Volume infused: 
Dose 1: (100 µM HBOC) 
Dose 2: (1.0 mg/kg NTG)  
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
12.4 G/L tHb N/A G/L tHb  
95.2 % SAT N/A % SAT 
 
 
3.8 % HbCO N/A % HbCO
 
 
0.6 % metHb N/A % metHb 
15.7 Vol % O2 ct N/A Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  
35 28 25 
120 120 120  
100 85 100  
150 140 145 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 114 161 387  352 
Dose 2 165 129 333  375 
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HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) + NTG 
Animal ID/Date of Experiment:3/24/2010 
Scheduled Delivery: 3/22/2010 
 
Weight: 252 g 
Baseline Hct: N/A Final Hct: N/A 
 
Volume infused: 
Dose 1: (100 µM HBOC) 
Dose 2: (1.0 mg/kg NTG)  
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
13.2 G/L tHb 13.1 G/L tHb  
101.7 % SAT 98.5 % SAT 
 
 
4.2 % HbCO 4.0 % HbCO
 
 
0.3 % metHb 0.6 % metHb 
17.8 Vol % O2 ct 17.1 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  
110 110 110 
35 35 35  
90 110 110  
100 105 100 
35 35 35 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 99 142 363  333 
Dose 2 136 109 333  324 
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HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) + NTG 
Animal ID/Date of Experiment:3/25/2010 
Scheduled Delivery: 3/22/2010 
 
Weight: 270 g 
Baseline Hct: N/A Final Hct: N/A 
 
Volume infused: 
Dose 1: (100 µM HBOC) 
Dose 2: (1.0 mg/kg NTG)  
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
N/A G/L tHb N/A G/L tHb  
N/A % SAT N/A % SAT 
 
 
N/A % HbCO N/A % HbCO
 
 
N/A % metHb N/A % metHb 
N/A Vol % O2 ct N/A Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  
80 75 85 
85 80 90  
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 98 162 342  342 
Dose 2 155 111 363  375 
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HBOC Top-load Study 
 
GROUP: HBOC-201 (P50 = 40 mmHg) + NTG 
Animal ID/Date of Experiment:7/14/2010 
Scheduled Delivery: 7/6/2010 
 
Weight: 277 g 
Baseline Hct: 36.1% Final Hct: 36.6 
 
Volume infused: 
Dose 1: (100 µM HBOC) 
Dose 2: (1.0 mg/kg NTG)  
 
Blood parameters as measured on OSM-3 
 
Initial ABG: Final ABG: 
11.3 G/L tHb 10.6 G/L tHb  
97.3 % SAT 91.1 % SAT 
 
 
3.8 % HbCO 3.5 % HbCO
 
 
0.4 % metHb 0.9 % metHb 
14.7 Vol % O2 ct 12.8 Vol % O2 ct 
 
 
Arteriolar Diameters (µm): 
 
Baseline Dose 1 Dose 2  
100 100 95 
50 50 45  
90 100 95  
105 105 100 
50 50 45 
100 100 95 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
Dose 1 99 142 363  333 
Dose 2 136 109 333  324 
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Hemorrhage & Resuscitation Animals 
HBOC Hemorrhage and Resuscitation Study 
 
GROUP: HSA 
Animal ID/Date of Experiment: 10/1/2010 
Scheduled Delivery: 9/7/2010 
 
Weight: 328 g 
Volume withdrawn/infused: 7.9 ml 
 
 BL H R20 R60 R120 
Hct (%): 43.7 29.6 19.7 13.4 13.4 
 
Blood parameters as measured on OSM-3 
 
 BL H R20 R60 R120 
G/L tHb 15.0 10.6 6.8 7.5 7.0 
% SAT 98.3 97.2 77.0 98.2 99.8 
% HbCO 3.9 4.2 4.0 4.5 4.6 
% metHb 0.9 1.0 1.2 1.4 1.3 
Vol % O2 ct 19.5 13.6 6.9 9.6 9.1 
Lactate 
(mmlol/L) 
1.7 6.2 1.4 0.9 0.9 
 
Arteriolar Diameters (µm): 
 
Baseline H  R20  R60  R120 
115 80 100 100 110 
120 90 105 110 115 
115 75 105 115 110 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
BL N/A N/A 
H N/A N/A 
R20 N/A N/A 
R60 N/A N/A 
R120 N/A N/A 
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HBOC Hemorrhage and Resuscitation Study 
 
GROUP: HSA 
Animal ID/Date of Experiment: 10/15/2010 
Scheduled Delivery: 9/27/2010 
 
Weight: 344 g 
Volume withdrawn/infused: 8.25 ml 
 
 BL H R20 R60 R120 
Hct (%): 42.2 30.2 19.9 19.9 N/A 
 
Blood parameters as measured on OSM-3 
 
 BL H R20 R60 R120 
G/L tHb 14.1 9.9 6.7 7.0 6.8 
% SAT 92.8 101.2 96.9 98.5 101.8 
% HbCO 4.1 3.8 4.6 4.5 4.7 
% metHb 0.7 0.7 1.1 1.3 1.1 
Vol % O2 ct 17.3 13.2 8.5 9.0 9.1 
Lactate 
(mmlol/L) 
0.6 7.7 1.7 1.7 1.4 
 
Arteriolar Diameters (µm): 
 
Baseline H  R20  R60  R120 
110 65 115 120 135 
110 60 115 115 120 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
BL 92 329 
H 20 229 
R20 109 352 
R60 91 405 
R120 99 422 
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HBOC Hemorrhage and Resuscitation Study 
 
GROUP: HSA 
Animal ID/Date of Experiment: 11/15/2010 
Scheduled Delivery: 9/27/2010 
 
Weight: 415 g 
Volume withdrawn/infused: 10.0 ml 
 
 BL H R20 R60 R120 
Hct (%): 39.4 28.1 17.1 17.1 16.9 
 
Blood parameters as measured on OSM-3 
 
 BL H R20 R60 R120 
G/L tHb 13.3 9.7 6.0 5.9 5.9 
% SAT 95.7 98.8 98.1 99.2 99.7 
% HbCO 3.9 3.8 4.1 4.3 4.4 
% metHb 0.8 0.7 1.2 1.2 1.2 
Vol % O2 ct 16.9 12.7 7.7 7.7 7.7 
Lactate 
(mmlol/L) 
0.8 12.1 1.1 1.1 1.1 
 
Arteriolar Diameters (µm): 
 
Baseline H  R20  R60  R120 
125 N/A 120 120 100 
120 N/A 120 125 120 
110 N/A 115 105 105  
110 N/A 110 115 115 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
BL 97 260 
H 29 88 
R20 116 377 
R60 96 378 
R120 89 378 
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HBOC Hemorrhage and Resuscitation Study 
 
GROUP: HBOC-201 
Animal ID/Date of Experiment: 10/6/2010 
Scheduled Delivery: 9/7/2010 
 
Weight: 353 g 
Volume withdrawn/infused: 8.5 ml 
 
 BL H R20 R60 R120 
Hct (%): 45 28.6 N/A 20.8 20 
 
Blood parameters as measured on OSM-3 
 
 BL H R20 R60 R120 
G/L tHb 15.1 10.0 N/A 12.9 12.6 
% SAT 93.5 88.4 N/A 78.8 83.9 
% HbCO 3.3 3.8 N/A 2.6 3.0 
% metHb 0.5 0.7 N/A 1.8 2.2 
Vol % O2 ct 18.9 11.7 N/A 13.5 13.9 
Lactate 
(mmlol/L) 
0.6 11.1 N/A 3.5 1.8 
 
Arteriolar Diameters (µm): 
 
Baseline H  R20  R60  R120 
90 65 85 95 90 
90 70 90 90 85 
20 10 20 20 25 
20 60 80 95 90  
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
BL 102 325 
H 18 232 
R20 117 387 
R60 92 427 
R120 95 460 
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HBOC Hemorrhage and Resuscitation Study 
 
GROUP: HBOC-201 
Animal ID/Date of Experiment: 11/10/2010 
Scheduled Delivery: 9/7/2010 
 
Weight: 405 g 
Volume withdrawn/infused: 9.75 ml 
 
 BL H R20 R60 R120 
Hct (%): 45 30.3 22.7 23.2 22.1 
 
Blood parameters as measured on OSM-3 
 
 BL H R20 R60 R120 
G/L tHb 15.2 10.2 13.5 13.3 12.6 
% SAT 79.7 98.7 75.7 61.6 71.9 
% HbCO 3.5 4.3 4.9 4.3 4.4 
% metHb 0.7 0.8 9.2 8.0 7.5 
Vol % O2 ct 16.1 13.3 12.2 10.0 11.1 
Lactate 
(mmlol/L) 
0.5 6.4 1.4 1.7 1.3 
 
Arteriolar Diameters (µm): 
 
Baseline H  R20  R60  R120 
135 115 145 140 145 
115 105 120 130 140 
50 65 60 80 75 
95 105 110 145 140 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
BL 103 337 
H 19 N/A 
R20 152 355 
R60 101 388 
R120 103 405 
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HBOC Hemorrhage and Resuscitation Study 
 
GROUP: HBOC-201 
Animal ID/Date of Experiment: 12/9/2010 
Scheduled Delivery: 11/15/2010 
 
Weight: 345 g 
Volume withdrawn/infused: 8.3 ml 
 
 BL H R20 R60 R120 
Hct (%): 45 N/A 27.1 26.7 25.7 
 
Blood parameters as measured on OSM-3 
 
 BL H R20 R60 R120 
G/L tHb 14.5 N/A 14.4 13.7 12.9 
% SAT 92.3 N/A 80.3 82.9 86.6 
% HbCO 1.4 N/A 2.6 2.8 3.3 
% metHb N/A N/A 1.2 1.7 1.9 
Vol % O2 ct 18.7 N/A 15.5 15.1 14.7 
Lactate 
(mmlol/L) 
1.4 N/A 2.2 1.5 1.7 
 
Arteriolar Diameters (µm): 
 
Baseline H  R20  R60  R120 
110 70 95 80 80 
35 35 25 30 30 
95 90 80 95 50  
65 70 35 60 20  
105 85 80 100 40 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
BL 81 295 
H 19 170 
R20 160 348 
R60 110 430 
R120 117 436 
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HBOC Hemorrhage and Resuscitation Study 
 
GROUP: HBOC-201 + NTG 
Animal ID/Date of Experiment: 10/12/2010 
Scheduled Delivery: 9/27/2010 
 
Weight: 310 g 
Volume withdrawn/infused: 7.5 ml 
 
 BL H R20 R60 R120 
Hct (%): 43.7 27.4 22.5 N/A N/A 
 
Blood parameters as measured on OSM-3 
 
 BL H R20 R60 R120 
G/L tHb 15.7 9.3 12.1 N/A N/A 
% SAT 94.5 97.9 69.1 N/A N/A 
% HbCO 4.1 4.2 2.8 N/A N/A 
% metHb 0.8 1.0 3.0 N/A N/A 
Vol % O2 ct 19.6 12.0 10.9 N/A N/A 
Lactate 
(mmlol/L) 
1.5 7.9 3.3 N/A N/A 
 
Arteriolar Diameters (µm): 
 
Baseline H  R20  R60  R120 
110 80 80 N/A N/A 
105 75 75 N/A N/A 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
BL 96 389 
H 17 256 
R20 111 449 
R60 N/A N/A 
R120 N/A N/A 
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HBOC Hemorrhage and Resuscitation Study 
 
GROUP: HBOC-201 + NTG 
Animal ID/Date of Experiment: 10/13/2010 
Scheduled Delivery: 9/27/2010 
 
Weight: 326 g 
Volume withdrawn/infused: 7.8 ml 
 
 BL H R20 R60 R120 
Hct (%): 40.8 28.4 22.9 12.1 21.1 
 
Blood parameters as measured on OSM-3 
 
 BL H R20 R60 R120 
G/L tHb 14.1 9.6 11.0 11.5 10.8 
% SAT 95.8 100.5 78.3 85.5 87.6 
% HbCO 4.2 4.4 3.1 3.3 3.6 
% metHb 0.8 0.7 3.3 2.8 3.0 
Vol % O2 ct 17.9 12.7 11.2 12.8 12.3 
Lactate 
(mmlol/L) 
0.9 7.5 3.6 3.6 2.2 
 
Arteriolar Diameters (µm): 
 
Baseline H  R20  R60  R120 
130 95 110 100 100 
110 80 120 105 105 
130 75 135 125 130 
130 75 135 125 130 
100 95 95 100 100 
120 85 110 110 115 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
BL 106 356 
H 31 N/A 
R20 132 332 
R60 104 419 
R120 116 418 
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HBOC Hemorrhage and Resuscitation Study 
 
GROUP: HBOC-201 + NTG 
Animal ID/Date of Experiment: 11/11/2010 
Scheduled Delivery: 9/27/2010 
 
Weight: 400 g 
Volume withdrawn/infused: 9.6 ml 
 
 BL H R20 R60 R120 
Hct (%): 43.3 33.3 20.9 19.9 19.6 
 
Blood parameters as measured on OSM-3 
 
 BL H R20 R60 R120 
G/L tHb 14.7 11.2 11.8 11.3 11.2 
% SAT 93.0 99.9 82.9 82.1 84.1 
% HbCO 3.8 3.9 4.8 4.5 4.5 
% metHb 0.8 0.9 9.5 8.1 6.9 
Vol % O2 ct 18.1 14.8 11.7 11.3 11.6 
Lactate 
(mmlol/L) 
0.5 10.0 3.2 2.4 1.6 
 
Arteriolar Diameters (µm): 
 
Baseline H  R20  R60  R120 
140 90 135 130 140 
150 35 40 45 40 
145 85 135 140 135 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
BL 88 331 
H 17 291 
R20 118 398 
R60 68 371 
R120 76 384 
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HBOC Hemorrhage and Resuscitation Study 
 
GROUP: HBOC-201 + NTG 
Animal ID/Date of Experiment: 11/29/2010 
Scheduled Delivery: 10/19/2010 
 
Weight: 455 g 
Volume withdrawn/infused: 11.0 ml 
 
 BL H R20 R60 R120 
Hct (%): 45.1 33.6 24.8 25.3 24.6 
 
Blood parameters as measured on OSM-3 
 
 BL H R20 R60 R120 
G/L tHb 15.1 11.3 12.7 12.7 11.6 
% SAT 95.5 100.4 89.9 95.1 93.1 
% HbCO 4.3 4.5 5.3 5.2 5.3 
% metHb 0.6 0.5 9.6 8.1 7.9 
Vol % O2 ct 19.1 15.0 13.5 14.5 13.0 
Lactate 
(mmlol/L) 
1.0 10.8 1.7 1.5 1.3 
 
Arteriolar Diameters (µm): 
 
Baseline H  R20  R60  R120 
75 70 95 110 95 
95 70 110 75 90 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
BL 98 330 
H 19 169 
R20 159 486 
R60 132 454 
R120 126 418 
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HBOC Hemorrhage and Resuscitation Study 
 
GROUP: HBOC-201 + NTG 
Animal ID/Date of Experiment: 12/2/2010 
Scheduled Delivery: 11/15/2010 
 
Weight: 340 g 
Volume withdrawn/infused: 8.2 ml 
 
 BL H R20 R60 R120 
Hct (%): 40.8 N/A 22.8 22.5 23.1 
 
Blood parameters as measured on OSM-3 
 
 BL H R20 R60 R120 
G/L tHb 14.5 N/A 11.2 11.2 11.8 
% SAT 94.3 N/A 89.5 86.8 87.9 
% HbCO 4.2 N/A 5.3 5.1 5.1 
% metHb 0.7 N/A 10.2 8.3 7.0 
Vol % O2 ct 18.1 N/A 11.8 11.7 12.7 
Lactate 
(mmlol/L) 
0.7 N/A 2.5 1.0 1.0 
 
Arteriolar Diameters (µm): 
 
Baseline H  R20  R60  R120 
85 85 95 105 105  
100 90 95 105 100 
35 40 45 40 35 
110 115 115 120 115 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
BL 98 330 
H 19 169 
R20 159 486 
R60 132 454 
R120 126 418 
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HBOC Hemorrhage and Resuscitation Study 
 
GROUP: HBOC-201 + NTG 
Animal ID/Date of Experiment: 12/3/2010 
Scheduled Delivery: 11/15/2010 
 
Weight: 340 g 
Volume withdrawn/infused: 8.2 ml 
 
 BL H R20 R60 R120 
Hct (%): 44.4 32.9 N/A N/A N/A 
 
Blood parameters as measured on OSM-3 
 
 BL H R20 R60 R120 
G/L tHb 14.4 11.1 N/A N/A N/A 
% SAT 96.9 102.8 N/A N/A N/A 
% HbCO 4.1 4.3 N/A N/A N/A 
% metHb 0.9 0.9 N/A N/A N/A 
Vol % O2 ct 18.4 15.0 N/A N/A N/A 
Lactate 
(mmlol/L) 
1.9 5.5 N/A N/A N/A 
 
Arteriolar Diameters (µm): 
 
Baseline H  R20  R60  R120 
140 135 110 N/A N/A 
120 110 105 N/A N/A 
90 85 80 N/A N/A 
 
MAP & HR: SBP/DBP values connected by arrows represent values prior to infusion of 
indicated dose followed by maximum values observed after indicated dose. 
 
 MAP (mmHg) HR (bpm) 
BL 100 337 
H 40 279 
R20 115 430 
R60 N/A N/A 
R120 N/A N/A 
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